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The present thesis dissertation is the result of several years of research at the 
Animal Cell Technology Unit of ITQB-UNL/iBET, Oeiras, Portugal, under the 
supervision of Dr Paula M. Alves and Dr Pedro E. Cruz. It gave me the 
opportunity to work in the challenging fields of cell culture and viral production 
for vaccination and gene therapy applications. 
 
This thesis intends to identify and investigate some of the major bottlenecks in 
the upstream bioprocesses for virus production. Two products were selected 
based on their importance in the gene therapy field (Adenovirus) and the 
challenging demand of developing a thermostable vaccine for the eradication of 
Peste des Petits Ruminant Virus in Africa. These products characteristics and 
complexity of their production systems were the starting point for the different 
challenges faced during this work. The main focus of this dissertation was 
based on the selection of the best cell host for production and the best 
formulation to maintain virus product quality during storage.  
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“Learn from yesterday, live for today, hope for 
tomorrow. The important thing is not to stop 
questioning.” 
 
Albert Einstein  
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Viral products, including viral vaccines and viral vectors, are important tools 
for disease prevention and therapy. Viral vaccines, such as attenuated or 
inactivated rabies virus, influenza virus or hepatitis virus vaccines are powerful 
tools to limit the number of serious viral infections and pandemics. This type of 
biopharmaceuticals are used to improve human quality of life with vaccination 
being the most cost-effective method available for preventing economic losses 
and increasing the lifespan of both people and livestock. On the other hand, 
adenoviruses, adeno-associated viruses and retroviruses are among the viral 
vectors currently being developed for delivering genetic material to the target 
cell in a growing number of gene therapy clinical applications.  
The production of viral products is typically based on cell culture, the 
exception being the use of eggs as a mean of virus replication prior to 
inactivation as in the case of influenza virus vaccine. Several factors must be 
considered when selecting an appropriate cell line for a given bioprocess. 
Productivity, is of course, important but other aspects such as process 
simplicity and cost, scalability, reproducibility, safety, regulatory history, 
production platform compatibility, and availability of preferred production 
media may also play a decisive role. As a result, new and improved platforms 
are continuously being developed propelled by the need to increase and 
improve product availability and quality.  
Two different viral systems, Adenovirus vectors (AdV) and Peste des Petits 
Ruminants (PPR) virus, were selected for this thesis due to their contrasting 
position on the viral products domain. AdV belong to the most widely used 
tools for the delivery of transgenes into cells in vitro and in vivo with 
applications ranging from gene therapy and cancer therapy, to the development 
of prophylactic and therapeutic vaccines. Adenovirus vectors have been 
extensively used for research both at preclinical and clinical levels (the majority 
in phase I/II clinical trials) and two products based on adenovirus for the 
treatment of cancer have been approved in China. Consequently, the market 
need for adenovirus is increasing, creating a demand for new production 
methodologies of high quality, high efficacy vectors.  
Contrary to AdV, which are non-enveloped viruses, PPR is an enveloped virus 
which makes it very sensitive to temperature. PPR has become the next 
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veterinary disease on target for elimination, after the successful eradication of 
Rinderpest in 2011. Several efforts are being taken to develop DIVA vaccines 
(which enable differentiation between infected and vaccinated animals) for PPR 
and to improve the efficacy of the current attenuated vaccine, via the increase 
of its thermal stability.  
Both products share similar challenges but there are also product specific 
bioprocess bottlenecks that need to be addressed. In this thesis, several cell 
lines and culture strategies were evaluated in their capacity to produce AdV and 
PPR vaccine. Several cell culture and virus production parameters were assessed 
namely multiplicity of infection (MOI), cell concentration at infection (CCI), the 
use of serum-free media and the scalability of the production process for both 
systems. Being the thermal stability a very important factor for vaccine use, 
approaches to improve the current PPR vaccine are also presented together with 
their application in one of the production laboratories.  
 
In Chapter 1, the state of the art on animal cell culture for virus production 
is presented. The several bioengineering challenges affecting upstream 
processing are reviewed. A special focus is also made to the factors affecting 
virus stability during production and storage.  
 
In Chapter 2, a newly developed human amniocyte-derived cell line (1G3 
cells) was evaluated in its ability to produce AdV and in comparison to the 
human cell line HEK293 typically used for those viral vectors. The impact of 
MOI, CCI and harvesting time (TOH) on AdV production were evaluated in shake 
flask and bioreactor. Overall, the AdV infection experiments with 1G3 cells 
showed that (i) infection was most efficient at a MOI of 5 infectious 
particles/cell; ii) infection done at a CCI 3x10
6
 cell/mL in bioreactor provided 
the higher virus titers; iii) the preferable time of harvest was 48 hours 
post-infection, corresponding to the higher virus concentration, mainly in the 
intracellular fraction. This strategy allowed a 3-fold increase in the AdV 
volumetric productivity obtained in batch culture in comparison to HEK293 
cells. The human amniocyte-derived cell line (1G3 cells) showed to be a valid 
alternative substrate for adenovirus vectors production.  
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The aim of Chapter 3 was to study the impact of adenovirus infection in two 
producer cell lines (HEK293 and 1G3 cells) metabolism, and gain further 
insights into the cell density effect which occurs at higher densities for 1G3 
cells. The exometabolome of both cell lines, infected at different concentrations 
in shake flask and bioreactor cultures, was analyzed by 
1
H-NMR spectroscopy. 
The cultures supernatant was analyzed along time to evaluate how the virus 
manipulation of the cell metabolism evolves in both cell lines.  
 
In Chapter 4, two scalable processes were evaluated as possible 
alternatives for the currently used production process of PPR attenuated vaccine 
that uses monolayers of Vero cells grown in roller bottles or static flasks, i.e. 
processes with very limited scalability. i) Microcarrier cell culture technology to 
produce PPR vaccine in Vero cells and ii) single cell suspension cultures of BHK-
21A or HEK293 cells, significantly simplifying the existing production process 
were studied.  
 
Two strategies to improve the stability of the current PPR vaccine are 
presented in Chapter 5. Firstly, new formulations based on the Tris buffer were 
tested, with and without the addition of sucrose and trehalose and compared 
with the formulation normally used to stabilize the vaccine, the Weybridge 
medium. The results show a virus half-life of 21 hours at 37ºC and 1 month at 
4ºC for the Tris/trehalose liquid formulation. In the lyophilized form, the 





doses/mL) for at least 21 months at 4ºC (0.6 log reduction), 144 hours at 37ºC 
(0.6 log reduction) and 120 hours at 45ºC (1 log reduction). Secondly, a strategy 
based on culture medium composition manipulation aiming at improving the 
intrinsic PPR vaccine stability was also evaluated. The addition of 25 mM 
fructose resulted in a higher virus production (1 log increase) with higher 
stability (2.6 fold increase compared to glucose 25 mM) at 37ºC.   
 
Chapter 6 presents the technology transfer operation of a new candidate 
formulation to the production platform of PPR vaccine preformed at National 
Veterinary Institute (NVI) in Ethiopia. The results showed an increased thermal 
stability of the vaccine, especially at 37 and 45ºC, as expected from results 
obtained in Chapter 5 which validates the data obtained.  
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Chapter 7 discusses the implications of the findings and main 
achievements of this thesis. The challenges and hurdles associated with viral 
manufacture using animal cell cultures and their effects during the production 
process are discussed.  
 
Overall, this thesis describes novel and/or alternative production processes 
for two of complex biopharmaceuticals (Adenovirus vectors and PPR attenuated 
vaccine) taking into account the current bottlenecks in their production. It 
contributes to improve current knowledge in vaccine process development 
trying to move towards more robust, cost-effective and safe (RCA formation for 
AdV) manufacturing. Furthermore, the results obtained for these two 
biopharmaceuticals can provide useful hits for production of other similar 
products or even be used as a starting point for development of new production 
platforms.  
 
Finally, it is important to highlight that the results obtained in Chapter 5 
were used to transfer the developed formulation to the production of the PPR 
vaccine in Ethiopia (Chapter 6), with the results showing an improvement in the 
stability of the vaccine produced thus demonstrating a successful technology 
transfer operation. 
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Os vectores virais e vacinas virais têm vindo a ganhar uma importância 
clínica cada vez mais relevante. Os vectores virais como o adenovírus, os vírus 
adeno-associados ou os retrovírus, são ferramentas que têm vindo a ser 
desenvolvidas para entregar material genético à célula alvo em terapia génica. 
As vacinas virais, como as vacinas da raiva (atenuada ou inativada), da gripe ou 
da hepatite, são ferramentas poderosas para limitar o número de infeções virais 
graves e pandemias. Estes tipos de produtos biofarmacêuticos são utilizados 
para melhorar a qualidade de vida dos seres humanos sendo a vacinação o 
método disponível mais rentável para a prevenção de perdas económicas e 
aumento do tempo de vida do homem, mas também dos animais. 
Muitos fatores têm que ser considerados na escolha da linha celular 
apropriada para qualquer bioprocesso. A produtividade é, naturalmente, uma 
consideração importante, mas outras questões incluem a facilidade e economia 
da sua utilização, a escalabilidade, a reprodutibilidade, a segurança, historial 
regulamentar, a compatibilidade com a plataforma de produção e a 
disponibilidade dos meios de produção pretendidos. Assim, são continuamente 
desenvolvidas novas e melhores plataformas para expandir e melhorar a 
disponibilidade e qualidade do produto. 
Dois sistemas virais, vectores adenovirais (AdV) e a vacina da  Peste des 
Petits Ruminants (PPR), foram selecionados para esta tese devido à sua posição 
contrastante no domínio dos produtos virais. Os AdV pertencem às ferramentas 
mais usadas na entrega de transgenes em células in vitro e in vivo com 
aplicações desde a terapia génica e a terapia contra o cancro, até ao 
desenvolvimento de vacinas profiláticas e terapêuticas. Este vectores têm sido 
extensivamente usados na investigação tanto nos níveis pré-clínico e clínico (na 
sua maioria em fase I/II) e dois produtos baseados em adenovírus para o 
tratamento de cancro foram recentemente aprovados na China. Por isso, as 
necessidades de mercado para os vectores adenovirais estão a aumentar, 
criando a necessidade de metodologias de produção de vectores concentrados 
com a garantia de qualidade e eficácia. 
Ao contrário dos AdV, que são vírus sem envelope e com ciclo celular lítico, 
o virus PPR têm envelope que os torna mais sensíveis à temperatura. A PPR 
tornou-se a próxima doença veterinária alvo para a completa eliminação, após a 
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erradicação da Rinderpest, conseguida em 2011. Vários esforços têm sido 
efetuados para o desenvolvimento de vacinas marcadoras de doença (capazes 
de diferenciar entre animais vacinados de animais infetados) e para melhorar a 
eficácia da vacina atenuada atual, passando pelo aumento da sua estabilidade 
térmica. 
Nesta tese, são apresentadas linhas celulares alternativas e estratégias de 
cultura para a produção de dois produtos virais relevantes, os vectores 
adenovirais e o vírus da PPR atenuado.  Vários parâmetros de cultura celular e 
produção viral são alvo de estudo nomeadamente a multiplicidade de infeção 
(MOI), a concentração na altura da infeção (CCI), a utilização de meios sem soro 
e a escalabilidade do processo para ambos os sistemas. Sendo a estabilidade 
térmica um factor muito importante na utilização de vacinas, alternativas para 
melhorar a atual vacina da PPR são também descritas juntamente com a sua 
aplicação num dos laboratórios de produção. 
  
No Capítulo 1, faz-se uma revisão do estado da arte em cultura de células 
de animais para a produção de vírus. Os vários desafios de bioengenharia que 
afetam o processo de produção são apresentadas. Um foco especial é feito 
também sobre os factores que afetam a estabilidade dos vírus durante a 
produção e o armazenamento. 
 
No Capítulo 2, é avaliada a aplicabilidade de uma linha celular humana 
derivada de amniócitos recentemente desenvolvida (células 1G3), em 
comparação com a linha celular normalmente utilizada, na produção de AdV, as 
células humanas HEK293. Os efeitos da MOI, da CCI e o tempo de recolha (TOH) 
na produção de AdV foram analisados em frascos agitados e em biorreator. Em 
geral, as experiências de infeção com as células 1G3 mostraram que (i) a 
infeção por AdV foi mais eficiente a uma MOI de 5 partículas infecciosas/célula, 
ii) a infecção feita a uma CCI 3 em biorreator, originou os títulos virais mais 
elevados, iii) o tempo de recolha preferível foi de 48 horas pós infecção, 
correspondente à concentração mais elevada de vírus, principalmente na fração 
intracelular. Esta estratégia permitiu um aumento de 3 vezes na produtividade 
volumétrica de AdV obtidos na cultura em batch, em comparação com células 
HEK293. A linha celular derivada de amniócitos humanos (células 1G3) mostrou 
ser uma alternativa válida para a produção de vectores adenovirais. 
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O principal objectivo do Capítulo 3 foi estudar o impacto na infeção por 
adenovírus no metabolismo de duas linhas de células de produção (as células 
HEK293 e as 1G3), e tentar obter conhecimentos sobre o efeito da concentração 
celular que ocorre a valores superiores nas células 1G3. O metaboloma 
extracelular exometabolome de ambas as linhas celulares, infetadas a 
diferentes concentrações em frasco agitados e em biorreatores, foi analisado 
por espetroscopia de 
1
H-RMN. Os sobrenadantes das culturas foram analisadas 
ao longo do tempo para avaliar o modo como a manipulação pelo vírus faz 
evoluir o metabolismo em ambas as linhas celulares. 
 
No Capítulo 4, dois processos escalonáveis foram avaliados como possíveis 
substitutos para a produção da vacina atualmente utilizada contra a Peste des 
Petits Ruminants (PPR) usando monocamadas de células Vero cultivadas em 
frascos estáticos ou frascos de rolantes. Na primeira aplicou-se a tecnologia de 
cultura de células em microsuportes para a produção da vacina PPR usando 
células Vero e na segunda foram usadas como alternativa culturas células em 
suspensão, as células BHK-21A ou HEK293, o que pode simplificar 
significativamente o processo de produção atualmente existente. 
 
Duas estratégias para melhorar a estabilidade da vacina atual PPR são 
apresentadas no Capítulo 5. Em primeiro lugar, novas formulações baseadas no 
tampão Tris foram testadas com e sem a adição de sacarose e trealose e 
comparadas com a formulação normalmente utilizada para estabilizar a vacina, 
o meio Weybridge. Os resultados mostram um tempo de semi-vida do vírus de 
21 horas a 37 ºC e 1 mês a 4 ºC para a formulação de Tris/trealose líquida. Sob 





/ml (> 10 doses/mL) durante pelo menos 21 meses a 4 º C (0,6 log 
perdidos), 144 horas a 37 ºC (0,6 log perdidos) e 120 horas a 45 ºC (1 log 
perdidos). Em segundo lugar, foi também avaliada uma estratégia baseada na 
manipulação da composição do meio de cultura com o objetivo de melhorar a 
estabilidade intrínseca da vacina PPR. A adição de 25 mM de frutose resultou na 
produção de vírus mais elevada (aumento de 1 log) e com uma estabilidade 
superior (2,6 vezes de aumento, em comparação com glucose 25 mM) a 37 ºC. 
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O Capítulo 6 apresenta os resultados da operação de transferência de uma 
nova formulação candidata na plataforma de produção da vacina contra a PPR 
realizados no Instituto Nacional de Veterinária (NVI), da Etiópia. Os resultados 
mostraram um aumento da estabilidade térmica da vacina, especialmente a 37 a 
45 ºC, tal como o esperado a partir dos resultados obtidos no Capítulo 5 
validando assim os dados obtidos. 
 
O Capítulo 7 discute os resultados apresentados nos outros capítulos e 
resume as principais implicações identificando as principais metas atingidas 
nesta tese. A identificação dos novos desafios e obstáculos associados ao 
fabrico viral utilizando culturas de células animais são discutidos.  
 
Em resumo, esta tese descreve novos processos de produção alternativos 
para dois biofármacos complexos tendo em consideração os desafios atuais de 
produção e propondo novas estratégias para superá-los. Contribui-se para 
melhorar o conhecimento atual do desenvolvimento de processos permitindo 
avançar para métodos de produção mais robustos, eficazes, económicos e 
seguros (sem formação de virus recombinantes no caso dos Adenovirus). Os 
resultados obtidos para os dois produtos podem ser úteis para a produção de 
outros produtos semelhantes, ou até um ponto de partida para o 
desenvolvimento de novas plataformas de produção. 
 
Finalmente, é de notar que os resultados descobertos no Capítulo 5 foram 
utilizados para transferir a formulação desenvolvida para a produção da vacina 
PPR na Etiópia (Capítulo 6) onde os resultados obtidos mostraram uma 
melhoria da estabilidade da vacina produzida demonstrando assim o sucesso 
desta operação de transferência de tecnologia. 
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Abbreviation Full form 
AdV Adenovirus 
ACF Animal Component Free 
BHK Baby Hamster Kidney 
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CCI Cell Concentration at Infection 
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Manufacturing of biopharmaceuticals involves the use of cell culture 
systems as a unique method of product development. These types of products 
are difficult to obtain by conventional pharmaceutical development processes. 
Cell culture is used in a wide range of applications such as development of 
model systems for research, analysis of cellular structures and their 
mechanisms, drug discovery and evaluation, stem cell research and production, 
genetic engineering and production of biologics such as antibodies, vaccines, 
viral vectors for gene therapy and proteins. The increase demand of animal cell 
bioprocess for biological products created great scientific and economical 
interest in research and development for this area. Each cell line shows its 
specificities, and its use for viral production has advantages but also 
disadvantages compared to the other cell lines. Based on a thorough 
understanding of the pros and cons of individual host cells for process 
performance, properties of other cell lines, specific aspects of virus–host cell 
interaction and process options can be better evaluated. Overall, a systematic 
comparison of cell lines might help to develop process optimization strategies, 
as well as to assess quality differences concerning the virus strains and 
antigens produced. 
 
1.1. Milestones of Cell Culture and viral applications 
The need for cell culture, especially at large scales, became apparent with 
the need for viral vaccines. The major epidemics of polio in the 1940s and 
1950s promoted a lot of effort to develop an effective vaccine. When it was 
finally demonstrated in 1949 that poliovirus could be grown in cultures of 
human cells, considerable interest was shown to develop large quantities of the 
polio vaccine using cell culture. The polio vaccine, produced from inactivated 
virus, became one of the first commercial products of cultured animal cells. 
After that it was realized that passage in cell culture was also a mean of 
attenuation, presumably by fortuitous selection of mutants better adapted to 
replication in vitro than in living hosts. Cell culture also permitted conscious 
selection of mutants by isolation of single clones and by incubation at 




between 1950 and 1980 saw the development of numerous attenuated viral 
vaccines, including those for polio (Sabin oral), measles, rubella, mumps and 
varicella. 
In 1961 Howard Temin discovered that specific genetic mutations could be 
inherited as a result of virus infection [1]. Based on his experimental 
observations he concluded that chicken cells infected with the Rous sarcoma 
virus (RSV) stably inherited viral specific gene mutations that contained the 
information for the generation of RSV progenies.  It became apparent that 
viruses possessed properties that could be very useful in delivering genes into 
cells of interest and that genetic engineering may become a new approach for 
treating genetic diseases. In 1966, Edward Tatum published a paper evoking 
the effectiveness of viruses to be used in somatic-cell genetics and possibly in 
genetic therapy [2].  
The first officially approved clinical protocol to introduce a foreign gene 
into humans was approved by the Recombinant DNA Advisory Committee (RAC) 
in December 1988. In that, no actual therapy was proposed, but instead, S.A. 
Rosenberg aimed at using gene marking techniques to track the movements of 
tumour-infiltrating blood cells in cancer patients [3]. 
Currently, more than 1800 approved gene therapy clinical trials worldwide 
have been conducted or are still ongoing. Up to date, cancer is by far the most 
common disease treated by gene therapy. It composes over 60% of all ongoing 
clinical gene therapy trials worldwide [4, 5]. Three gene therapy products for 
cancer have recently received market approved, two in China and one in 
Europe, increasing the confidence in further research and commercialization. 
Vaccine development has led to eradication of smallpox and the elimination of 
poliomyelitis and measles from large parts of the world, saving millions of 
lives. The use of vaccines has also contributed to promote animal health by 
preventing disease outbreaks that can have a devastating effect on animal 
production and contributed to the eradication of Rinderpest in 2011. 
Meanwhile several other types of vaccines have been obtained and are in 
commercial manufacture or are under development, being most of them viral 
based. In Table 1.1 are highlighted some of the milestones during the history 




Table 1.1: Some important events in the historical of cell culture and vaccine 
development and gene therapy products. 
Year Vaccine Event 
1796 
Edward Jenner had first speculated that protection from smallpox disease could be 
obtained through inoculation with a related virus, vaccinia or cowpox. He tested his 
theory by inoculating eight-year-old James Phipps with cowpox pustule liquid 
recovered from the hand of a milkmaid, Sarah Nelmes. 
1879 Louis Pasteur created the first live attenuated bacterial vaccine (chicken cholera). 
1884 
The first live attenuated viral vaccine (rabies) was developed by Louis Pasteur, using 
desiccated brain tissue inactivated with formaldehyde. 
1885 Louis Pasteur first used rabies vaccine in humans. 
1896 Cholera and typhoid vaccines were first developed. 
1897 
Plague vaccine was introduced, following the preparation of anti-plague horse serum 
at the Pasteur Institute by Alexandre Yersin. 
1918 Whole-cell inactivated bacterial vaccine (pertussis whooping cough). 
1923 Toxoid vaccine prepared from inactivated bacterial toxins (diphtheria). 
1930 
Cell culture was developed and shown to be able to grow virus, thus paving the way 
for the subsequent production of viral vaccines. 
1931 Freeze-dried vaccine approved by FDA (smallpox). 
1949 Viral vaccine produced in vitro with non-neural human cells by Enders (polio). 
1951 The first human cell line, HeLa was established. 
1954 
Freeze drying process for smallpox vaccine greatly improved by Collier to allow 
global distribution. 
1955 
The first polio vaccine was licensed - an inactivated poliovirus vaccine (IPV) produced 
in vitro with primary monkey kidney cells pioneered by Dr. Jonas Salk. 
1962 
Vero cells were originally isolated from the kidney of a normal (i.e., non-diseased) 
adult African green monkey by Y. Yasumura and Y. Kawakita at the Chiba University 
in Chiba, Japan. 
1962 
Attenuated Measles Vaccine Developed (Rubeovax) was developed by Maurice 
Hilleman and colleagues. 
1962 Human diploid cell line (WI-38) established by Hayflick. 
1977 Last case of smallpox outside of the laboratory. 
1980 
Rabies human diploid-cell vaccine (Imovax Rabies by Mérieux and Wyvac by Wyeth) 
were licensed. 
1980 The World Health Assembly certified the world free of naturally-occurring smallpox. 
1981 
The first hepatitis B viral vaccines (plasma-based), developed by Merck and also by 
the Pasteur Institute, were licensed. 
1986 
Recombinant virus-like particle hepatitis B vaccine (Recombivax HB by Merck) was 
licensed. 
1987 
Protein-conjugated Haemophilus influenzae type b vaccine (PRP-D, ProHibit by 
Connaught) was licensed. 
1988 
First officially approved clinical protocol to introduce a foreign gene into humans 
was approved. 
1998 
The first vaccine for the prevention of HIV/AIDS (Aidsvax) entered Phase III trial, the 
first large-scale human trial of an HIV vaccine. 
2003 First gene therapy product approved in China, Gendicine
TM
. 
2007 FDA approves first U.S. vaccine for humans against the avian influenza virus H5N1. 
2009 
FDA approved new vaccine (Cervarix, GlaxoSmithKline) for the prevention of cervical 
cancer. 
2011 
The World Organisation for Animal Health   declares the Eradication of Rinderpest, 
the second disease in history to be fully wiped out. 
2012 
FDA approved first seasonal influenza vaccine manufactured using cell culture 
technology (Flucelvax, Novartis). 
2012 First gene therapy product approved in Europe, Glybera. 




2. Viral products 
Viruses are amongst the simplest biological systems. They behave as 
intracellular parasites and contain a limited set of genes that encode 
information for their replication, encapsidation and cell-to-cell propagation. 
Viruses have been under considerable investigation as a model to study the 
basic concepts of biology and virology and due to their impact in animal and 
human health. The main areas of application of viruses include vaccine 
development and gene therapy [6]. 
 
2.1. Types of viruses  
The nature of the viral genome has many implications on the life cycle of 
the virus. Viral genome consists of one or more fragments of single-stranded 
(ss) or double-stranded (ds) RNA or DNA. Most DNA and positive (+) ssRNA 
viruses rely on host cell machinery for initiating the replication and 
transcription of viral genome, not requiring de novo synthesis of other virus 
gene products. Others, such as dsRNA or negative (-) ssRNA viruses have to 
deliver into the cell their own polymerase for the synthesis of viral proteins 
essential for initiating viral replication as host cells do not possess the 
machinery to cope with dsRNA or negative (-) ssRNA. In addition, many dsRNA 
viruses deliver their genome within a protein capsid to avoid contact between 
the dsRNA and the cell cytosol [6]. 
 
2.1.1. Virus with DNA 
A DNA virus has DNA as its genetic material and replicates using a DNA-
dependent DNA polymerase. The nucleic acid is usually dsDNA; ssDNA is less 
common as during replication ssDNA typically expands to dsDNA. This class of 
viruses belong to group I or group II of the Baltimore classification system for 
viruses [7]. Group I virus includes the Adenoviridae, Herpesviridae (herpes 
simplex virus - HSV) and Baculoviridae (Autographa californica multicapsid 
nucleopolyhedrovirus) families while group II virus includes the Parvoviridae 
and Circoviridae families (Table 1.2). Although group VII viruses such as 
hepatitis B (hepatitis B virus - HBV) contain a DNA genome, they are not 
considered DNA viruses according to the Baltimore classification, but rather 
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reverse transcribing viruses because they replicate through an RNA 
intermediate [6]. 
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2.1.2. Virus with RNA 
Conversely, an RNA virus has RNA as its genetic material. This nucleic acid 
is usually ssRNA but may be dsRNA. The International Committee on Taxonomy 
of Viruses classifies RNA viruses as those that belong to group III, group IV or 
group V of the Baltimore classification system for viruses [8] and does not 
consider viruses with DNA intermediates as RNA viruses. These viruses are 
included in group VI and possess ssRNA genomes that replicate using reverse 
transcriptase. Viruses such as the human immunodeficiency virus (HIV), simian 
immunodeficiency virus (SIV) and rous sarcoma (RS) virus (members of the 
Retroviridae family) are included in this group [6].  
 
2.1.2.1. Group III: dsRNA viruses 
DsRNA viruses represent a large group of pathogens whose genome can be 
monopartite or segmented up to 12 fragments. These viruses do not release 
the free dsRNA genome in infected cells and require that transcription and 
synthesis of new dsRNA genomes take place in confined environments. 
Reovirus and Rotavirus, members of the Reoviridae family are included in this 
group (Table 1.3).  
 
2.1.2.2. Group IV: (+) ss RNA viruses 
Contrasting with the dsRNA or the (−) ssRNA viruses, the genomes of (+) 
ssRNA viruses are infectious. Icosahedral (+) ssRNA viruses represent a large 
fraction of all viruses known and include important human pathogens; 
poliovirus, human rhinoviruses, hepatitis A virus, Norwalk group of viruses, 
astroviruses, and members of the alpha- and flaviviruses which carry an RNA-
containing nucleocapsid are some examples. Unlike (−) ssRNA viruses, the 
nucleoproteins responsible for protecting the genome from unspecific cellular 
RNA binding are not expressed in (+) ssRNA viruses. Thus, the synthesis of 
progeny viruses requires that the capsid proteins of these viruses specifically 
package the viral RNA genome while excluding the ubiquitous cellular RNA. 
Group IV includes the Flaviviridae (hepatitis C virus - HCV), Coronaviridae 
(severe acute respiratory syndrome virus – SARS virus), Picornaviridae and 
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2.1.2.3. Group V: (-) ss RNA viruses 
Negative ssRNA viruses are classified into seven families: Rhabdo-, 
Paramyxo-, Filo-, Borna-, Arena-, Bunya- (Hantaan virus and rift valley fever 
virus - RVFV) and Orthomyxoviridae (Influenza). The first four families are 
characterized by non-segmented genomes. The remaining three have genomes 
comprising two, three and six to eight (-) sense RNA segments, respectively. 
The large group of (-) sense RNA viruses includes: i) highly prevalent human 
pathogens such as respiratory syncytial virus (RSV), parainfluenza and Influenza 
viruses; ii) two of the most deadly human pathogens, Ebola and Marburg 
viruses; iii) viruses with a major economic impact on the poultry and cattle 
industries, namely the Newcastle disease virus (NDV), rinderpest virus and 
Peste des Petits Ruminant virus (Table 1.3) [6].  
 
2.2. Gene therapy 
Gene therapy involves the use of nucleic acids (DNA or RNA) for the 
treatment, cure or prevention of human disorders. Depending on the type of 
disease, this can be achieved either by delivery of a functional, therapeutic 
gene as a substitute for the defective or missing endogenous counterpart or by 
reducing the levels of a harmful defective gene product, using various 
sophisticated tools including naked oligonucleotides, viral and non-viral 
vectors. 
In the late 1970s and early 80s, the emergence of techniques for 
subcloning mammalian genes into prokaryotic plasmids and bacteriophages 
were correctly foreseen as precursors of techniques for human gene therapy. 
Parallel investigations on the biology of avian and murine onco-retroviruses led 
to the development of retroviral vectors, which began to be used in the mid-
80s as a tool for gene transfer into mammalian cells. The first human trial of 
gene transfer was carried out in the late 80s for the treatment of patients with 
advanced metastatic cancer. The process consisted in introducing the gene 
coding for resistance to neomycin into human tumor-infiltrating lymphocytes 
by retroviral-mediated gene transduction, before their infusion into patients; 
thus, using the new gene as a marker for the infused cells [3]. Since then, there 
has been a remarkable expansion in the number of vector systems available to 
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express human genes directly associated with disease states for therapeutic 
purposes (Table 1.4).  
 
Table 1.4: Vectors used for Gene therapy  
Virus Family/Vector Advantages Limitations 
Adenoviridae/ 
Adenovirus 
- High efficiency 
- Transduces quiescent and 
dividing cells 
- >30 kb transgene capacity 
- Easy to produce in high titers 




- Existing humoral response to 
certain serotypes 
Retroviridae/ 
Murine leukaemia virus 
- Broad tropism 
- Low immunogenicity 
- Stable integration 
- Insertional mutagenesis 
- Unable to transduce quiescent 
cells 
- Inactivation by serum 
Retroviridae/ 
Lentivirus 
- Low immunogenicity 
- Stable integration to 
quiescent cells 
- Insertional mutagenesis 
- Potential risk of 




- Transduces quiescent and 
dividing cells 
- Very long expression time 
- Non-pathogenic, low 
immunogenicity 
- Broad tropism 
- Very small transgene capacity 




- High titer 
- Broad host range 
- Efficient transgene expression 
- Low transgene capacity 
- Highly cytotoxic 
- Short term expression 
Alphaherpesviridae/ 
Herpes simplex-1 
- Broad host range, 
- High titer, 
- Large capacity 







- High titer 
- Large transgene capacity 
- Easy production 
- Non-pathogenic 
- Limited transduction 
- Production in insect cells 
- Unstable genome 
Non-viral vectors 
- Easy preparation, 
- non-pathogenic 
- Limited transduction 
- Bacterial contaminants 
 
 
Gene therapy trials using retroviral vectors to treat X-linked severe 
combined immunodeficiency (X-SCID) constitute one of the most successful 
applications of gene therapy to date. X-SCID is a disease in which the patient 
has neither cell - mediated immune response nor is able to generate 
antibodies. A high rate of immune system reconstitution was observed in 
patients treated in the X-SCID gene therapy trials [9]; but, 5 out of more than 
20 patients developed a leukemia-like illness, of which 4 fully recovered after 




Despite these results, gene therapy trials to treat X-SCID due to deficiency 
of the adenosine deaminase enzyme continue with relative success in the USA, 
France, UK, Italy and Japan. In the last decade, the process of retroviral vector 
production has been under considerable investigation as it presents many 
difficulties, mainly due to vector instability and low cell productivities 
hampering the attainment of high viral titers. Strategies based on the 
manipulation of sugar carbon sources [12, 13], lipids [14], temperature [15] or 
osmotic pressure [13] used in bioreaction and on the establishment of 
pioneering packaging cell lines such as 293 FLEX [16] and Flp293A [17] show 
potential to increase the yields of infectious retroviral vectors. This will allow 
the generation of high quality clinical preparations for gene therapy 
applications. 
Adenovirus (AdV) vectors are also efficient vehicles for delivering nucleic 
acids into mammalian cells (see more information of this vectors in section 3.2 
below). The human adenovirus type 2 and 5 are the most used vector 
backbones for adenovirus-mediated gene transfer. However, due to a number 
of significant disadvantages such as the need to immunosuppress or tolerize 
patients to a potentially debilitating virus [18, 19], vectors from different 
serotypes or derived from non-human adenovirus (bovine, sheep and birds) 
were developed [20, 21]. Recently, canine adenovirus serotype 2 (CAV-2), 
produced in dog kidney cells, have been gaining increasing attention due to 
their emerging potential for the study of the pathophysiology and potential 
treatment of neurodegenerative diseases like Parkinson’s, Alzheimer and 
Huntington, amongst others. The first clinical trial using recombinant 
adenovirus was carried out in 1993 with cystic fibrosis (CF) patients [22]. Two 
years later, the first recombinant adeno-associated virus trial was initiated in CF 
patients [23]; trials in hemophilia B patients commenced shortly after [24]. 
Inevitably, lentivirus and recombinant herpesvirus vectors have also entered in 
clinical trials [25-27]. All four viral vector systems mentioned above are highly 
efficient systems for gene transfer and expression in vivo in non-dividing cells. 
In fact, more than 50% of all viral vectors currently undergoing clinical trials are 
adenovirus (22.2%), retrovirus (18.4%), adeno-associated virus (6%), Lentivirus 
(5%) or herpes simplex virus (3.2%) (Figure 1.1).  
Due to their inability for replication and absence of toxicity in mammalian 
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cells, baculoviral vectors have emerged as gene therapy vehicles for the 
treatment of a wide range of human diseases. Recently, a genetically modified 
recombinant baculovirus encoding for a cherry-red fluorescent protein under 
the control of a strong mammalian cell promoter (cytomegalovirus promoter) 
proved to be effective in transducing a human liver carcinoma cell line, HepG2 
[28]. 
 
Figure 1.1: Vectors used in Gene Therapy Clinical Trials. 
(Source:  Journal of Gene Medicine Clinical Trial Database http://www.abedia.com/wiley/index.html) 
 
Other studies indicate that baculoviruses show promising gene expression 
efficiencies in liver [29], skeletal muscle [30], brain [31] and eye [32]. 
Importantly, baculoviral vectors present similar efficiencies to adenoviral 
vectors in transducing human smooth muscle cells, human cardiomyocytes and 
fibroblasts [33]. The major challenge is the production of high recombinant 
baculovirus titers [34]. Although metabolic engineering approaches have shown 
to improve baculovirus titers at high cell densities [34, 35], platforms for the 
production of baculoviral vectors to be used in gene therapy clinical trials have 
not yet been implemented. 
The first gene therapy products entered the market through China: 
Gendicine
TM
 (SiBiono GeneTech) in 2003 and Oncorine
TM
 (Shangai Sunway 
Biotech) in 2006 for cancer treatment. Gendicine
TM
 is a replication defective 
AdV5 vector expressing p53 from a Rous sarcoma virus (RSV) promoter, and is 
approved for use in head and neck squamous cell. Oncorine
TM
 is an oncolytic 
virus product derived from AdV5 vector for nasopharyengeal carcinoma 




China's State Food and Drug Administration (SFDA) approved Gendicine without 
data from a standard phase III clinical trial [36]. Consequently, soon after the 
approval of Gendicine™, there was discussion about the efficacy of the 
treatment [37]. In 2004, Ark Therapeutics Group plc received the first 
commercial GMP Certification in the EU for the manufacture of commercial 
supplies of gene-based medicines (Cerepro®). Cerepro® is an adenoviral vector 
harboring the gene for the Herpes simplex virus thymidine kinase (HSV-tk), 
developed by Ark Therapeutics Group plc and intended for the treatment of 
malignant brain tumors. In 2008, Cerepro® became the first and so far the only 
adenoviral vector that has completed a phase III clinical trial [38]. 
Finally in 2012, Glybera® (uniQure biopharma, Netherlands) received 
market approval for the treatment of lipoprotein lipase deficiency (LPLD) using 
an adeno-associated vector, being the first gene therapy product approved in 
the Western World. Hopefully, these achievements will facilitate further 
research and commercialization of valuable gene therapy products.  
 
2.3. Vaccine development 
The development process for vaccines is unique. Vaccine development is 
highly capital intensive and risky. Given the importance of safety with biologics, 
the vaccine industry is highly regulated. Vaccine development is normally 
carried out in an iterative fashion. Less than one in ten vaccine candidates 
actually achieves the market. The high attrition rate is due to the 
unpredictability of the biological microorganisms needed to produce vaccines, 
and to the uncertainty of how immune system will process and react to the 
vaccine antigen. Some vaccine candidates may produce appropriate levels of 
immune response, but induce important adverse reactions. Other vaccine 
candidates may be safe, but ineffective at preventing diseases. With the current 
tendency to combine several antigens into a single vaccine, the challenges 
associated with developing safe and effective vaccines are even greater. 
Research to discover new vaccine antigens and novel approaches to 
immunization usually takes several years, and costs tens of millions of dollars. 
Once a discovery is made, several developments must be undertaken to reach 
the licensing stage. 
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Vaccines based on live viruses have been traditionally effective and 
relatively easy to produce. The elimination of smallpox was accomplished 
through mass vaccination with the live vaccinia virus, a mildly pathogenic 
animal virus related to smallpox. Likewise, live attenuated vaccines are well 
tolerated and highly immunogenic. The live attenuated poliovirus vaccine 
developed by Dr. Albert Sabin in 1961 eradicated poliovirus disease in the 
Western hemisphere and drastically reduced their incidence rate worldwide. 
Vaccines against infectious diseases such as the yellow fever, typhoid fever, 
mumps and shigella are also based on lived attenuated viruses. The attenuation 
of viruses is accomplished through one of the following methods: 
1) attenuation of the pathogen by physical means; 2) selection of naturally 
occurring mutants that lead to infection with abortive replication of the 
pathogen while retaining its immunogenicity. Inactivated (killed) vaccines can 
also stimulate a protective immune response. The inactivated poliovirus 
vaccines (IPOL, Sanofi Pasteur SA), Influenza vaccines (Fluarix, GlaxoSmithKline) 
and typhoid fever vaccines (Typhim Vi, Sanofi Pasteur MSD) constitute some 
examples. The disease causing organism is inactivated with chemicals such as 
formaldehyde; the main drawback of these vaccines is that they require 
boosting for continuous, efficient immune response. Nowadays, using 
molecular biology and DNA manipulation methods, it is possible to express 
protective proteins in adequate live vectors with the purpose of designing live 
vaccines against various types of pathogens. In addition, the development of 
reverse genetics systems for the recovery of viruses from cDNA has made it 
possible to rapidly generate recombinant attenuated derivatives.  
Advances in molecular biology allowed also the development of platforms 
for the production of virus-like particles (VLPs) as vaccines against emergent 
diseases. Virus-like particles are composed by viral structural proteins that, 
when expressed in recombinant systems, form multi-protein structures 
mimicking the organization and conformation of authentic native viruses but 
lacking the viral genome.  Table 1.5 lists some examples of current licensed 
vaccines and presents the different types of vaccines and corresponding 
advantages and disadvantages. 
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2.3.1. Veterinary versus Human Vaccines 
The burden of infectious diseases in livestock and other animals continues 
to be a major constraint to sustained agricultural development, food security, 
and participation of developing and in-transition countries in the economic 
benefits of international trade in livestock commodities [42]. 
The criteria for successful animal or veterinary vaccines can be very 
different from those for human vaccines depending on the animal groups 
under consideration. For example, criteria for companion animal vaccines are 
similar to those for human vaccines in that the health and welfare of the 
individual animal are primary concerns. The main objective of livestock 
vaccines, on the other hand, is to improve overall production for the primary 
producers, and the cost-benefit resulting from vaccination is the bottom line 
for this industry [43]. 
The process of developing veterinary vaccines has both advantages and 
disadvantages over human vaccine development. On the one hand, the 
potential returns for animal vaccine producers are much less than those for 
human vaccines, with lower sales prices and smaller market sizes, resulting in a 
much lower investment in research and development in the animal vaccine area 
than in the human vaccine area, although the complexity and range of hosts 
and pathogens are greater. For example, the market size for the recently 
launched human vaccine (Gardasil) against papillomavirus and cervical cancer is 
estimated to be greater than 1 billion U.S. dollars, while the most successful 
animal health vaccines (e.g., against foot-and-mouth disease [FMD] virus in 
cattle and Mycoplasma hyopneumoniae in pigs) enjoy a combined market size 
that is 10 to 20% of this figure.   
On the other hand, veterinary vaccine development generally has less 
stringent regulatory and preclinical trial requirements, which can make up the 
largest cost in human vaccine development, and a shorter time to market 
launch and return on investment in research and development. In contrast to 
human vaccine development, veterinary scientists are also able to immediately 
perform research in the relevant target species. This is an obvious advantage 
over human vaccine development, as experimental infections, dose-response 





3. Adenovirus  
Adenoviruses were first discovered half a century ago by Rowe and 
colleagues while they were trying to culture adenoid tissue in the laboratory 
[44]. Ever since, these viruses have been the object of intense study, mainly as 
a model system for basic eukaryotic cellular processes such as transcription, 
RNA processing, DNA replication, and translation. 
 
3.1. Adenovirus Biology 
Adenovirus is a non-enveloped, icosahedral virus of 60–90 nm in diameter 
with a linear, double-stranded DNA genome of 30–40 kb. The capsid is 
composed of 240 hexon capsomeres forming the 20 triangular faces of the 
icosahedron, and 12 penton capsomeres with spike-shaped protrusions located 
at the 12 vertices (Figure 1.2). 
 
 
Figure 1.2: Adenovirus particle structure. 
(Source: ViralZone:www.expasy.org/viralzone, Swiss Institute of Bioinformatics) 
 
In addition to the major capsid protein (hexon) and the penton base and 
fiber proteins associated to form the penton capsomere, several hexon- and 
penton-base-associated proteins are stabilizing components of the capsid. 
Histon-like viral core proteins are associated with the DNA packaged within the 
capsid. Altogether, the adenoviral particle has a molecular weight of about 150 
MDa. The terminal globular domain or ‘‘knob’’ region of the homotrimeric 
protruding fibers of the AdV capsid is responsible for the primary virus 
attachment to the cellular receptor, the coxsackie- and adenovirus receptor 
(CAR). All serotypes except group B adenoviruses have been shown to use CAR 
as a primary docking receptor. Following the initial attachment, the interaction 
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between an RGD-motif exposed in a protruding loop of the penton base protein 
with a cell surface integrin molecule (αvβ1, αvβ3, or αvβ5) serving as secondary 
or internalization receptor triggers the virus uptake by clathrin-dependent 
receptor-mediated endocytosis. The endosomal uptake of the virus and release 
into the cytoplasm is accompanied by a stepwise dismantling of the capsid, 
leading to the microtubuliassisted transport and finally very efficient delivery of 
the core protein-coated viral genome to the nucleus [45]. 
 
Figure 1.3: Human Adenovirus type 5 genome. 
(Source: ViralZone:www.expasy.org/viralzone, Swiss Institute of Bioinformatics) 
 
The structural organization of the AdV genome is depicted in (Figure 1.3). 
The first Ad gene to be expressed is the immediate early E1A gene encoding a 
transactivator for the transcription of the early genes E1B, E2A, E2B, E3 and E4, 
as well as protein functions involved in cellular transformation, together with 
an E1B protein. The E2 region encodes for proteins required for viral DNA 
replication: DNA polymerase, DNA-binding protein and the precursor of the 
terminal protein. Replication of the viral genome, which depends on ‘‘inverted 
terminal repeats’’ (ITRs) of 100–140 bp in length at both ends as cis-acting 
elements (origin of replication) and one copy of the terminal protein (TP) 
covalently attached to each 5’ end as initiation primer, starts about 5–6 h after 
infection. Core and capsid proteins and a cysteine protease important for 
proteolytic trimming of TP and other structural proteins are expressed from a 
common major late promoter after sophisticated splicing of long precursor 
transcripts. Intranuclear virion assembly starts about 8 h after infection and 




 progeny particles per cell which can be 
released after final proteolytic maturation by cell lysis 30–40 h post-infection, 




3.2. Adenovirus vectors 
Recombinant AdV vectors provide a highly versatile system for mammalian 
gene transfer and are widely used in vaccine development and in a variety of 
gene therapy applications, particularly for gene-based therapy of cancer, 
including immunotherapy (Table 1.6).  
 
Table 1.6: Applications of Adenovirus vectors. 
Gene therapy in the treatment of cancer  
          (i) tumour suppressors 
          (ii) oncolytic and sensitizing drug therapy 
          (iii) vaccines 
Gene therapy for genetic diseases 
           e.g. Cystic fibrosis 
Supplementary therapy  
           e.g. neurodegenerative diseases such as Parkinson's 
Production of proteins 
Adenovirus recombinant vaccines 
 
These applications are facilitated by several important advantages of AdV 
over other vectors, including (1) convenient and simple methods of vector 
construction, (2) efficient transduction of proliferating and quiescent cells, (3) 
efficient production to high yields, in well-defined cell systems, and (4) high 
stability, allowing purification and long-term storage (Table 1.4, page 12). 
The human adenovirus type 2 and 5 are the most used vector backbones 
for adenovirus-mediated gene transfer. Foreign DNA can be inserted in at least 
three regions of the adenoviral genome: E1, E3 and the short region between 
E4 and end of genome. The first generation of adenoviral vectors has deleted 
E1 and/or E3 regions, which severely impaired their ability to replicate. Deletion 
of the E1 region impairs viral replication while deletion of the E3 region 
provides additional free space. Even in the absence of E1 genes first generation 
AdV vectors are still able to replicate at very low levels, thereby inducing a 
cellular immune response which is the major impediment to the use of these 
vectors. Even though anti-AdV antibodies existing in most humans pose an 
obstacle to readministration of AdV, these vectors can be used for application 
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where short-term gene expression is required, such as in cancer gene therapy 
and vaccination. The second and third generations of AdV vectors have deleted 
E1, E2 and E4 coding sequences [46]. They are less immunogenic than the first 
generation vectors and provide a larger capacity for transgene insertion [47] 
[48] [49]. Fourth generation AdV vectors, also called “high capacity” or “gutless” 
vectors contain only ITR repeats and a packaging signal and can accommodate 
up to 37 kb of foreign DNA [50, 51]. After entering the nucleus, AdV DNA 
persists episomally without inserting into host genome [51], thus providing 
only transient expression of the transgene. Such expression is nonetheless 
adequate for cancer gene therapy, where the final goal is to kill the tumor cell 
[46].  
Currently, AdV vectors are being tested as subunit vaccine systems for 
numerous infectious agents ranging from malaria to HIV-1 (Table 1.7). 
Additionally, they are being explored as vaccines against a multitude of tumor-
associated antigens. They are attractive vaccine vectors as they induce both 
innate and adaptive immune responses in mammalian hosts.  
 
Table 1.7: Adenoviral vector vaccines in development for human and veterinary use. 
Human Ref. Veterinary Ref. 
Plasmodium falciparum [52] Avian Influenza virus [53] 
Mycobacterium Tuberculosis [54] Mycobacterium Tuberculosis [55] 
Influenza virus [56] Foot-and-mouth disease virus [57] 
HIV-1 [58] PPR virus [59] 
Hepatitis C virus [60] Rabbit Hemorrhagic Disease virus [61] 
Measles virus [62] Classical Swine Fever virus [63] 
Seoul virus [64] Infectious Bronchitis virus [65] 
Rift Valley Fever virus [66] Rabies virus [67] 
Japanese Encephalitis virus [68] Rift Valley Fever virus [66] 







4. Peste des petits ruminants 
Peste des petits ruminants (PPR) is a highly contagious and economically 
important viral disease affecting goats, sheep and wild ruminants. It is 
characterized by high fever, ocular and nasal discharges, pneumonia, necrosis 
and ulceration of the mucous membrane and inflammation of the gastro-
intestinal tract leading to severe diarrhea [73]. Morbidity and mortality rates 
vary but can be as high as 100 and 90%, respectively.  
The disease caused by PPR virus (PPRV), commonly referred to as ‘‘PPR’’, 
was first reported from West Africa in the early 1940s and was later (1962) 
found in Senegal and subsequently recognized as being endemic in west and 
central Africa (1981). It has also been reported in Sudan (1984) and in east 
Africa in Kenya and Uganda (1995) and in Ethiopia (1994). PPR was first 
reported in 1987 in southern India, where it caused epidemics for several years 
without apparent further spread. The Arabian Peninsula, the Middle East and 
the remaining parts of the Indian sub-continent were swept by an epidemic of 
PPR in 1993–1995. Since then the disease has remained endemic in most of 
these regions and on much of the Indian sub-continent [74]. Figure 1.4 shows 
the current known distribution of PPRV.   
 
 
Figure 1.4: Peste des Petits Ruminants distribution map for Jan-Jul 2015. 
(Source: World Organization for Animal Health, http://www.oie.int/) 
 
 
4.1. Peste des Petits Ruminants Virus Biology 
PPRV is classified in the Morbillivirus genus from the Paramixoviridae 
family along with other important animal and human pathogens like rinderpest 
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virus (RPV), measles virus (MV), canine distemper virus (CDV), phocine 
distemper virus (PDV) and dolphin morbillivirus (DMV) [73, 75].  
PPRV virions, as the other morbilliviruses, are enveloped particles 
containing a single strand RNA of negative polarity (Figure 1.5). The genome is 
composed of 15,948 nucleotides. Most viruses in this genus are spherical, and 





Figure 1.5: Morbillivirus molecular biology. A. Virion; B. Genome.  
(Source: ViralZone:www.expasy.org/viralzone, Swiss Institute of Bioinformatics) 
 
This genomic RNA is wrapped by the nucleoprotein (N) to form the 
nucleocapsid into which are associated two other viral proteins: the 
phosphoprotein (P) and the large protein (L). The phosphoprotein is the co-
factor of L, the viral RNA dependant RNA polymerase (RdRp). To the viral 
envelope which derives from the host cell membrane are associated three viral 
proteins: the matrix protein (M) which is located inside the envelope and serves 
as a link between the nucleocapsid and the two external viral proteins, the 
fusion protein (F) and the haemagglutinin (H). By this position, M plays an 
important role in ensuring efficient incorporation of nucleocapsids into virions 
during the virus budding process. The haemagglutinin allows the virus to bind 
to the cell receptor during the first step of the viral infection process. This 
binding is followed by the fusion of the viral envelope with cell membrane, a 
process mediated by F and this leads to the delivery of the nucleocapsids into 




and their functions, both F and H are very important for the induction of 
protective host immune response against the virus and most of the neutralizing 
antibodies are directed against H. However N, the most abundant and also the 
most immunogenic among PPRV proteins, does not induce protective immunity 
against the virus [76]. 
PPRV isolates can be grouped into four distinct lineages on the basis of 
partial sequence analysis of the fusion (F) protein gene. Lineages 1 and 2 are 
found exclusively in West Africa while lineage 3 has been found in eastern 
Africa (Ethiopia), Arabia (Oman, Yemen) and in southern India (Tamil Nadu). 
The fourth lineage is confined to exclusively the Middle East, Arabia and the 
Indian sub-continent [77].  
 
4.2. Peste des Petits Ruminats Vaccines 
Vaccination against PPR is an effective means of controlling the disease. 
Heterologous rinderpest vaccine was used for many years to control PPR 
disease. However, after the eradication of rinderpest, it was necessary to 
restrict the use of this vaccine.  
The first attenuated vaccine developed against PPR involved using the 
lineage I African isolate, Nigeria 75/1 through serial passages on Vero cells 
[78]. Several trials have demonstrated the efficacy of this vaccine on more than 
98,000 sheep and goats in the field between 1989 and 1996. During those 
trials no unwanted side effects such as abortion in pregnant animals were 
recorded. It was demonstrated also that animals vaccinated with this 
attenuated PPRV were unable to transmit the challenge virus to in-contact 
animals. Anti-PPRV antibodies generated by vaccinated animals last for at least 
3 years, the effective economic life of the animals. PPRV Nigeria 75/1 belongs 
to lineage I. During the development process of the attenuated vaccine based 
on this virus, different PPRV strains were used as challenge viruses and all 
failed to induce disease in the vaccinated animals, result demonstrating the 
potential worldwide effective use of this vaccine to control PPR.  
Subsequently, three more attenuated vaccines were developed in India by 
using the lineage IV Indian isolates. Since lineage IV is mostly restricted to 
Asian countries, the use of Nigeria 75/1 vaccine in Asian countries may 
increase the likelihood of mixing up of lineages and the development of 
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mutants with high virulence. Thus, it is imperative to consider using the 
lineage-specific vaccine available for use in Asian countries. To this effect, a 
live-attenuated Vero cell-adapted vaccine against PPRV, Sungri/96 vaccine, was 
developed by the IVRI. The Sungri isolate was adapted in Vero cells and was 
found to be attenuated fully at 59 passages (P-59). This vaccine has been 
tested extensively both experimentally as well as in the field and has been 
found to be safe and potent in small ruminants. The third and fourth 
conventional live-attenuated vaccines were PPRV Arasur 87 (sheep origin) and 
Coimbatore 97 (goat origin), respectively, which were developed by TANUVAS. 
These vaccines are being used in southern states of India. They are also as 
equally safe and protective as Sugri 96 in sheep and goats and have potential 
for commercial vaccine production [79]. 
The attenuated homologous PPRV vaccines are now the only vaccines 
permitted for use in sheep and goats to protect them against PPRV infections 
[76]. The PPR available vaccines are summarized in Table 1.8. 
 Nowadays these vaccines are produced in Vero cells using classical 
techniques, i.e. in T-flasks or roller bottles. These strategies involve high 
efforts concerning consumables and have limited scalability, significantly 
increasing the bioprocess costs. Thus there is a need for better vaccine 
production processes for controlling future PPR outbreaks.  
Alternative PPR vaccines are under development to counteract the major 
disadvantage when using classical live attenuated vaccine is that the antibody 
responses they induce in animals cannot be distinguished from those following 
a natural infection (Table 1.8). 
This makes sero-epidemiosurveillance of the disease impossible in endemic 
areas where a vaccination programme has been or is being implemented. A way 
to combine activities, vaccination and serosurveillance, for the better 
management of the disease would be the use of DIVA vaccines, the acronym 
used for vaccines which enable differentiation between infected and vaccinated 
animals. Originally this term was applied to gene-deleted marker vaccines for 
large DNA viruses when used with their vaccine specific serological tests, but it 
can also apply to subunit vaccines, heterologous vaccines or some killed whole 




which is used in conjunction with non-structural protein-based serological 
tests. It can be used also for recombinant-based vaccines [76]. 
Table 1.8: PPR available vaccines. 





Botswana Vaccine Institute PPR-VAC® Live Nig 75/1 Botswana 




Live Nig 75/1 Turkey 
Dollvet Pestdoll-S Live Nig 75/1 Turkey 
Intervac (PVT) Ltd. Pestevac Live Nig 75/1 Pakistan 






















National Veterinary Institute 
Peste des Petits 
Ruminants 
Vaccine 
Live Nig 75/1 Ethiopia 
Nepal Directorate of Animal 
Health 
Peste des Petits 
Ruminants 
Vaccine 
Live Nig 75/1 Nepal 
Vetal Company Pestvac K™ Live Nig 75/1 Turkey 
Indian Veterinary Research 
Institute (IVRI) 
PPRV Sungri/96 Live Sungri 96 India 
Tamil Nadu Veterinary and 
Animal Sciences University 
(TANUVAS) 
TN MIB /87 Live Arasur 87 India 










Live Egypt 87 Egypt 
Merck Animal Health OVILIS® PPR Live Sungri/96 n.a. 
Hester Biosciences Limited 
PPR Vaccine - 
Sungri 96 
Live Sungri 96 India 
PPR Vaccine - 
Nigerian 75/1 
Live Nig 75/1 India 
Indian Immunologicals Limited Raksha PPR Live Sungri 96 India 
National Veterinary Research 
Institute 
Peste des Petits 
Ruminants 
Virus Vaccine 
Live PPR V 75/1 Nigeria 
(Sources: The Center for Food Security and Public Health, http://www.cfsph.iastate.edu ; MSD 
Animal Health, http://www.merck-animal-health.com; [80]) 
 
Table 1.9: PPR new candidate vaccine types. 
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Vaccine Type Characteristics Ref. 
Viral vector 
Recombinant vaccinia virus 
(rVV) 
rVV  simultaneously expressing F and H proteins 
of rinderpest virus (RPV) 
[81] 
Modified Vaccinia virus 
Ankara virus (MVA) 
MVA expressing either H or F protein of PPRV [82] 
Recombinant capripoxvirus 
(rCPV) 
rCPV expressing either F or H protein of RPV [83] 
rCPV expressing H protein of PPRV [84] 
rCPV expressing F protein of PPRV [85] 
rCPV expressing either H or F protein of PPRV [86] 
rCPV expressing either H or F protein of PPRV [87] 
Recombinant canine 
adenovirus type-2 (rCAV-2) 
rCAV-2 expressing H protein of PPRV [59] 
Recombinant human 
adenovirus type-5 (rHAV-5) 
rHAV-5 expressing either F or H protein of PPRV [88, 89] 
Recombinant adenovirus 
(rAdV) 
rAdV expressing H and F proteins of PPRV [90] 
rAdV expressing H protein of PPRV [91] 
Chimeric virus 
Chimeric baculovirus (BV) 
Chimeric BV carrying a membrane bound form of 
H protein of PPRV 
[92, 93] 
Chimeric BV carrying immunodominant 
ectodomains of F protein of PPRV 
[94] 
Reverse genetics 
Recombinant peste des 
petits ruminants virus 
(rPPRV) 
rPPRV expressing green fluorescent protein (GFP) [95] 




H protein subunit vaccine 





VLP composed of PPRV M and H (or F) proteins [98] 
Nucleic acid 
Suicidal DNA vaccine 
Recombinant pSCA1 plasmid expressing H protein 
of PPRV 
[99] 
(Source: Adapted from: [100]) 
 
Following the DIVA approach, the F protein of PPRV was inserted into the 
genome of an attenuated capripox virus vaccine [85]. The resulting 
recombinant virus expressed the PPRV F protein on the surface of infected 
cells, which was recognized by an anti-F monoclonal antibody. This 
recombinant was then tested in goats and shown to be effective in protecting 




which expressed the PPRV H protein was also produced and it is effective at a 
minimal dose of 10 pfu [84]. Another recombinant PPRV vaccine has the 
rinderpest vaccine virus genome as the backbone into which the matrix (M), the 
F and H protein genes of RPV were replaced by those of PPRV. The resulting 
chimeric virus proved to be a safe and effective vaccine which could protect 
goats against virulent challenge with PPRV [101]. A recombinant Canine 
Adenovirus type 2 expressing the H gene of PPRV was generated in MDCK 
transfected and used to immunize goats. All vaccinated animals produced 
antibodies upon primary injection that were effective in neutralizing PPRV in 
vitro [59]. 
  
5. Virus production process 
A virus production process compromises four main steps (Figure 1.6).  
Since viruses only grow within living cells, viruses for therapeutic applications 
are propagated in cells (e.g. in chicken eggs) or in continuous cell lines (e.g. 
Vero cells). Once the virus has been propagated, it must then be isolated from 
the cells and the cell-culture medium. This may be achieved by several 
techniques including chemical lyses of the cell, centrifugation and filtration, or 
homogenization. 
 
Figure 1.6: The four steps in viral production. 
 
 The next step, purifying the virus, may likewise involve multiple techniques 
of centrifugation, ultra-filtration or chromatography, or chemical purification. 
At this stage, viruses may also be chemically inactivated for killed vaccine 
preparations. Then the viral preparation is formulated by mixing it with the 
constituents that allow each dose to be safely delivered in the right 
concentration. This is the point where the product may also be combined with 
other antigens (e.g. combined vaccines like the measles–mumps-rubella 
vaccine). The formulated product is filled in vials or syringes. Some vaccines or 






An animal cell-based bioprocess for virus production has the particularity of 
constituting a system where the cell physiology is often sharply modified and 
redirected by the virus infection. It differs considerably from a cell-based 
recombinant protein synthesis that constitutes ultimately a consequence of a 
stable cell physiological state. As a consequence, parameters for a virus 
production bioprocess establishment have to be worked out by studying both, 
the cell growth and the virus replication steps. 
The production of viruses encompasses several bioengineering challenges 
(Figure 1.7) that must be carefully addressed in order to improve up- and 
downstream processing with the final goal of maximizing performance and 
reducing production costs. In general, all virus culture processes start by 
growing the cell line of choice to the desired cell concentration for infection.  




Figure 1.7: Upstream process parameters that influence quality and quantity of virus 
production. (Source: [102]) 
 
In some cases virus production can be obtain, not by infection but by 
transfection of cells with plasmids containing the all the viral components (e. g. 
lentivirus [103] or AAV vectors [104]) or by packaging cell lines that 




293 FLEX [16] and Flp293A [17] developed for retrovirus production. In here it 
will be focused mainly in the processes performed by viral infection. 
 
 
5.1.1. Cell lines for Viral Vaccine production 
Virus productions were initially performed using the natural host of the 
virus. Upon the establishment of cell culture technology in 1950s, animal cell 
cultures gradually replaced live animals in the preparation of viral antigens for 
vaccine. The observation by Enders and co-workers [105] that non nervous 
tissue culture could be used to replicate and produce poliovirus paved the way 
to large scale production of vaccines. This discovery led to the development of 
the first commercial product generated using mammalian cell cultures (primary 
monkey kidney cells), the poliovirus vaccine. Regrettably, primary monkey 
kidney cells presented many drawbacks such as the relatively high risk of 
contamination with adventitious agents (contamination by various monkey 
viruses), shortage of donor animals, use of endangered animals as cell source, 
use of non or insufficiently characterized cell substrates for virus production, 
limited expansion and obligatorily adherent cell growth [106-109]. In the 
1960s, human diploid fibroblast cells, WI-38 [110] and MRC-5 [111], and baby 
hamster kidney cells (BHK-21 (C13)) were established and used for the 
production of a vaccine against rabies virus [112] and foot and mouth disease 
[113], respectively.  
The manufacturing capability for viral vaccines produced in embryonated 
eggs and conventional/ classical cell substrates, such as chicken embryo 
fibroblasts, has now reached its capacity limit.  This constraint may be 
overcome by utilizing other recognized cell substrates such as Madin Darby 
Canine Kidney (MDCK) (dog origin), Chinese Hamster Ovary (CHO) (hamster 
cells) or Vero cells (monkey origin) or as an alternative, introduce new cell 
substrates of human or avian origin. Using new cell substrates may prove to be 
a highly replication-proficient way of producing live viral vaccines such as 
Influenza A viruses. 
The Vero cell line was the first continuous mammalian cell line, established 
from African green monkeys in 1962, and is currently the most widely accepted 
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by regulatory authorizes for vaccine development due to the fact that Vero-
derived human vaccines have been in use for nearly 30 years (Table 1.10).  
 
Table 1.10: Some Human viral licensed vaccines produced in cell lines. 
Vaccine name Manufacture Tradename 
Cell Line for 
production 





Hepatitis A Vaccine, 
Inactivated 
Merck & Co., Inc. VAQTA MRC-5 
H5N1 pandemic influenza 
vaccine, inactivated 
Baxter AG Preflucel Vero 
Japanese Encephalitis Vaccine, 
Inactivated, Adsorbed 
Intercell Biomedical IXIARO Vero 
Measles Virus Vaccine Live Merck & Co., Inc. ATTENUVAX chick embryo cell 
Measles, Mumps and Rubella 
Virus Vaccine, Live 
Merck & Co., Inc. M-M-R II 
chick embryo cell 
chick embryo cell 
WI-98 
Measles, Mumps, Rubella and 
Varicella Virus Vaccine Live 
Merck & Co., Inc. ProQuad 
chick embryo cell 
chick embryo cell 
WI-98 
MRC-5 
Poliovirus Vaccine Inactivate Sanofi Pasteur, SA IPOL Vero 
Rabies Vaccine Sanofi Pasteur, SA Imovax MRC-5 
Rotavirus Vaccine, Live Oral GSK Rotarix Vero 
Rotavirus Vaccine, Live Oral Merck & Co, Inc. RotaTeq Vero 
Smallpox (Vaccinia) Vaccine, 
Live 
Acambis Inc. ACAM2000 Vero 
Varicella Virus Vaccine Live Merck & Co, Inc. Varivax MRC-5 
Zoster Vaccine, Live Merck & Co., Inc. Zostavax MRC-5 
(Adapted from: [6]) 
 
Currently, there are several human viral vaccines licensed using cell 
substrates (see Table 1.10) or under clinical trials such as the Influenza vaccine 
produced using Vero [114-116], MDCK [117, 118] or PER.C6 [119, 120] cells 
amongst others [121]. Despite these significant advances in vaccine 
manufacturing, there are vaccines still produced in eggs such as the recently 
approved Influenza A (H1N1) 2009 monovalent vaccines from CSL, Medimmune 
LLC or Novartis Vaccines and Diagnostics.  
Novel cell substrates originate predominantly from avian and human (or 




HEK293 cells, PER.C6 cells and CAP cells. These human cell lines were 
developed by transforming or stably transfecting human embryonic kidney cells 
(HEK293), human embryonic retinal cells (PER.C6), and primary human 
amniocytes (CAP, from CEVEC) with the early region 1 (E1) of adenovirus type 5 
(AdV5) [122-125]. Due to its glycosylation machinery, human cell lines have 
also emerged as a new and powerful alternative for the production of human 
therapeutic proteins. Biopharmaceutical companies and researchers are 
evaluating the best expression system to produce human recombinant proteins 
and today most companies are considering the clinical, quality, and 
productivity implications of their expression system selections.  
Nowadays, additional novel cell substrate of avian origin are available such 
as the duck embryonic stem cell line EB66 [126] or the CR (Cairina Retina) cell 
line derived from muscovy duck retinal tissue. The CR cell line was 
subsequently transfected with AdV5 E1-genes and AdV5 pIX gene resulting in 
AGE1.CR.pIX. AGE1.CR.pIX also supports replication of the Vaccinia Virus 
MVA85A, giving rise to high yield of this increasingly popular live attenuated 
vaccine strain [127, 128]. 
 
 
5.1.2. Cell lines for Adenovirus production 
The most common and well documented packaging cell line for adenovirus 
production is the HEK293 cell line, which contains the E1 region of the 
adenovirus [122]. Homologous recombination between the left terminus of 
first-generation adenovirus vector or helper-virus DNA and partially overlapping 
E1 sequences in the genome of HEK293 cells normally lead to the generation of 
replicative competent adenoviruses (RCA) [129]. The presence of RCA is clearly 
undesirable as they may replicate in an uncontrolled manner. In recombinant 
adenovirus batches to be used in human patients, RCA is potentially 
hazardous, especially in immuno-compromised patients, being associated to 
inflammatory responses [130]. The FDA guidelines demand the presence of 
less than 1 RCA in 3x10
10
 vector particles for clinical applications (Biological 
Response Modifiers Advisory Committee, 2001). 
Alternative host cell lines have been developed to overcome this problem 
either by reducing the overlapping sequences or by eliminating any overlap, as 
is the case of N52.E6 cells [123] and PER.C6 cells [125]. The PER.C6 cell line, 
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derived from human embryonic retinal cells, licensed by Crucell, The 
Netherlands, has been established for industrial applications (e.g. full 
traceability available) due to its reduced propensity to generate RCA and its 
capacity to achieve high yields of adenovirus vectors. Much of the industrial 
development of PER.C6 has been driven by collaboration between Crucell and 
Merck & Co. for the generation of an Ad vector-based vaccine against HIV 
infection. Due to commercial reasons the PER.C6 cell line is currently not freely 
available to the research community.  
Human amniocytes were identified as an alternative cell source for the 
reproducible generation of stable cell lines following transformation with E1 
functions [123] and E1/pIX genes [124]. The design of the transforming 
plasmid construct in one of the cell lines (N52.E6) was similar as in PER.C6 cells 
[123], in principle excluding the generation of RCA due to the absence of any 
sequence overlap between vector DNA and the integrated E1 region. Production 
yields of AdV vectors in N52.E6 cells have been high. Because of legal reasons 
this cell line is currently not distributed.  
There have been additional attempts to generate production cell lines for 
AdV vectors. Unlike the cell lines discussed above, they all were based on 
established cell lines such as HeLa and A549 cells [131-134]. To our knowledge 
these cell lines have not been distributed broadly. One of the cell lines, 
developed by Farson and colleagues [134], was generated by retrovirus-
mediated gene transfer without antibiotic selection, having the E1A and E1B 
expression constructs on different retroviral vectors. In principle, this design 
could reduce the generation of HDEPs that have been observed in PER.C6. In a 
similar approach, E1A and E1B functions were consecutively introduced by 
plasmid transfection/selection into A549 cells [135]. To prevent E1A-mediated 
apoptosis the E1A construct contained small deletions within the E1A coding 
region resulting in the removal of amino acids 4 to 25 and 111 to 123 from the 
E1A proteins. In A549 cells expressing this mutant form of E1A, expression of 
the E1B 55K protein was sufficient for efficient transcomplementation of AdV 
vectors while expression of the E1B 19K protein inhibiting E1A-induced 





Another disadvantage of human adenoviral vectors is their limited clinical 
use; 90% of the population has developed pre-existing humoral and cellular 
immunity to those vectors [18]. Sustainable platforms for the generation of 
vectors from different human serotypes or derived from non-human adenovirus 
at similar or greater titers than those obtained with human adenovirus vectors 
and free of detectable levels of RCA are required [20, 21]. One example is the 
production of canine adenovirus type 2 (CAV-2) vectors in dog kidney cells [18, 
19]. With these vectors, the risks associated with RCAs are diminished, if not 
completely eliminated, because CAV-2 does not propagate in human cells; also, 
CAV-2 transduces human-derived cells at an efficiency similar to that of human 
adenovirus type 5, and are amenable to in vivo use [18]. Novel cell lines for the 
production of these CAV-2 vectors are under evaluation, with emphasis in 
MDCK cells [136, 137]. 
 
5.1.3. Cell growth conditions and viral infection 
Production methods differ according to the cell type used: adherent or 
suspension cell culture. Adherent cell lines have shown a higher cell specific 
productivity compared to suspension-adapted cell lines [138]. Nevertheless, 
surface requirements for cell growth make these processes difficult to scale up 
to large volumes and high cell densities. The use of roller bottles and cell 
factory systems for cell cultivation offer a large surface for cell growth. Scale-up 
is linear and up to 10 cell factories have been used to produce AdV within the 
HEK293 cell line. Specific productivity was maintained high with active gassing 
and 8×10
3
 infectious particles (ip)/cell were achieved [139]. Roller bottles have 
been also used for the cultivation of Vero cells and the production of rabies 
virus [140] and PPR virus [141] amongst others.  
A great step towards the establishment of high-concentration cell cultures 
and industrial bioprocesses was done by the cell cultivation on suspended 
beads, named microcarriers. Batches of 6000L Vero cell cultures [142] on 
microcarriers can be performed in bioreactors in serum-free medium, with no 
loss in productivity, and have been used for the production of vaccines as 
rabies and poliomyelitis [114]. Several types of microcarriers have been 
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evaluated for cell culture and virus production, from macroporous [143] to 
solid matrices [144, 145].  
Microcarriers also offer a better scalable solution to for the production of 
AdV with adherent cell lines; with Cytodex-1 and Cytodex-3 microcarriers up to 
1.5 × 10
4
 ip/cell have been produced in spinner flasks whereas 2×10
4
 ip/cell 
have been produced in small-scale static cultures [146]. Iyer et al. have 
demonstrated that specific productivity was similar using Cytodex-3 
microcarriers in serum containing cultures and in suspension serum-free 
culture in a bioreactor [138]. However, recovery of virus from the cells attached 
to microcarriers is cumbersome, requiring cell detachment from the 
microcarriers by trypsinization. 
Suspension cell lines are better suitable for large scale production since 
they avoid the use of microcarriers facilitating viral production processes 
(Table 1.11). 
Table 1.11: Engineering Challenges for Cell Cultivation Methods Microcarriers Free Cell 
Suspension. 
Microcarriers Single Cell Suspension 
Anchorage dependent cells. 
Cell expansion often occurs in roller-flasks 
prior to bioreactor. 
Cells grow in single cell suspension. 
Culture is homogenous and sampling is 
easy. 
Process is simple, scalable and robust. No 
additional factors or proteins are 
necessary for adhesion or expansion. 
Costs are lower. 
Major Challenges Major Challenges 
 Shear stress and mixing 
adaptation of stirrer speed for 
attachment. 
 Sub-passages. 
 Longer lag phase. 
 Microcarrier preparation (swelling 
and autoclaving). 
 Trypsin/or other detachment 
agent for cell-passaging. 
 Increase volume. 
 Lengthen cell-culture lead time. 
(adapted from [147]) 
 
 HEK293 cells have been adapted to suspension and are widely used for the 
production of AdV [102], lentivirus [103], adeno-associated virus [104] and 
have been also evaluated for the production of influenza virus [148]. PER.C6 
cells were also exploited for the manufacture of classical vaccines including 




 Recently, Vero cells [149] and MDCK cells [150] have been able to adapt to 
suspension which constitute valuable information for the development of a low-
cost high-productivity process using a suspension culture of Vero cells to 
produce viral vaccines. 
Different operation modes have been developed to achieve high titer yields 
for virus production: (i) the batch mode provides the easiest approach as no 
extra feeding is required and the risk of contamination is lower, given the 
simplicity of operation; (ii) the fed-batch mode is easy to operate and readily 
scalable; it is primarily used to extend culture lifetime by supplementing 
limiting nutrients and/or reducing the accumulation of toxic metabolites; and 
(iii) the perfusion mode consists in retaining the cells leading to a higher cell 
concentration inside the bioreactor, while fresh medium is supplied, allowing 
replenishing of nutrients and removal of toxic metabolites (Figure 1. 8). 
 
 
Figure 1. 8:  Modes of culture operation. Source: ([151]) 
 
The optimization of culture media for animal cell cultures, has received a 
lot of interest for many years owing to its critical impact on the development of 
bioprocesses based on animal cell technology.  Many attempts have been made 
to replace serum and to design serum-free media [138, 152-155]. Serum 
contains thousands of beneficial components, including growth factors, 
cytokines, hormones, attachment factors, essential nutrients such as trace 
elements and other unknown components promoting cell survival and 
proliferation in vitro. Nevertheless, the use of animal sera shows many 
shortcomings such as the potential introduction of animal-derived proteins and 
contaminants (e.g., fungi, bacteria, viruses, or Bovine Spongiform 
Encephalopathy (BSE) agent), a non-defined composition, a variable quality and 
a high cost. Moreover, the presence of serum in culture medium complicates 
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downstream processing. Various formulations of serum-free and animal/human 
protein-free media are commercially available for the cultivation of several cell 
lines. 
Large-scale manufacturing processes typically use fully controlled stirred 
tank bioreactors, which allow not only monitoring but also controlling several 
the culture parameters like pH, DO and temperature, for both microcarrier and 
suspension culture. Overall, the ideal production process for a therapeutic 
product should meet several acceptance criteria: i) use of safe cell lines; ii) use 
of animal component-free culture medium and iii) rapid production process 
that yields high concentrations of the product in a cost effective way. The 
expected virus productivity (cell-specific and volumetric) depends on the overall 
virus and the cell line used to propagate it.  
New trends for the use disposable culture-ware like Wave® [156] show 
numerous advantages for GMP production, such as avoiding the need for 
validated cleaning and sterilization. This makes this type of bioreactor the 
method of choice, providing that a manageable number can be used to produce 
the desired amount of viral particles.  But scaling vaccine production requires a 
significant investment in time and money. Even for relatively simple processes, 
like vaccine packaging, up to 2 years may be required to install and validate 
new packaging machinery. Building a new manufacturing facility takes on 
average 5 years to complete and validate with regulatory authorities.  
 
5.1.3.1. Infection 
Process-related parameters such as the multiplicity and time of infection 
(MOI and TOI, respectively), time of harvest (TOH) and cell concentration at 
infection (CCI) strongly influence virus productivities. Adequate MOI, defined as 
the number of virus particles per cell at the time of infection, is determinant for 
attaining optimal yields; the lowest possible MOI is desired to avoid rapid 
depletion of costly and certified master virus banks and to ensure that the 
infection kinetics is reproducible between different production scales.  
The optimum MOI is dependent on the virus seed properties and virus 
construct. The seed properties to consider include: the ratio of total to 
infectious particles (tp/ip ratio), the stability of the virus during storage and 




the measurement of virus particles is defined by the specific assay format and 
the specific standard used. Different laboratories use different methods, which 
frequently make the direct comparison of MOIs from one system to the other 
difficult or even impossible. The optimal MOI is determined for each system to 
ensure that the cells are infected with an adequate number of viral particles for 
maximum volumetric virus productivity.  
Because AdV infections are rapid (a regular infectious cycle takes about 48 
hours) and lytic, processes are usually configured as single-round infections 
with MOI >1 to ensure all that cells are infected. For AdV cultivation processes, 
a MOI of 5–200 virus particles/cell (vp/cell) is typically used, resulting in an 
amplification ratio usually higher than 200 in HEK293 [157, 158] and PER.C6 
cells [159, 160]. On the other end enveloped virus have different infection 
cycles, (released by budding from the cells), the MOI used for this type of virus 
are inferior, normally lower than 1, which takes several cycles of virus 
attachment, replication, and release before all cells in a culture are infected. In 
vaccine production processes at large scale the use of low MOI avoid the 
preparation and handling of large volumes of virus seeds. For influenza virus 
production in Vero and MDCK cells it is typically used a MOI of 0.001-0.5 [161-
163]. The same range of MOIs are also used for the production of Rabies virus 
in Vero cells [164] and BHK cells [165], the production of  Japanese encephalitis 
virus [166], parainfluenza virus type 3 (PIV3) and respiratory syncytial virus 
[167], among others. Recently, Yamada et al. reported the production of AdV 
with a very low MOI (0.001), however this requires several medium exchanges 
and the vectors are only collected 10 days-post infection [168].  
The harvest time depends on several factors, such as the virus itself and the 
cell line used. A medium that will sustain cell viability for longer periods will 
also improve the final titers. For lytic virus like AdV, because the titer is 
maximal when cell viability is still high, the time of harvest is generally in the 
range of 48–72 hours post infection (hpi). At this point the cells are harvested 
and further lyzed by freeze–thaw or by use of a detergent. In this way AdV has 
been preferably recovered in the intracellular fraction thus allowing a reduction 
of volumes in the downstream processing. For viral vaccine productions, with 
low MOIs, the harvest time is normally much longer ranging from 96 hours to 
more than 2 weeks depending on cell line and culture process used [169, 170]. 
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The virus then mainly recovered in the supernatant leading to high volumes to 
be handled in downstream. 
For production of influenza virus, rabies virus and others, in Vero, MDCK 
and other cells adherent cultures, several strategies have been applied to 
increase the cell concentration for infection and consequently virus 
productivity. The increasing the concentration of microcarriers [171], changing 
the type of microcarriers [143],  change the culture medium for infection [154], 
alteration of the culture mode [172, 173], were some of the strategies applied. 
The cell culture in serum-free and serum containing medium have been also 
evaluated on cell growth and viral productivity [152, 163, 167, 169]. Production 
of influenza virus in 1,200 L was possible with 5x10
6
 Vero cells in stirred tank 
bioreactor with Cytodex-3 microcarriers [161]. It has been showed that viral 
productivity was dependent upon the metabolic state of the cells rather than 
the phase of growth at which the cells were infected [174].  
Despite the fact that medium formulations, that allow maximum cell growth 
up to 3–9x10
6
 cell/mL for HEK293 and PER.C6, in serum-free media are 
available [157, 175, 176], optimal AdV production titers in batch culture cannot 
be achieved beyond a CCI of 5x10
5
 cell/mL. This is often referred to as the 
‘‘cell density effect’’. Garnier et al. demonstrated that growing cells to 
0.3-0.5x10
6
 cell/mL and infecting the cells will result in a good productivity 
[177]. Infection at 1x10
6
 cell/mL requires media exchange at the time of 
infection in order to maintain a similar specific yield. By implementing a media 
exchange at the time of infection, Zhang et al. (2001) have reported one log 
increase in their final volumetric productivity (pfu/mL) at day 6 in the 
supernatant [178], at a cell concentration of 1.5x10
6
 cell/mL. Liu and Shoupeng 
(2001) showed an improved infection when the cells are between 40% and 70% 
of cell maintenance phase [179]. Also the authors mention the importance of 
changing at least 90% of the medium at the infection time. It is generally 
accepted that infecting cells at 1x10
6
 cell/mL is the optimal cell concentration 
after medium renewal. Studies on the cell environment have permitted to 
enhance specific AdV productivity through better cell culture environment 
control (medium formulation and feeding strategies). These strategies have 
also been developed to increase the cell concentration at infection to ultimately 




productivity obtained at low cell concentration constant without feeding. The 
cell density effect describes a drop in the specific virus production when the 
cell concentration is above 0.5×10
6
 cell/mL [180]. 
The major hypothesis behind the cell density effect is that nutrient 
depletion and metabolite accumulation hinders cell metabolism and renders 
them unable to support viral production at high cell densities. Consequently, in 
order to improve substrate renewal and metabolite removal, production modes 
have gained in complexity from batch to perfusion system. Fed-batch strategies 
have failed to maintain a high specific productivity above 2×10
6
 cell/mL [177]. 
High cell concentration at high viability could only be attained using perfusion 
systems through a continuous renewal of medium. Compared to a batch cell 
culture infected at 0.5×10
6
 cell/mL with medium replacement, specific 
productivity has been maintained at 1.8×10
4
 virus vp/cell when infection was 
performed on a 3 L perfusion cell culture at ~3×10
6
 cell/mL, with 2–3 
volumes/day under serum-free conditions [181]. Up to 4.1×10
10
 vp/mL has 
been produced under these conditions. Cortin et al. (2004) have infected 8×10
6
 
cell/mL at 35 °C at 1 volume/day in 5% serum containing medium to produce 
~8×10
9
 ip/mL [182]. Production of replicating AdV vectors in HeLa cells has 
been successfully performed at infection densities of 5 to 14.6×10
6
 cell/mL at 
1.5–2 volumes/day, under serum-free conditions [182]. Productivities have 
reached 3–6×10
11
 vp/mL and 3–5×10
4
 vp/cell [183].  
Another avenue to explain the cell density effect has been studied by Zhang 
and co-workers [184]. They demonstrated that a decrease in the proportion of 
cells in S phase was also responsible for a decrease in specific productivity at 
high cell densities. Ferreira et al. chemically synchronized HEK293 cells at each 
phase of the cell cycle and a 2.6-fold increase in AdV cell specific titer was 
obtained when the percentage of cells at the S phase of the cell cycle was 
increased from 36% to 47% [185]. S phase synchronization was also obtained 
by decreasing the culture temperature to 31ºC during 67 hours and restoring it 
to 37ºC during 72 hours. By using this strategy they were able to synchronize 
57% of the population in the S phase of the cell cycle obtaining an increase of 
7.3-fold on AdV cell specific titer after infection. 
Besides the cell cycle phase of the cell, the specific metabolic requirements 
for both cell growth and virus production have been analyzed. Analysis of 
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central cell metabolism has permitted to identify differences in consumption 
and production rates during growth and infection [160, 186]. A favorable 
metabolic state for AdV production has been defined by an increase in 
glycolytic fluxes, in TCA fluxes and in ATP production rates upon infection 
[187, 188]. This state might be prolonged at higher cell densities if the feed 
rate is adjusted [188]. In better medium/feeding strategies, glucose enters 
more efficiently into the TCA cycle and glutaminolysis and amino-acid 
catabolism rates are reduced. Lower lactate and ammonia production rates 
have been consequently observed [188, 189]. Metabolic flux analysis is 
therefore useful to determine culture conditions resulting in enhanced 
productivity. It provides a basis for a rational approach to improve medium and 
feeding strategies, to design better cell lines with improved TCA activity and 
ATP production rates and to implement on-line control of such fluxes.  
 
5.1.3.2. Physical parameters 
Physical parameters such temperature, pH, dissolved oxygen (DO) and 
partial CO
2
 pressure should also be studied and optimized for each virus 
cultivation system.  
The optimum virus cultivation temperature can be different from the 
optimum cell growth temperature (37°C) and should be optimized. The 
decrease of temperature during virus infection has been applied for several 
virus production processes, mainly due to lower viral stability. Jardon and 
Garnier (2003) reported significantly increased virus productivity at 35°C 
compared to 37°C for the cultivation of AdV in HEK293 cells and temperature 
affecting also the cellular metabolism and the rate of cell death post-infection 
[190].  Several virus processes with Vero cells have been performed with shift 
to lower temperatures post-infection (35-33°C) to increase viral yields, namely 
hepatitis A virus [191], attenuated chimeric virus of parainfluenza virus type 3 
and respiratory syncytial virus [167]. However, some times the decrease of 
temperature has a detrimental effect on the type of virus produce, as in the 
case of retrovirus were the virus produced at 32°C were more unstable than 





The pH is another parameter that needs to be taking into account for cell 
growth and viral infection. For the production of Rabies virus in Vero cells for 
example, the pH used for cell culture (7.2) is changed to 7.4 during viral 
infection phase [193]. For the production attenuated chimeric virus of 
parainfluenza virus type 3 and respiratory syncytial virus, also in Vero cells, it 
was showed that cell growth and virus production were pH-independent at in 
the pH range of 7.0-7.4 [167]. Retrovirus production in the range 6.0 to 7.8  of 
pH levels revealed a significant decrease in virus titers at levels below 6.8 and 
above 7.2, optimum titers being achieved in cultures at pH 7.2 [194]. The pH 
effect on AdV production was evaluated in HEK293 cells showing no virus 
production at pH 6.7 and 7.7 but only at 7.2, with no effect on cell growth 
observed [190]. Xie et al. using PER.C6 cells found the optimal pH for AdV 
production to be 7.3 [195]. They observed under different pH conditions (6.8–
7.6) that cell metabolism in both infected and non-infected cultures was 
dramatically changed leading to significant differences in glucose/glutamine 
consumption and lactate/ammonium production. Ferreira et al. studied effect 
of ammonia accumulation on intracellular pH (pHi) and its consequent effect on 
AdV production showing that AdV volumetric productivities were lower when 
the cells were exposed to the lower pH (pHi 7.0) [196].  
There are only few published reports addressing the effects of other 
process parameters such as DO and pCO
2
 on virus cultivation. In most 
controlled processes for AdV and other virus, the DO is usually set at greater 
than 30% of air saturation [197]. For insect cells and VLP production with 
baculovirus it has been showed that, although the DO did not show a 
significant effect upon cell growth in the range from 10 to 50%, cell infection 
and specific productivity were dramatically affected. The production was 
optimal at a DO of 25% with decreases higher than 50% being observed when 
the DO decreased to 10 or increased to 50% [198]. For the production of Rabies 
virus or Hepatits A virus in Vero cells it has been used a DO for cell growth (40-
50%) and then a reduction of that value to (25-30%) during cell infection phase 
[191]. It has been reported for Vesicular Stomatis virus (VSV) production in Vero 
cells a decrease in viral productivity with an increase of the oxygen partial 
pressure due to an increase of the reactive oxygen species that increase the 
oxidation of the viral proteins [199]. Dissolved oxygen levels in the range 20-
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80% in retrovirus production experiments had no significant effect on titers 
[194]. 
  It has been showed In most cases pCO
2
 is not controlled and sometimes 
not even monitored, although Jardon and Garnier report a decrease in virus 
productivity with increased pCO
2
 [190]. 
Shear stress can also be an important variable for bioreactor operation due 
to its influence on cell growth and product expression. Owing to the lack of cell 
walls, animal cells are highly sensitive to hydrodynamic shear stress typically 
generated in stirred-tank bioreactor vessels (i.e. agitation mixing and bubble 
sparging). Cell injuries due to fluid-mechanical forces arise mainly from either 
the shear stress generated by hydrodynamic mixing or the cell-bubble 
interactions generated by air sparging. The hydrodynamic shear stress could 
inhibit culturing of anchorange-dependent cells on microcarriers [200], since 
the cells adhering to microcarrier surface are less robust to disperse fluid-
mechanical forces than the freely-suspended single cells.  
 
5.1.3.3. Process monitoring 
The success of a bio-product requires a controlled and monitored process 
and a well characterized product. For virus quantification, several assays have 
been developed such as plaque-forming unit (pfu) and tissue culture infectious 
dose 50 (TCID
50
) assays to determine the number of infectious virus particles, 
and optical absorbance measurement or electron microscopy (EM) to determine 
the number of total particles [201]. Other methods for quantification are based 
on flow cytometry [202], slot-blot analysis [203],  real-time Q-PCR [204, 205], 
and high performance liquid chromatography (HPLC) [206, 207], only some of 
which are suitable for in-process monitoring [208]. A very important step 
towards standardization and harmonization has been the development by the 
Adenovirus Reference Material Working Group (ARMWG) of an adenovirus 
standard [209] that is widely used by the industry. The Adenovirus Reference 
Material (ARM) is currently distributed through the ATCC. 
Typically, small-scale virus cultivation processes implemented in disposable 
culture-ware are monitored with off-line sampling. For these processes, process 
parameters such as pH are not typically controlled, and process definition is 




cultivation process. As the production scale increases, so does the need for a 
tighter process control. The cultivation of virus can be controlled by on-line 
monitoring methods to assure batch-to-batch reproducibility. Cell 
concentration at infection is a critical process parameter to ensure maximum 
and reproducible volumetric virus production. Although off-line methods can 
be used to monitor cell concentration, an on-line method to trigger the 
infection point is very useful for large-scale stirred tank bioreactor processes. 
The status of infection has been monitored using a variety of non-invasive on-
line measurements to provide useful information. Particularly, the oxygen 
uptake rate (OUR) and the capacitance signal have been correlated to viable cell 
growth prior to infection [181, 210]. At infection both signals are affected. An 
increase in respiration has been noted together with an increase in capacitance 
measurements [177, 181, 211]. This correlates well with an increase in cell 
metabolic activity and an increase in cell size upon infection. In an attempt to 
measure the kinetics of infection of a GFP-expressing AdV, a fluorescent probe 
has been designed by Gilbert et al [212]. This probe was used to monitor the 
AdV production kinetics and as a tool to identify the appropriate harvest time. 
At-line monitoring of GFP cells by flow cytometry has given valuable 
information on AdV production kinetics [213]. These monitoring tools have 
however been of limited success in providing indications on the relative 
efficiency of AdV productions. 
 
5.2. Purification 
The development of fast and efficient purification procedures that permit 
high recovery of infectious particles, removal of host cell proteins and DNA, 
clearance of unpackaged viral DNA and also concentration of virus formulations 
is essential for their use in vaccination and gene therapy. As impurities and 
contaminants can induce immunological and biological responses, they must 
be removed to comply with strict regulatory guidelines. The regulations for 
human bioproducts are much more rigorous than for animals. These increases 
the complexity of downstream processes, including polishing steps to make 
sure the viral product do not contain any detrimental element for human health 





Figure 1. 9: Virus purification steps. 
 
Viruses are quite large when compared with biomolecules such as proteins, 
peptides, glycoproteins, sugars and nucleic acids that are inevitably present in 
lysates harvested from virus-infected cells. In fact, viruses really should be 
considered molecular assemblies. While proteins typically range from 0.005 to 
0.08x10
6
 Da, viruses generally exceed 5x10
6
 Da and can have a size of up to 
1000 nm. Purification strategies based on viral size have included a variety of 
methods such as density-gradient ultracentrifugation, ultrafiltration, 
precipitation, two-phase extraction systems and size exclusion chromatography 
(SEC) [102, 214, 215]. High-speed preparative centrifugation 
(ultracentrifugation), using cesium chloride (CsCl) or sucrose gradients, has 
traditionally been used to process many viral vector preparations.  
Virus purification protocols that are more amenable to scale-up generally 
involve some type of chromatographic procedure. Adsorption of virus particles 
to solid phases, in fact, provides a convenient and practical choice for 
fractionating and recovering viruses from cell and media contaminants. While 
they are somewhat imperfect in their selectivity, adsorption methods do offer 
several important advantages in large-scale virus purification: (1) high flow 
rates can be used, thus limiting the processing time, (2) biological activity of 
labile viruses is often preserved, since mild conditions are generally used to 
elute the virus from the chromatographic matrix, (3) scale-up is relatively easy, 
(4) large volumes of cell lysates can be processed and (5) the cost of operation 
is relatively low. However, it is important to remember that the design of 
suitable selective chromatographic protocols for virus purification must take 
into account the structure and physical and chemical surface properties of the 
viruses [102, 214, 215].  
Purification is not within the scope of this thesis. For a more detailed 
assessment of the virus purification processes described in the literature it is 





5.3. Formulation and storage 
All vaccines are susceptible to damage by elevated temperatures and many 
are also damaged by freezing. The distribution, storage, and use of vaccines 
therefore present challenges that could be reduced by enhanced 
thermostability, with resulting improvements in vaccine effectiveness. 
Lyophilization has been the most successful approach used for the 
development of stable live virus formulations [216]. But when compared to 
refrigerated liquids they are at a clear disadvantage in terms of cost, 
complexity and ease of administration (Table 1.12). Despite the drawbacks of 
lyophilization it is usually required for long-term storage of live viruses. Frozen 
storage of liquid formulations is one alternative to lyophilization; however, this 
approach significantly increases the difficulty and cost of maintaining an 
effective cold chain during distribution.  
 
Table 1.12: Advantages and disadvantages of Liquid and Lyophilized formulations. 
Formulation Advantages Disadvantages 
Liquid 
- Convenient 
- Cost of goods (economical) 
- Competitive 
- Applicable to many commercially 
available delivery devices 
- Less stable than lyophilized 
formulations 
Lyophilized 
- More stable than liquid 
formulations 
- Can achieve higher concentration 
formulation 
- Cost of goods (expensive) 
- More complex process and 
technical transfer 




Historically, viral formulations have consisted of glycerol (10-50% v/v) in 
phosphate or Tris buffers with additions of other excipients such as salts, 
sugars and bovine serum albumin. It has been shown that the addition of 
cryoprotectants to viral suspensions (e.g. glucose, sucrose, sorbitol, and 
trehalose) decreases the loss of infectivity of viral vectors and enhances their 
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stability during freeze-drying and storage [217-219]; furthermore, pH is a 
critical factor for the maintenance of viral titers [220, 221]. 
To maintain the viral characteristics several formulations have been 
developed that allow the long term storage in liquid and lyophilized form [217, 
218, 222] from several months to more than one year in refrigerated 
conditions (2-8ºC). For more information on this topic we recommend the 
reading of the following references [223-226]. 
Besides the stability during viral vaccines storage, the process of 
production can also affect the final virus potency, as the stability of enveloped 
viruses can be compromised in cell culture bulks due to temperature. Previous 
studies from our laboratory have shown significant increase in the intrinsic 
retrovirus stability, when production was carried out at high concentrations of 
glucose or fructose [12]. It was also observed that, independently of the 
osmotic agent used, higher medium osmolalities enhanced retrovirus stability 
[13]. Ideally, stabilization approaches should be incorporated into vaccines 
early in the development process. 
Significant changes in the stability profile may occur following exposure to 
temperature stresses exerted through fluctuations in handling or storage 
conditions. The temperature sensitivity of vaccines has led to the development 
of cold chain requirements for all vaccines [227]. There was a great deal of 
interest in making vaccines heat stable and removing them from cold chain 
storage to facilitate outreach and to help manage the impending impact of the 
introduction of new vaccines in countries with limited cold chain capacity. 
There was also a growing body of evidence that cold storage facilities and 
transportation methods in both developing and industrialized countries often 
inadvertently expose vaccines to freezing temperatures [228].  
Because of this, the stability characteristics of each vaccine must be 
determined empirically through testing, and the storage and handling 
conditions be defined to ensure that, over the stated shelf-life of the vaccine, 





6. Scope of the thesis 
The work presented in this thesis focused on the development and 
improvement of new platforms for production of valuable virus products with 
impact on human and animal health.  
Different cell lines were assessed for the production of Adenovirus vectors 
(AdV) and Peste des Petits Ruminants virus (PPR) and the culture parameters 
affecting viral production were determined for each system. Moreover, since 
viral stability during shipping and storage is one of the main concerns for 
vaccine effectiveness, different approaches were also evaluated and applied to 
improve PPR vaccine stability.   
A schematic representation of the main aims proposed for this thesis, as 
well as the strategies that were employed to address them, are summarized on 
Figure 1.10. 
 
Figure 1.10: Diagram of the main aims and strategies followed in this this thesis. 
 
The strategies followed attempted to meet the new tendency of acceptance 
benchmarks for an ideal production process:  i) use of safe cell lines; ii) use of 
animal component-free culture medium and iii) rapid production process that 
yields high concentrations of the product with great quality in a cost effective 
way. We believe that our findings provide invaluable knowledge for rational 
viral vaccine bioprocess development. The processes developed herein can be 
applied to other producing systems by filling the gaps in the production 
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Recombinant adenovirus vectors (AdV) have been used for the development 
of vaccines, as gene therapy vectors and for protein production. Currently, the 
production of clinical grade batches of recombinant E1-deleted Adenovirus type 
5 vectors (HAdV-5) is performed using human derived HEK293 or PER.C6 cell 
lines. In this work we describe the generation of new human amniocyte-derived 
cell line named 1G3 and show that it can be used as a very promising cell host 
for AdV production in serum-free conditions, allowing for production in high cell 
concentration cultures and avoiding the typical cell density effect observed for 
HEK293. By design this cell line makes the generation of replication competent 
adenovirus (RCA) during production of E1-deleted Ad vectors very unlikely.  The 
impact of the culture system (static versus agitated) and AdV infection 
parameters such as multiplicity of infection (MOI), time of harvesting (TOH) and 
cell concentration at infection (CCI) were evaluated and compared with HEK293. 
Using stirred tanks bioreactors, it was possible to grow 1G3 cells to cell 
densities of up to 9 x 10
6
 cell/mL using serum-free media. Moreover, without a 
medium exchange step at infection, a 3-fold increase in AdV volumetric titers 
was obtained, as no cell density effect was observed at CCI 3. Overall our 
results clearly demonstrate the potential of the human amniocyte-derived newly 
established cell line 1G3 for AdV production in a serum-free scalable process, 
paving the way for further process improvements based on fed-batch or 
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Remarkable progress has been made during the last two decades in the 
development and application of adenoviral vectors (AdV) for gene therapy and 
vaccination. In many cases, AdV became the vector of choice due to their ability 
to replicate at high titers in complementary cell lines and to effectively deliver 
therapies such as vaccines, cancer therapeutics, and therapeutic genes [1-3], 
establishing itself as the most widely used delivery vector in gene therapy 
clinical trials [www.wiley.com/legacy/wileychi/genmed/clinical/]. 
Currently, the clinical grade recombinant E1-deleted human adenovirus type 
5 (HAdV-5) vectors for gene therapy and vaccination purposes are produced in 
cell lines based on  human embryonic kidney cells following immortalization 
with sheared HAdV-5 genomic DNA and containing the first 4344 nucleotides of 
HAdV-5 including the E1 functions (HEK293 cells) [4] or on human embryonic 
retinoblasts transformed with HAdV-5 E1A and E1B encoding sequences (PER.C6
 
cells) [5]. Safety concerns have been described for HEK293 cells especially 
regarding their tumorigenicity and their tendency to generate replication 
competent adenovirus (RCA) at larger scales of production [6, 7]. Poor 
documentation concerning their isolation and banking also raises special 
concerns from the regulatory authorities. The PER.C6 cell line has been widely 
adopted by the industry for AdV production, mainly due to its improved 
documentation of history and properties [5]. However, in two publications 
regarding PER.C6 cells, the generation of unusual vector recombinants have 
been observed, resulting in vector specimens carrying and expressing E1 
functions [8, 9]. Moreover, PER.C6 prices and licensing are also prohibitive for 
academic institutions, limiting the progress of R&D for new clinical gene 
therapy and vaccines application using these cells.  
More recently, human amniocytes were identified as an alternative cell 
source for the generation of stable cell lines following transformation with E1 
[10] and E1/pIX [11] functions. The design of the E1 DNA construct in one of 
the cell lines (N52.E6) was similar to that of PER.C6 cells [5], in principle 
excluding the generation of RCA due to the absence of any overlap sequence 
between vector DNA and the integrated E1 region. Several other cell lines were 
established under the rational of reducing the homology of their viral DNA 
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sequences with viral vectors genome (reviewed in [12]). This strategies have 
been applied using different human parental cell types namely lung carcinoma 
(A549 cells) [13, 14], embryonic lung [15], embryonic retinoblasts [5, 16], and 
HeLa cells [17, 18].  Unfortunately, the HeLa cell line is not allowed for 
commercial use because of its high tumorigenicity. 
Since Garnier et al. [19] used HEK293 cells, several efforts have been made 
worldwide towards establishing scalable processes suitable for commercial AdV 
manufacturing. Several variables and parameters have been shown to affect AdV 
production, such as temperature, pH, cell concentration at infection (CCI), 
multiplicity of infection (MOI), time of harvesting (TOH), culture medium (serum 
containing versus serum-free media), cell culture system (adherent, aggregated 
and suspension cells from small culture flasks to high volume bioreactors) [20, 
21]. A significant amount of literature exists trying to cope with the cell density 
effect observed for infections at CCI higher than 1 x10
6
 cell/mL, a phenomenon 
that leads to a significant decrease in cell specific virus yields [20, 22-25]. 
Approaches to maintain AdV cell specific titers at increased cell densities 
consist in infecting the cells after medium exchange [23, 26, 27] or under 
perfusion [28-30]. However, these procedures add the extra complexity of a cell 
separation step and increase the production costs due to medium exchange. 
Other approaches consist of the use of a fed-batch strategy, using non-
ammoniagenic medium, or cell cycle synchronization among others, but its 
success has been limited [1, 2, 22-24, 31-35].  In this way, the cell density effect 
issue still needs to be further addressed for HEK293 and PER.C6 cells and AdV 
production. 
For manufacturing purposes, especially for large-scale production, 
suspension adapted cell lines are more convenient, improving the scalability of 
the process. Furthermore, suspension cell lines can be cultured in serum-free 
media and are devoid of any bovine-derived additives facilitating downstream 
purification, as well as certification of clinical-grade batches. 
The main objective of this work was to assess the performance of the newly 
developed human amniocyte-derived 1G3 cell line for the production of HAdV-5 
and to evaluate the possibility for development of a scalable and serum-free 
bioprocess for HAdV-5 production. Cell cultivation and HAdV-5 production was 
evaluated in different culture systems: T-flask, shake flask and controlled 
stirred tank bioreactor (STB). The impact of MOI, CCI and TOH on HAdV-5 
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productivity was studied and directly compared to HEK293 cells. The results 
demonstrate that the 1G3 cell line can be a promising candidate for scalable 
production of HAdV-5 in serum-free medium, using a batch bioprocess mode 
and infecting at higher CCIs, paving the way for further improvements in 
volumetric productivities based on fed-batch or perfusion modes as shown for 
several virus systems namely baculovirus [36-38], influenza [39] and even in 
other studies with AdV [28, 29] . 
2. Materials and methods 
2.1. Generation of pSTK146UBE2I, used for immortalization of primary 
human amniocytes 
Plasmid pBKSII E1B, containing the HAdV-5 E1B promoter and E1B coding 
sequence and SV40 sequences (intron and 3´ UTR), was modified by site-
directed mutagenesis to remove the splice donor (SD) at nt. 3510 of HAdV-5 and 
to introduce a NdeI restriction site. The resulting plasmid, named pBKSII E1B QC 
NdeI, was digested with BamHI and NdeI to delete a 1 kb fragment containing 
the SV40 DNA sequences. The human UBE2I intron was isolated by PCR using as 
template genomic DNA isolated from low passage human N52.E6 cells [10] and 
using oligonucleotides #73 (5´-gttcagCATATGcaggtacggggcctccgcctctg-3´) and 
#74 (5´-TCAAGGTGGGGGAGGGTtctgtgccagagacaaaaacacaagac-3´). The 
resulting PCR product, named “PCR intron“, was flanked by a NdeI site 
(underlined in oligo #73) and codon-optimized Ad5 sequences (nt. 3595 to nt. 
3612) potentially encoding the C-terminal part of E1B 84R [40] at the 5´or 
3´end (capital letters in oligo #74), respectively. The mutagenesis would also 
result in an amino acid exchange by replacing amino acid 5 from the end (Gln) 
with an Asn and in the introduction of a stop codon.  
The 3´ UTR of UBE2I was isolated using oligonucleotides #75 (5´- 
gaACCCTCCTCCACCTTGAATTGCCCGTTTCCATACAGGGTC-3´) and #76 (5`- 
ctggatccGCGGTGGGGCTGCAGGTG-3´(SEQ ID NO: 29)) resulting in a PCR 
product named “PCR 3´ UTR”, which is flanked by the same Ad5 sequences (nt. 
3595 to nt. 3612) as mentioned above and a BamHI restriction site (underlined 
in oligo #76) at the 5´ or 3´ end, respectively. The overlapping Ad5 sequences 
at the 3´end of “PCR intron“ and at the 5´end of  “PCR 3´ UTR” allowed fusion 
of these two PCR products using oligonucleotides #73 and #76. The resulting 
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PCR fusion fragment flanked by NdeI and BamHI was then inserted into the NdeI 
and BamHI sites of pBSK E1B QC NdeI resulting in plasmid pBSK E1B UBE2I. 
To generate pSTK146 UBE2I, the BglII/ BamHI fragment from pBSK E1B 
UBE2I containing the UBE2I intron, the C-terminal part of E1B 84R and UBE2I 3´ 
UTR was subcloned into the BglII and BamHI sites of pSTK146. The resulting 
plasmid was named pSTK146UBE2I. A simplified map is shown in (Figure 1A).  
 
2.2. Cell lines and culture media 
The HEK293 cell line was purchased from ATCC (CRL-1573). The generation 
of the new 1G3 cell line was performed essentially as in [10] and is described in 
more detail in the results section. HEK293 and 1G3 cells were maintained in 
DMEM with 10% FBS (v/v) and 4 mM of glutamine (all from Invitrogen, UK). Cells 
were sub-cultured twice a week in T-flasks and maintained in a humidified 
atmosphere at 37°C with 5% CO
2
 in air. For cell harvesting, the monolayer was 
washed with phosphate-buffered saline followed by incubation with 0.05% 
trypsin-EDTA (Invitrogen, UK) until cell detachment became evident. 
 
2.3. Stirred Cultures 
Cells were adapted to grow in suspension cultures as single cells in 
serum-free Ex-Cell™ 293 medium (SAFC Biosciences, UK) supplemented with 4 
mM glutamine (Invitrogen, UK). This was performed by successive passing of 
cells directly in the serum-free medium, starting with adherent cells in mid-
exponential phase. 
Shake flasks cultures were performed by inoculating 500 mL shake flasks 
(80 mL of working volume) with 0.5 x 10
6
 cell/mL that were maintained in an 
orbital shaker at 130 rpm in humidified atmosphere at 37°C with 8% CO
2
 in air. 
pH, dissolved oxygen (DO) and temperature were monitored using the SFR 
Shake Flask Reader (PreSens GmbH, Germany). 
Stirred-tank bioreactor (STB) cultures were performed using Biostat DCU-I 
Bioreactors with 1 or 2 liter vessels (Sartorius Stedium, Biotech GmbH, Germany) 
equipped with rushton impellers, which were inoculated at 0.5 x 10
6
 cell/mL 
and the working volume was set to half of the vessel volume. pO
2
 was controlled 
at 50% air saturation with constant airflow of 0.01 L/min by sequentially varying 
the nitrogen and oxygen partial pressure in the gas inlet and the agitation rate. 
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The pH was controlled at 7.2 by aeration with CO
2





2.4. Cell concentration determination  
Cells were counted using a Fuchs–Rosenthal haemocytometer chamber with 
trypan blue exclusion method. 
 
2.5. AdV production 
The vector used consisted of an E1-deleted HAdV-5, expressing green 
fluorescent protein as transgene (HAdV5-GFP). This vector is based on plasmid 
pGS66 that contains HAdV-5 sequences from nt 1 to 440 and from nt 3523 to 
35935 [10]. In this plasmid the E1 region is replaced by an expression cassette 
consisting of the hCMV immediate early promoter, a cDNA coding for the eGFP 
protein and the SV40 polyA signal. HAdV5-GFP vector was rescued by cleavage 
of the plasmid DNA with SwaI (flanking the adenovirus ITRs) followed by 
transfection in N52.E6 cells [10], and by production and purification with CsCl 
gradients according to standard procedures. 




 in DMEM 
supplemented with 10% FBS (v/v) and 4 mM of glutamine and allowed to grow 
for 3 days. At a confluency of 70-80%, infection was performed with a MOI of 5 
infectious particles (ip) per cell by exchanging the culture media with fresh 
media containing the vectors. 
In stirred cultures, for evaluation of the impact of MOI and TOH in 1G3-
mediated AdV production, cells were grown to a concentration of 1 x10
6
 cell/mL 
and infected with MOIs of 0.05, 0.5, 5, 10 and 20. To evaluate the effect of CCI, 
1G3 and HEK293 were infected at 1, 2, 3 or 5 x10
6
 cell/mL with a MOI of 5. 
Extracellular vector particles were collected from the cell supernatant after 
centrifugation at 1000 g for 10 min at 4°C. For intracellular vector harvesting, 
the resulting cell pellet was resuspended in lysis buffer (Tris/HCl 10mM, pH 8.0 
and 0.1% (v/v) Triton-X 100) disrupting the cells and clarified at 3,000 g for 10 
min at 4°C. All samples were stored at -85°C. 
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2.6. AdV titration 
AdV titration was performed by monitoring the expression of GFP reporter 
gene after infection of HEK293 cells seeded in 24-well plates as previously 
described [24]. Briefly, cells were seeded at 0.25 x 10
6
 cell/well and infected 
24 hours post infection (hpi) with 1 mL of serial dilutions of the AdV samples in 
medium (DMEM with 10% (v/v) FBS). Cells were trypsin-detached at 17-20 hpi 
and the percentage of GFP-positive cells determined by flow cytometry (CyFlow 
Space, Partec, Germany). 
 
2.7. Assessment of the generation of replication competent adenovirus 
(RCA) during production  
The generation of RCA was evaluated by performing serial passages in two 
cellular clones (1G3 and 1D9 cells) of an E1-deleted adenovirus vector 
expressing EGFP (HAdV5-GFP) and finally using A549 and HeLa cells as indicator 
cells for the detection of RCA generated during serial passage. This assay was 
performed in two different ways, in high and a low infection formats. 
In the first format, each cell line was seeded in 6-well dishes at 1.5 x 10
6
 
cells per well (10 wells per cell line). Cells were infected with HAdV5-GFP at a 
multiplicity of infection (MOI) of 10 infectious particles per cell and harvested 
after 48h. The cells were lysed by freezing/thawing three times. 10% (v/v) of 
each cell lysate was used to infect cells of the same cell line for another 
infectious cycle. This procedure was repeated for a total of 15 passages. 
In a second assay format, cells were infected with 0.1% (v/v) of cell lysate 
from the previous passage (low infection format) and harvested when a 
cytopathic effect (CPE) became visible after 5-8 days, thus allowing for several 
rounds of replication. This procedure was also repeated for 15 passages. 
RCA detection was performed essentially as described previously [5]. The 
assay was performed on human A549 and HeLa cells, which do not allow for 
replication of E1-deleted Ad vectors. Only in the case of RCA generation, a full 
infectious cycle can occur, resulting in a CPE. The final lysate after serial 
passage was used for infection of HeLa cells for 4 days. Afterwards, the HeLa 
cells were lysed by 3x freezing/thawing and the lysate was added to A549 cells 
for 10 days. A visible CPE on A549 would indicate the presence of RCA, as an 
E1-deleted Ad vector would not replicate in either HeLa or A549 cells. To test 
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the detection limit of this assay, control HeLa dishes were infected with lysates 
spiked with HAdV-5 wild-type particles at very low multiplicity of infection. The 
assay has been found sensitive enough to detect 6 wild-type particles per 
infected HeLa dish. 
After 15 vector passages, no RCA was detected in any lysate of amniocyte-
based cell lines (a total of 40 lysates were tested), while three in 20 final lysates 
of 293 cells were found to contain RCA. 
 
2.8. Cell growth characterization 
The maximum specific growth rates (µ
max












respectively the viable cell concentration at the initial time and for time t. 




2.9. Metabolic characterization 
Glucose (Glc), Lactate (Lac) and Glutamine (Gln) were quantified with an 
automated enzymatic assay (YSI 7100 Multiparameter Bioanalytical System, 
USA). Ammonia (NH4
+
) was quantified by enzymatic assay K-AMIAR (Megazyme, 
Ireland). The specific metabolic rates (qMet) were calculated using the equation: 
qMet=Met/(t.X
v
), where Met is the variation in the metabolite concentration 
during the time interval t and X
v
 is the difference in viable cell concentration 
during the same time interval. The apparent metabolic yield (YMet1/Met2) was 




. The oxygen uptake rate (OUR) was 
determined using the equation: OUR=KLa.(C*-C), where the KLa (determined 
using the gassing-out method [41]) is the oxygen transfer coefficient, C* and C 
are the oxygen concentration at saturation and in solution, respectively. The 
oxygen specific consumption rate (qO
2











Human Amniocyte-derived Cells for the Production of Adenovirus Vectors 
 75 
3. Results 
3.1. Rationale and generation of pSTK146UBE2I 
Previously we had generated the N52.E6 cell line by immortalization of 
primary human amniocytes with plasmid pSTK146 [10]. This plasmid, 
containing the E1 region of HAdV-5 from nt 505 to 3522, expresses the E1A 
functions from the murine PGK promoter and the E1B 55K and 19K proteins 
from the endogenous E1B promoter. To prevent generation of RCA during 
production of E1-deleted Ad vectors in E1 complementing producer cells, most 
of the E1B intron, the E1B splice acceptor (SA) and the 3' UTR (overlapping with 
the protein IX gene) had been replaced with the corresponding elements from 
SV40, i.e. intron, SA and polyA signal [10]. Following transient transfection of 
pSTK146 in HeLa cells we now noted in Western blot analysis using an antibody 
for detection that recognizes the N-terminus of E1B that relatively little 55K E1B 
protein was produced, while a prominent band was visible at about 37 kDa, 
while in N52.E6 cells only a 55 kDa (full-length) E1B signal was visible (data not 
shown). RT-PCR analysis indicated that the E1B truncation was due to an 
aberrant splicing event involving a splice donor (SD) downstream from the 
known E1B SD (SD1) and the SV40 SA (data not shown). With the idea to 
potentially increase immortalization efficiency (by expressing larger amounts of 
full-length E1B 55K protein) we replaced the SV40 intron/SA/polyA elements 
with a short intron, including SD and SA, and a 3'UTR of the human UBE2I gene. 
In addition, we inserted a short sequence from the 5'UTR of the pIX gene, 
potentially allowing for expression of the minor E1B 84R protein [40]. This 
sequence was codon-optimized, which as a side effect considerably reduced 
homology with the natural pIX sequence (Figure 2. 1). As a consequence, in a 
stretch of 21 nucleotides, only 15 nucleotides were homologous to the HAdV-5 
sequence and with not more than 3 nucleotides in a row, making recombination 




Figure 2. 1: Rationale for 1G3 cell line generation. A. Simplified map of pSTK146UBE2I that was 
used for immortalization of primary human amniocytes. The E1A region is under control of the 
murine PGK promoter. The E1B region is under control of the endogenous E1B promoter. Splice 
donor (SD) and splice acceptor (SA) of the UBE2I intron are indicated. B. Scheme of the E1 region in 
HAdV-5 wildtype virus and in HEK293 cells, of an E1-deleted Ad vector expressing eGFP and of the 
new 1G3 cell line described in this manuscript. The top panel indicates relevant features of HAdV-5 
(NCBI Reference Sequence AC_000008.1). 
The region of significant overlap between the genome of the E1-deleted AdV5-GFP vector and left 
part of the HAdV-5 genome in HEK293 cells potentially resulting in homologous recombination 
and the generation of RCA is indicated with red crosses. The numbers 440 and 3522 delineate the 
deletion of the E1 region in typical E1-deleted Ad vectors, and in particular in the eGFP -expressing 
vector AdV5-GFP used in this study. 
The insert at the bottom of the figures provides the details of the modified 5' UTR of the pIX gene 
present in the 1G3 cell line. The small letters indicate the intron and the capital letters the exon 
sequence (i.e. indicating the location of the splice acceptor). The ATG start codon of the pIX coding 
sequence is indicated, which is modified in the 1G3 cell so that a TGA stop codon is introduced 
instead. 
 
3.2. Generation of cell line 1G3 
The generation of permanent amniocyte cell lines was approved by the 
ethics committee of the University of Ulm. Following written informed consent 
of the donors, primary cells obtained as a side product from diagnostic 
amniocentesis were cultivated, basically as described in [10]. Further details of 
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the cultivation of primary cells are provided in [42]. The primary cells had a 
normal karyotype and tested negative for HIV, HBV, HCV, CMV and EBV. 
Primary cells, cultivated following standard procedures, were transfected 
with plasmid pSTK146UBE2I following its linearization with BspHI, which cleaves 
in the plasmid backbone, and using linear polyethyleneimine (PEI) as 
transfection reagent. Primary cells in 6 cm culture dishes and at a confluency at 
50-70% were transfected with 2μg linearized plasmid DNA per dish in 150mM 
NaCl using linear polyethyleneimine (PEI), pH 7, at a N/P 
(nitrogen/phosphorous) ratio of 45 for transfection. Expression of the plasmid-
encoded HAdV-5 E1 genes after chromosomal DNA integration is sufficient to 
achieve immortalization of the cells. Therefore, additional selection was not 
required. Twenty-four hours after transfection cells were transferred to 14 cm 
dishes using TrypLE Select (Gibco) for detachment. Several weeks after 
transfection, when foci of immortalized cells became visible, individual cell 
clones were isolated and expanded.  These were subsequently tested for 
complementation of an E1-deleted Ad vector. Clones with good productivities 
were single-cell cloned by limited dilution. From these the 1D9 and the 1G3 cell 
lines were selected for further analysis. Further details of the procedure are 
described in [42]. The 1G3 cell lines was adapted to growth in suspension 
culture as described in the Material & Methods section and further analysed in 
the present study. 
 
3.3. Human amniocyte 1G3 cell line produces significant amounts of 
AdV in static culture conditions without RCA formation 
To determine the potential of the 1G3 cell line for AdV production, its 
specific cell growth and metabolic properties were initially studied in a static 
culture system and in comparison with the widely studied HEK293 cell line.  
The obtained cell growth profiles showed that both cell lines had similar 
growth rates (μ
max
), although 1G3 cells were able to attain a higher maximum 






) (Table 2. 1). Concerning 
metabolic activity, 1G3 cells presented lower glucose uptake rates (q
Glc
) 
resulting in smaller lactate production rates (q
Lac
) when compared to HEK293 
cells. However, there were no differences observed for the molar ratio Y
Lac/Glc
 
between the two cell lines, suggesting similar metabolic profiles in terms of 
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glycolysis and oxidative metabolism. The molar ratio Y
Glc/Gln
 was lower for 1G3 
cells (3.2 and 4.9, respectively for 1G3 and HEK293), indicating that 1G3 cells 
presented an increased glutamine metabolism over glucose as carbon source 
than HEK293 cells in this culture system and serum containing conditions 
(Table 2. 1).  
 
Table 2. 1: Cell growth characterization for the two cell lines in T-flask, shake flask and STB. 
Parameters 
T-Flask Shake Flask STB 


















 7.0 ± 0.7
a
 7.7 ± 0.8
b
 5.4 ± 0.6
b
 9.2 ± 0.9
b



















































3.2 ± 0.4 4.9 ± 0.6 6.5 ± 1.0 4.2 ± 0.9 6.5 ± 0.9 5.6 ± 1.5 
Xv
max
 – maximal viable cell concentration (the error corresponds to the 10 % error associated to cell 
counting method); μ
max
 – specific growth rate and t
d
 – duplication time;, q
Glc
 – specific glucose 
uptake; q
Lac
 – specific lactate production; q
Gln
 – specific glutamine uptake ; Y
Lac/Glc
 molar ratio lactate 
production/glucose uptake ; Y
Glc/Gln
 – molar ratio glucose uptake/glutamine uptake (the errors 
corresponds to the standard deviation associated with the parameter estimation). 
 
For assessment of AdV productivity the infection was performed by 
complete medium exchange in order to exclude any nutrient limitation at time 
of infection. The maximal AdV productivity was observed at 48 hpi for both cell 
lines. The obtained results showed that although 1G3 cells enabled efficient 
AdV replication, producing significant titers (1.0x10
9
 ip/mL), the cell-specific 
productivity of infectious vector particles in this culture system was 2.4-fold 




 ip/cell, respectively) (Figure 2. 2). 
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Figure 2. 2: Adenovirus vector (AdV) production in 1G3 and HEK293 cells in static cultures.  
AdV productivities (gray) and titers (white) obtained at 48 hpi for 1G3 and HEK293 cells cultured in 
static conditions. (Mean ± SD, N=2, Error bars represent the standard deviation of quadruplicate 
sample assay). 
 
The RCA generation was assessed in both cell lines after 15 AdV serial 
passages and none was detected in any lysate of 1G3 (40 lysates tested), while 
3 out of 20 final lysates of the HEK293 cells were found to contain RCA. 
 
3.4. Human amniocyte 1G3 cell line grows in single cell suspension to 
high concentrations in stirred culture systems 
In order to meet the high quantities required for clinical applications, the 
development of scalable and robust AdV production processes is imperative. In 
this context, 1G3 and  HEK293 cells were adapted to grow in single cell 
suspension in shake flasks by successive passages in a commercially available 
serum-free medium (Ex-Cell
TM
 293). Cell growth and AdV production were 
evaluated both in shake flasks and STB for 1G3 and HEK293 cells. 
For both systems, high viable cell densities were obtained after 120 h in 
culture (Table 2. 1). Although no significant differences were observed for the 
determined growth rates of the two cell lines, 1G3 cells were able to attain 
higher maximum cell densities (7.7 and 9.2 x 10
6
 cell/mL, respectively, for 
shake flask and STB) in comparison with HEK293 (5.4 and 6.1 x 10
6
 cell/mL, 
respectively, for shake flask and STB). Under controlled environmental 
conditions enabled by the STB system a slight increase of the maximum cell 
densities was observed for the two cell lines relative to the results obtained in 
shake flask. Also, the obtained Y
Lac/Glc
 ratio was lower for both cell lines in STB 
cultures relative to shake flask, suggesting an increase of oxidative metabolism, 





ratio was higher for 1G3 cells indicating that these cells, relatively to HEK293, 
have an increased preference for glucose over glutamine as carbon source 
(Table 2. 1) in suspension cultures and serum-free conditions.  
 
3.5. Human amniocyte 1G3 cell line presented higher AdV productivities 
than HEK293 cells at CCI 3 in stirred culture systems 
In order to maximize AdV production, MOI and TOH were initially optimized 
in 1G3 cells, by infecting cells at 1 x 10
6
 cell/mL in shake flask with different 
MOIs (0.05, 0.5, 5, 10, 20 and 50) (Figure 2. 3). The obtained results identified 
higher AdV production for MOIs of 5 and 10. Concerning TOH, for these MOIs 
higher titers were obtained at 48 hpi with similar profiles also observed for 
HEK293 cells (data not shown). 
 
 
Figure 2. 3: Effect of MOI in AdV titers obtained for 1G3 cells cultured in shake flasks. The cells 
were infected at different MOIs at a CCI of 1 x 10
6
 cell/mL. Data correspond to the maximal titers 
obtained between 36 and 72 hpi. Error bars represent the standard deviation of quadruplicate 
sample assay. 
 
AdV production is known to be dependent on the CCI, with lower specific 
productivities being obtained at higher CCI, which has been described as the 
“cell density effect” [20] . To evaluate this, 1G3 and HEK293 cells were infected 
at different CCIs in shake flask (CCI 1, 3 and 5 x10
6
 cell/mL for 1G3 cells; CCI 1, 
2 and 3  x10
6
 cell/mL for HEK293 cells) and STB (CCI 1, 3 and 5 x10
6
 cell/mL for 
both cells). In all cases a MOI of 5 was used, based on the previous MOI 
optimization.  
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Figure 2. 4: Cell growth and Adenovirus vector (AdV) productivity in 1G3 and HEK293 cells in 
suspension cultures. A. Growth profile of 1G3 and HEK293 cells infected at cell concentration at 
infection (CCI) of 1, 2, 3 and 5 x 10
6
 cell/mL cultured in shake flasks and stirred tank bioreactors 
(STB). B. AdV productivities obtained for 1G3 and HEK293 cells infected at CCI of 1, 3 and 5 x 10
6
 
cell/mL cultured in shake flasks and STB (Mean ± SD, N=2 for CCI 1 and CCI 3, Error bars represent 
the standard deviation of quadruplicate sample assay) 
 
Concerning cell growth profiles after AdV infection, only a slight increase in 
cell concentration was observed during the first 24 hpi for all CCIs, both in 
shake flask and STB (Figure 2. 4), which should be mainly related to the high 
MOI used in all experiments performed. After this period the cell concentration 
and viability decreased, which was more pronounced in shake flasks than in 
STB. In shake flasks, this was also followed by a decrease in pH along culture 
time, reaching values below 6 (Figure 2. 5 A).  DO values were always above 
75%, indicating no oxygen limitation in the shake flasks experiments during 
growth or infection for both cell lines. Also, for shake flasks cultures, the 
specific oxygen consumption, depicted by the qO
2
 values determined for both 
Chapter 2 
 82 
cell lines, revealed no significant differences during the cell growth phase 
(Table 2. 2). After infection, a decrease in qO
2
 was observed, which was even 




Figure 2. 5: A. pH and DO profiles for 1G3 and HEK293 cells infected at CCI of 1, 2, 3 and 5 x 10
6
 
cell/mL cultured in shake flasks. B. Metabolite profiles for 1G3 and HEK293 cells during growth 
and infection at different CCIs cultured in shake flasks. Glucose (Glc) and Glutamine (Gln) (full 
symbols); Lactate (Lac), and Ammonia (NH
4
+
) (empty symbols).  
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Infections performed at CCI 1 in shake flask showed no glucose or 
glutamine limitations. However, at higher CCIs glutamine was depleted at 
48 hpi (Figure 2. 5 B), reaching concentrations lower that 1 mM for infections at 
CCI 3 and vestigial at CCI 5. The determined specific consumption/production 
rates for all the metabolites analyzed decreased during the infection phase and 
with the increase in CCIs (Table 2. 2), suggesting lower metabolic activity in 
terms of central energy metabolism pathways. For CCI 3, the molar ratio Y
Glc/Gln
 
determined for the infection phase increased, suggesting an increase in 
glutamine utilization as energy source. This may be explained by the decrease 
in glucose availability registered at these later stages of culture. Nevertheless, 
this was followed by a slight increase in the Y
NH4+/Gln
 ratio, indicating lower 
efficiency in glutamine utilization with higher ammonia production. 
 
Table 2. 2: Metabolic characterization for the two cell lines during growth and infection at CCI’S 1 
and 3 in shake flask cultures. 
Parameter 
1G3 HEK293 






















 4.4 ± 0.7 2.3 ± 0.4 1.6 ± 0.2 3.9 ± 0.6 2.8 ± 0.4 1.4 ± 0.2 
q
Glc 
 9.9 ± 1.3 8.8 ± 0.2 6.0 ± 0.4 8.0 ± 0.3 10.3 ± 0.5 4.8 ± 0.6 
q
Lac
 12.1 ± 3.1 8.8 ± 0.6 5.5 ± 0.2 10.8 ± 1.9 13.1 ± 0.5 5.9 ± 0.6 
q
Gln 
 1.5 ± 0.1 1.3 ± 0.3 0.5 ± 0.1 1.9 ± 0.4 2.1 ± 0.4 0.5 ± 0.2 
q
NH4+













0.7 ± 0.3 1.2 ± 0.2 1.9 ± 1.1 0.8 ± 0.2 0.9 ± 0.2 1.8 ± 0.6 
q
O2
 - specific oxygen uptake, q
Glc
 – specific glucose uptake; q
Lac
 – specific lactate production; q
Gln
 – 
specific glutamine uptake; q
NH4+
 – specific ammonia production; Y
Lac/Glc
 molar ratio lactate 
production/glucose uptake; Y
NH4+/Gln
 – molar ratio ammonia production/glutamine uptake.; Y
O2/Glc
 – 
molar ratio oxygen uptake/glucose uptake; Y
O2/Gln
 – molar ratio oxygen uptake/glutamine uptake 
(the error corresponds to the standard deviation associated with the parameter estimation); CCI - 
cell concentration at infection; CCI 1 – 1x10
6
 cell/mL; CCI 3 – 3x10
6
 cell/mL.  
 
As for AdV production in shake flask, the results showed a significant drop 
in the specific AdV productivity for CCIs above 1 x 10
6
 cell/mL, for both cell 
lines (Figure 2. 4). Nevertheless, higher specific productivities were obtained 
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with 1G3 cells at CCI of 3, relatively to HEK293 cells (392 and 267, respectively 
for 1G3 and HEK293 cells).  
The translation of this AdV production bioprocess from shake flask into fully 
controlled STB resulted in a general increase of the productivities for all tested 
CCIs (Figure 3). In this system, the same strong negative dependence of specific 
productivities on CCI occurred for HEK293 with a 10-fold decrease in the 
specific AdV productivities at the higher CCIs (1342, 182, and 142 ip/cell at CCI 
1, CCI 3 and CCI 5, respectively). This effect was completely abolished for 1G3 
cells in STB cultures, where in fact an increase of 2.9-fold was observed for CCI 
3 relatively to CCI 1 (701 and 2036 ip/cell, respectively for CCI 1 and 3). As for 
CCI 5, although the specific AdV productivity (892 ip/cell) decreased relatively 
to CCI 3, it was maintained at similar levels as those obtained for CCI 1. The 
increase in cell specific AdV productivity in 1G3 cells at CCI 3 resulted in a 3.3-
fold increase of the maximum volumetric titers obtained relatively to HEK293.  
    
4. Discussion 
In this study, we describe the generation of a new human cell line for 
production of HAdV-5 based Ad vectors, named 1G3, and we show that this cell 
line represents a promising and efficient alternative for AdV production to the 
traditionally used HEK293 or the commercial PER.C6 cell line. By establishing a 
robust and reproducible bioprocess for AdV production in 1G3 cells, from small 
scale static culture conditions up to fully controlled and scalable STB, we 
demonstrated that the attained productivities can be comparable or even higher 
than in HEK293. Human amniocyte-derived cells have been previously described 
as efficient platforms for biopharmaceuticals production, namely CAP cells from 
CEVEC that have shown to be good substrates for recombinant protein 
production [43] and virus production like influenza [44], with similar 
productivities to HEK293 cells [45]. However, these cells have only been 
evaluated for AdV productions in small scale experiments [10]. In order to 
reduce the chances of RCA generation in AdV production 1G3 cells were 
transformed with a plasmid containing the Ad5 E1A and E1B genes plus 
modified sequences from the pIX gene, with little overlap between vector and 
cellular DNA upon vector production. This resulted in no detectable RCA levels 
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in a total of 40 independent small scale assays of 15 serial passages of AdV. On 
the other hand, in HEK293 cells the presence of RCA was detected in 3 out of 
20 assays. These results demonstrated that 1G3 cells can offer a safer 
alternative for AdV production, in comparison with HEK293, due to the 
restricted viral genome sequences that were inserted in the host cell genome.  
In this work, growth and infection studies with 1G3 cells were performed in 
T-flask, shake flask and STB, in order to demonstrate the potential of 1G3 cells 
for AdV production. These studies were always performed in parallel 
experiments performed using HEK293 cells, for a direct comparison of the 
performance of both cell lines. It was shown that in static conditions 1G3 cells 
could produce significant titers of AdV (1.0x10
9
 ip/mL; 1.7 x10
3
 ip/cell), 




 ip/cell). By 
moving from static towards stirred culture systems, a decrease in the specific 
AdV productivities for both cell lines was observed, which was more 
pronounced in HEK293 cells. This occurrence has already been reported for AdV 
production in HEK293 cells, as well as for the production of other viral vectors 
in other cell lines [20, 46]. Nevertheless, stirred culture systems are more 
appropriate for scalable production processes, enabling large-scale production 
of clinically relevant titers. Adaptation of 1G3 cells cultivation in suspension  in 
a serum-free culture medium was successful, enabling to attain cell densities 
above 5×10
6
 cell/mL within 120 h, which was the maximum cell concentration 
observed for HEK293 cells and has also been described for PER.C6 cells [27] or 
CAP cells [39, 44].  
Process-related parameters such as MOI, TOH and CCI strongly influence 
virus productivities and need to be evaluated for each system. The optimal MOI 
was determined to ensure that the cells were infected with an adequate number 
of viral particles for maximum volumetric virus production. The highest AdV 
titers were obtained with MOIs of 5 to 10 and TOH of 48 hpi, similar to those 
normally applied for HEK293 and PER.C6 cells [20, 21]. Given this, a MOI of 5 
was selected as optimal for the CCI studies in order to reduce the amount of 
AdV stock used for infection, which in the case of industrial processes can help 
in saving costly certified master virus banks. Extensive literature has described 
the occurrence of the ‘‘cell-density effect’’ in HEK293 and PER.C6 cultures where 
the cell specific productivity decreases with an increase of CCI [20, 25, 27]. This 
effect seems to limit the range of the CCI to 0.5–1x10
6
 cell/mL in order to attain 
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the maximal productivity. In this work, a decrease of AdV productivity with the 
increase of CCI was observed for both cell lines in the shake flask culture 
system. However, in STB this effect did not occur for 1G3 cells, where the 
specific AdV productivities were similar for CCI 1 and 5 and a 3-fold increase 
was achieved for CCI 3, resulting in higher titers.  Moreover the ratios physical 
to infectious for 1G3 cells were similar to those obtained for HEK293 cells (data 
not shown). The experiments for 1G3 cells at CCI 3 and HEK293 cells at CCI 1 
were performed twice and the profiles for cell growth and AdV production were 
similar between independent runs at different cell passages showing the 
robustness of the cell line for AdV production. 
Under controlled conditions 1G3 cells showed the potential to give rise to 
higher AdV titers. This result shows that 1G3 cells present a different behavior 
towards the cell density effect than HEK293 cells, a phenomenon which requires 
further investigation.  
For the development of new bioprocesses the Food and Drug Administration 
(FDA) has created the process analytical technologies (PAT) initiative which 
encourages designing, analyzing, and controlling of manufacturing processes 
as early as possible in the development phase [47]. On-line monitoring of 
essential process parameters such as DO and pH in small devices can prove to 
be of great value to achieve process and product consistency, as well as process 
understanding from small scale to bench-scale devices [48, 49] or scale-down 
[50]. Significant advances have been made equipping small culture devices such 
as microplates [51, 52], T-flasks [53] and shake flasks [41, 54] with DO and pH 
sensors. In this work, on-line monitoring of these parameters in shake flask 
revealed no limitations on oxygen during all cultures. This culture system is 
widely used in the early development phases for several processes and the 
more information acquired the better for the design of scale-up strategies. 
Monitoring DO along culture time in shake flasks enabled to calculate qO
2
 for 
both cell lines, during growth and infection phases, which revealed similar 
oxygen consumption profiles with a decreased after infection. Moreover, the 
obtained values are in agreement with those available in the literature for CAP, 
HEK293 and other cell lines [39, 55]. As for pH, in shake flask it was shown that 
during infection values lower than 7 were attained, which is below the optimum 
value described in the literature for AdV production (7.2 for HEK293 [56] and 
7.3 for PER.C6 [26]). 
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In the case of the STB the DO was maintained at 50% air saturation, which is 
in the range described for most controlled systems reported in the literature for 
AdV production (30-80% air saturation) [20, 21]. Lower partial pressures of 
oxygen can contribute to an increased productivity, as it has been reported for 
Vesicular Stomatitis virus (VSV) production in Vero cells, where high DO 
conditions led to a decrease in viral productivity due to an increase in reactive 
oxygen species generation [57]. Thus, the lower levels of DO and a stable pH 
registered in STB cultures, relative to shake flasks, could be of help to explain 
the increase in AdV productivities obtained in this culture system.  
Additionally, the main carbon sources, glucose and glutamine, were at 
limiting concentrations at higher CCI’s for both cell lines, which could also have 
affected the AdV productivities, as previously reported for HEK293 cells at CCI 3 
[22]. 1G3 cells, like HEK293 and PER.C6 cells exhibited a preference for glucose 
over glutamine metabolism with a ratio Y
Glc/Gln
 in the order of 5–10 mol/mol [27, 
58].  Still, in stirred culture systems the Y
Glc/Gln
 was higher for 1G3 cells than for 
HEK293 cells, which may suggest that glutamine depletion during infection 
could have less impact on the AdV productivity of this cell line. In static 
cultures, the contrary was observed showing that the use of different culture 
medium with serum and distinctive culture system leads to changes in the cells 
metabolic behavior. This has been demonstrated in other production systems 
like avian cells for the production of influenza where changing from roller 
bottles to bioreactor systems impacts on cell metabolism [46].    
It has been reported that feeding with glucose and glutamine could not 
reconstitute the cell specific productivity at a CCI 3. However, a complete 
medium exchange at the time of infection could improve the productivity at this 
cell concentration [22]. Further studies concerning the impact of AdV on the 
cellular metabolic requirements of both cell lines are on-going using NMR and 
mass spectrometry. This may provide important cues for metabolic engineering 
strategies necessary to increase the cell-specific productivity at higher CCI and 
to understand the differences obtained between 1G3 and HEK293 cells. 
Overall, the AdV infection experiments with 1G3 cells showed that (i) 
infection was most efficient at a MOI of 5; ii) infection at a CCI 3 in STB allowed 
higher AdV titers; iii) the optimal time of harvest was 48 hpi, corresponding to 
the higher intracellular AdV concentration. This strategy allowed a 3.3-fold 
increase in the AdV volumetric production obtained in batch culture in 
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comparison to HEK293 cells. The results presented showed the great potential 
of 1G3 cells for AdV production in different culture systems, relevant for the 
different stages of process development.  
5. Conclusions 
The development of robust, scalable and safer cell culture systems for viral 
production is in the focus of both academic and industrial research. In this work 
we describe the generation of a new human cell line based on primary 
amniocytes and we show that it is both a good cell host for AdV production and 
a good alternative to HEK293 cells. The design of the cell line essentially 
excludes the generation of RCA by homologous recombination. The translation 
from static cultures to shake flask and then to stirred tank bioreactors 
demonstrates an easy cell adaptation to different culture systems with 
maintenance of AdV production yields that allows for a smooth and 
straightforward scale-up.  
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Impact of Adenovirus infection in host cells metabolism evaluated by 
1
H-







Adenoviruses are powerful vehicles for gene transfer vaccination and gene 
therapy applications. Although highly exploited in clinical settings, key aspects 
of adenoviral biology are still to be disclosed. Importantly, the adenoviruses 
subversion of host cell metabolism to fuel their own replication is not clear. 
The aim of this work was to gain insights on the metabolism of two human cell 
lines (HEK293 cells and an amniocyte-derived cell line, 1G3) after infection and 
replication of an adenoviral vector (AdV5) commonly used in gene therapy and 
vaccine clinical trials. We used 
1
H-NMR spectroscopy, which allowed the 
quantification 35 metabolites in cell culture supernatants, with low sample 
preparation in a relative short time. The metabolic profiling identified 
significant differences between both cell lines in non-infected cultures, namely 
in glutamine and acetate metabolism, as well as by-product secretion. The 
main response to adenoviral infection was the increased glucose consumption 
and lactate production rates. Infected cultures, with and without glutamine 
supplementation, confirmed the exhaustion of this amino acid as one of the 
main causes of lower adenovirus production at high cell densities (10- and 1.5-
fold less infectious particles per cell, in HEK293 cells and 1G3 cells, 
respectively). Moreover, different degrees of glutamine dependency for each 
cell line were highlighted. Overall, the observed changes in amino acids 
metabolism and by-products formation during infection were mapped, which 
can be useful for targeted bioprocess optimization. 
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Recombinant adenoviral vectors (AdV) with E1 gene deletion are amongst 
the most efficient viral vectors for gene delivery, both in vivo and in vitro, and 
have been the choice in several therapeutic and vaccination applications. 
Production of E1-deleted human AdVs is usually performed in host cell lines 
that express the adenovirus E1A and E1B genes, being HEK293 host cell line of 
choice [1, 2]. However, safety issues concerning HEK293 cells tumorigenicity 
and their propensity to produce replication competent adenoviruses (RCAs) 
have arisen [3]. To obviate this, alternative producer cell lines were established, 
including the 1G3 cell line derived from human amniocytes, which was 
transformed with a plasmid containing the Ad5 E1A and E1B genes plus 
modified sequences from the pIX gene. These cells contain no overlapping 
sequences with AdV type 5 (AdV5), minimizing or eliminating the probability of 
generating RCAs [4]. 
A bottleneck that has been recognized for several years is the decrease of 
adenovirus productivity after infecting HEK293 or PER.C6 cells at cell 
concentrations higher than 1×10
6
 cell/mL, resulting not only in low cell-specific 
product yields, but also considerably lower volumetric titers [5-7]. Most 
attempts to overcome this cell density effect in adenovirus production consisted 
in supplementing the culture medium with glucose, glutamine, a range of 
different complex nutrient mixtures, or performing complete or partial medium 
exchange at infection [8-12]. Strikingly, Adenovirus replication in the 1G3 cell 
line is less hampered at high cell concentration infection than in HEK293 cells 
[4]. Thus, a better understanding of how the infection process impacts the 
metabolism of producer cells would give us important information to increase 
productivity in high cell density cultures. 
It has been reported that viral replication induces major changes in cell 
physiology and metabolism [13]. The metabolic efficiency to supply precursors 
for biosynthesis was proven to impact the synthesis of viral components, their 
assembly, release and final production levels [13, 14]. However, the metabolic 
characterization of AdV production processes has been mostly restricted to the 
analysis of the main extracellular metabolites, such as glucose, lactate, 
ammonia and glutamine [9, 15, 16]. While these studies provide an overview of 
cell metabolism, a larger picture of the overall metabolic state is required for 
Metabolic Alterations Induced by Virus Infection 
 97 
understanding the key cellular mechanisms operating during growth and virus 
production.  
In this work, we applied 
1
H nuclear magnetic resonance (
1
H-NMR) 
spectroscopy to generate data that permits a comparison of the 
exometabolomes of 1G3 and HEK293 cells, during growth and upon adenovirus 
infection at different cell concentrations. 
1
H NMR allows profiling a wide range 
of compounds in the culture supernatant, while requiring minimal sample 
preparation and providing high reproducibility in a relatively short time.  
     
2. Materials and methods 
2.1. Cell lines and cell culture 
HEK293 cells (ATCC CRL-1573 , adapted to grow in single cell suspension) 
and 1G3 cells  [4] were routinely cultured in serum free Ex-Cell
TM
 medium 
(Sigma-Aldrich, USA) supplemented with 4 mM glutamine (Invitrogen, UK), using 
500 mL shake flasks (80 mL working volume). Cultures were seeded at a cell 
concentration of 0.5x10
6
 cell/mL and were maintained on an orbital shaker at 
130 rpm and incubated in humidified conditions at 37
o
C with 8% CO
2
 in air.  
 
2.2. Virus stock preparation and titration 
A recombinant E1-deleted AdV type 5 expressing the Green Fluorescence 
Protein (AdV5-GFP) was used in this work. The AdV5-GFP virus was amplified in 
HEK293 cells cultured in monolayers using T-flasks and purified by CsCl 
gradients. AdV titration was performed by monitoring the expression of GFP 
reporter gene after infection of HEK293 cells seeded in 24-well plates, as 
previously described [17]. Briefly, cells were seeded at 0.25 x10
6
 cell/well and 
infected after 24 hours with 1 mL of serial dilutions of the AdV samples in 
DMEM with 10% (v/v) FBS. Cells were trypsin-detached at 17–20 hours post-
infection (hpi) and the percentage of GFP-positive cells determined by flow 




2.3. Viral replication in shake flask and bioreactor cultures  
1G3 cells and HEK293 cells were grown in shake flasks or stirred tank 
bioreactors with an inoculum of 0.5x10
6
 cell/mL. Shake flasks cultures were 
performed in 500 mL shake flasks (80 mL of working volume) that were 
maintained in an orbital shaker at 130 rpm in humidified atmosphere at 37°C 
with 8% CO
2
 in air. Bioreactor cultures were performed with 1L working volume 
in Biostat DCU-I 2-L vessels (Sartorius Stedium, Biotech GmbH) equipped with 





controlled at 50% air saturation with constant airflow (0.01 L/min) by 
sequentially varying the nitrogen partial pressure, agitation rate and oxygen 





.Once cells reached a concentration of 1 and/or 3 x 10
6
 cell/mL, 
cultures were infected with a multiplicity of infection (MOI) of 5 infectious 
particles (ip) per cell. For virus infections experiments at CCI 3x10
6
 cell/mL in 
bioreactor, glutamine was added at 48 h after inoculation to a final 
concentration of 5 mM. Samples were collected along culture time for cell 
counting. Supernatant samples were clarified at 1000 g for 10 min and stored 
at -20
o
C for metabolome analysis. Virus production was assessed at 48 hpi. 
Culture samples were centrifuged at 1000 g for 10 min at 4
o
C and the 
supernatants kept at -85ºC for titration of extracellular virus. In order to 
quantify intracellular virus content, cell pellets were ressuspended in 10 mM 
Tris buffer at pH 8.0, supplemented with 2 mM MgCl
2
 (Merck, Darmstadt, 
Germany) and 0.1% (v/v) Triton X-100 (Sigma-Aldrich, St. Louis, MO). Cells were 
disrupted by vortexing for 1 min and debris removed by centrifugation at 3000 
g for 10 min at 4
o
C. The resulting cell lysate was dispensed into small aliquots 
and stored at -85
o
C, until further use. 
 
2.4. Cell concentration and viability determination 
Cell concentration and viability were determined by counting the cells on a 
haemocytometer using the Trypan Blue dye exclusion method.  
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2.5. Exometabolome Analysis 
1
H-NMR was performed in a 500MHz Avance spectrometer (Bruker, Billerica, 
MA) equipped with a 5-mm QXI inversed probe. Spectra were acquired using a 
NOESY-based pulse sequence with water pre-saturation, performing 256 scans 
with 4 s acquisition time, 1 s relaxation delay and 100 ms mixing time at 25ºC. 
DSS-d6 (Cat.No. 613150, Isotec, Sigma-Aldrich, St. Louis, MO) was used as 
internal standard for metabolite quantification in all samples. Samples were 
mixed with phosphate buffer (pH 7.4) prepared in D
2
O (Cat.No. 151882, Sigma-
Aldrich, St. Louis, MO) at a 2:1 ratio to minimize pH shifts. Before spectra 
acquisition, the spectrometer was calibrated by determining the 90º pulse and 
the water chemical shift center of each sample. 
Each spectrum was phased, baseline corrected and integrated using 
Chenomx NMR Suite 7.1 (Chenomx, Inc., Edmonton, Alberta, Canada). Most 
metabolites are defined by several clusters at different chemical shifts, which in 
some cases may overlap or be affected by the damping effect caused by water 
suppression, inducing an underestimation of their concentrations. Therefore, 
after automatic fitting of each metabolite, the best resolved and farthest peak 
from the water region was chosen for manual adjustment and metabolite 
quantification. This method allowed accurate quantification of 35 metabolites. A 
detailed explanation of the method developed and Chemical shifts of clusters 
used for quantification, errors and limits is reported in Duarte et al. (2014) [18].  
 
Table 3. 1: List of metabolites identified and quantified by 1H-NMR. 
Metabolites identified and quantified by 
1
H-NMR 
Glucose Histidine Tryptophan Glycerol 
Lactate Isoleucine Tyrosine Hypoxanthine 
Glutamine Leucine Valine Isobutyrate 
Glutamate Lysine Acetate Glyc-3-PC 
Alanine Methionine Choline Phosphocholine 
Arginine Phenylalanine Citrate Pyruvate 
Asparagine Proline Ethanolamine Succinate 
Aspartate Serine Formate Thymidine 




3. Results  
3.1. Exometabolome analysis during growth of HEK293 and 1G3 cells 
HEK293 and 1G3 cells were grown in the same serum-free media and the 
supernatant composition analyzed along culture time using 
1
H-NMR. The final 
goal was to detect and quantify the highest amount possible of extracellular 
metabolites, in order to obtain an extended overview of both cells 





Figure 3. 1: A) Profiles of 1G3 and HEK293 cells growth cultured in shake flasks. B) Evolution of 
the 
1
H-NMR spectrum of the supernatant over culture time (0h, 24h, 96h, 120h and 192h) for 
HEK293 cells. (Xv – viable cell concentration; DSS – internal standard for metabolite quantification). 
 
 
Besides the main substrates (glucose and amino acids) and lactate, normally 
analyzed in mammalian cell cultures, it was possible to quantify pyruvate, 
acetate, the phospholipid precursors choline and ethanolamine, the nucleotide 
precursors hypoxanthine and thymidine, as well as several by-products (Figure 
3. 2, Table 3. 1).  
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Figure 3. 2: Concentration profiles of selected metabolites in shake flask cultures of 1G3 and 
HEK293 cells. 
 
Despite the similar growth profiles of HEK293 and 1G3 cells (Figure 3. 1A), 
the concentration profiles of specific metabolites were markedly different 
(Figure 3. 2). For instance, when glutamine is above 1 mM in the medium, 
HEK293 cells secrete alanine at higher rates than 1G3 cells. When glutamine is 
limiting, 1G3 cells start to consume glutamate and alanine, while HEK293 cells 
do not consume glutamate but take up alanine at higher rates. Another 
interesting difference between these cell lines concerns acetate, which was 
avidly uptaken by HEK293 cells until depletion, while 1G3 cells consumed it at a 
lower rate and only during the later phase of growth. 
Pyruvate uptake was similar for the two cell lines, and was higher during the 
first 96 hours of culture (Figure 3. 2). Choline and ethanolamine are part of the 
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medium composition but both cell lines consume preferentially choline as 
precursor of cell membrane phospholipids. At 144 hours of culture, choline 
concentration was exhausted and HEK293 cells, but not 1G3, started to take up 
ethanolamine. The nucleotide precursor hypoxanthine was depleted very early 
in both cultures, and thymidine was more rapidly consumed by HEK293 cells.  
Regarding metabolite secretion, lactate was the main by-product, being 
secreted at high levels in both cell lines, but other metabolites were also 
accumulated. Glycerol and isobutyrate also accumulated in the supernatant 
towards the end of the growth phase in both cell cultures. Formate was 
secreted until 72 hours of culture in the case of 1G3 cells and at a higher rate 
until 144 hours for HEK293 cells, following which it started to be consumed. 
The TCA cycle intermediates, like succinate, were also secreted to the 
supernatant. Finally, phosphocholine and glycerol-3-phosphocholine (Glyc-3-PC), 
both by-products from choline metabolism, were detected in increasing 
amounts after the initial 48 hours of culture (Figure 3. 2).  
Overall, the results show that these human cell lines, derived from different 
tissues, exhibit several metabolic differences when cultured in the same 
medium. In particular, they respond differently to exhaustion of glutamine, 
consuming or not some medium components, and secrete at different rates by-
products. 
 
3.2. Impact of adenovirus infection  
To evaluate the impact of adenovirus infection at the exometabolome level, 
1G3 and HEK293 cells were infected with AdV5-GFP and supernatant samples 
were collected over time and analysed by 
1
H-NMR. Both cell lines were infected 
at two different cell concentrations (1 and 3x10
6
 cell/mL) with a MOI of 5 ip/cell. 
The per cell productivity was lower when infection was performed at high cell 
concentration (Table 3. 2). Productivity levels for 1G3 cells decreased from 375 
to 268 ip/cell, but still correspond to a 2.3-fold increase in volumetric titer. In 
the case of HEK293 cells, productivity levels presented a more pronounced 
decrease from 605 to 35 ip/cell, corresponding to 16-fold less AdV5-GFP per 
cell when were infected at CCI3.  
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Table 3. 2: Volumetric (ip/mL) and specific (ip/cell) adenovirus yields at 48 hpi in shake flask for 
1G3 and HEK293 cells at CCI 1 or 3x10
6
 cell/mL.  
 1G3 cells HEK293 cells 
 CCI1 CCI3 CCI3/CCI1 CCI1 CCI3 CCI3/CCI1 
ip/mL 3.8 x 10
8
 8.6 x 10
8
 2.3 6.1 x10
8
 1.3 x 10
8
 0.2 
ip/cell 375 268 0.7 605 37 0.1 
 
Metabolite uptake and secretion rates were determined during the early 
phase of infection (from 0 to 24 hpi; Figure 3. 3). As a major response to 
adenovirus infection, both cell lines increased consumption of glucose (on 
average 2-fold) and secretion of lactate (up to 4-fold). Although these rates 
decreased at high CCI, their up-regulation upon infection could still be 
observed. Concerning glutamine, HEK293 cells consumed this amino acid at 
higher rates than 1G3 cells, as observed under non-infected conditions. Alanine 
secretion/consumption was not affected by adenovirus infection: at low cell 
densities, HEK293 cells produced alanine at higher rates than 1G3 cells, while 
at high cell concentrations HEK293 cells consumed alanine at higher rates than 
1G3 cells. Glutamate secretion increased over 3-fold in infected cultures. 
Choline consumption increased upon infection at CCI1, while at CCI3 remained 
similar to non-infected conditions for both cell lines.  
 
Figure 3. 3: Specific uptake/secretion rates of metabolites in non-infected and infected shake flask 
cultures, at CCI1 and CCI3. Specific rates were calculated by linear fit of extracellular metabolite 
concentrations vs. the integral of cell number. Negative values represent consumption and positive 




Analysis of other metabolites further pointed out interesting differences in the 
response of each cell line to adenovirus infection. For instance, acetate 
consumption and formate secretion increased upon infection of HEK293 cells at 
low CCIs but not for 1G3 cells. Succinate secretion increased in infected 
cultures of HEK293 cells at CCI1, while it decreased for 1G3 cells. No other 
relevant changes were observed. 
 
3.3. Impact of adenovirus infection in bioreactor cultures with glutamine re-
feed 
Next, we evaluated the impact of adenovirus infection at low and high cell 
densities under oxygen and pH controlled conditions (Figure 3.4A). To avoid 
glutamine exhaustion, as observed in shake flask cultures at CCI3, the 
concentration of this amino acid was replenished to 5 mM, 24 hours prior 
infection (Figure 3.4B). Infections performed at CCI1 produced over 1.5-fold 
higher ip’s per cell than in shake flask cultures (Figure 3.4C). Moreover, a cell 
density effect on adenovirus replication was not observed for 1G3 cells, while 
for HEK293 cells the per cell productivity decreased to half when infection was 
performed at CCI3 compared to CCI1.  
The culture media composition was analyzed along culture time and specific 
uptake/secretion rates were determined for non-infected and infected 
bioreactor cultures (Figure 3.4D). The two cell lines displayed different rates of 
glucose consumption and lactate production in non-infected cultures (around 2-
fold-higher for 1G3 cells). Upon infection, these rates were up-regulated by a 
factor of 3 for HEK293 and 1.5 for 1G3 cells at CCI1 and with less extent for 
both cell lines at CCI 3.  With regard to glutamine consumption, 1G3 cells 
maintained the same uptake rate in non-infected and infected cultures at both 
CCI’s, while HEK293 cells increased glutamine consumption by 2-fold upon 
infection (as opposed to what was observed in shake flask cultures). Alanine 
secretion was higher for HEK293 cells, increasing by 2-fold at CCI1 and 
decreasing 3-fold at CCI3 compared to non-infected conditions. By turn, 1G3 
cells kept the same alanine secretion rate in non-infected and infected cultures 
(as observed in shake flask cultures) (Figure 3.4D). 
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Figure 3. 4: Adenovirus replication of 1G3 and HEK293 cells in bioreactor cultures infected with 
AdV5-GFP at CCI 1 or 3x10
6
 cell/mL. A) Viable cell concentration profiles (Xv). The arrows represent 
the time of infection (CCI 1 and CCI 3 and the time of glutamine re-feed). B) Profiles of glutamine 
concentration. C) Volumetric (ip/mL) and specific (ip/cell) AdV5-GFP yields at 48 hpi and titers 
normalized to CCI1. D) Specific uptake/secretion rates of metabolites in non-infected and infected 
bioreactor cultures. Specific rates were calculated by linear fit of extracellular metabolite 
concentrations vs. the integral of cell number. Negative values represent consumption and positive 
values represent secretion of metabolites. 
 
Formate secretion increased in infected cultures at CCI1 for both cell lines in 
bioreactors, while in shake flask cultures, an increase was only observed for 
HEK293 cells. Also, choline consumption and glycerol-3-phosphate secretion 
increased upon infection at CCI1 and decreased at CCI3 for both cell lines.  
 
4. Discussion 
Viruses require host cellular metabolism to provide the energy and 
molecular building blocks needed for successful replication. In this study, we 
resorted to 
1
H-NMR spectroscopy to identify metabolic differences between two 
human cell lines, 1G3 and HEK293, in scenarios of growth and adenovirus 
infection at low and high cell densities. It was possible to detect and quantify 
Chapter 3 
 106 
changes in culture media composition throughout culture time, including 
metabolites that are not normally analysed in mammalian cells cultures. More 
specifically, we could identify and precisely quantify 35 metabolites, such as 
acetate, pyruvate, formate, TCA cycle intermediates, amino acids, lipid and 
nucleotide precursors.  
Glutamine was the most consumed amino acid by both 1G3 and HEK293 
cells, however HEK293 cells consumed glutamine and secreted alanine at higher 
rates than 1G3 cells. Moreover, when glutamine was at limiting levels, HEK293 
cells consumed alanine at higher rates, but 1G3 cells started to take up 
glutamate in addition to alanine. It has been shown that adapting HEK293 cells 
to grow in glutamate supplemented medium instead of glutamine could 
contribute for an increase in AdV productivity [8].  
Another interesting difference was the acetate consumption observed by 
HEK293 cells, but not in 1G3 cells. The principal entry point of acetate into 
mammalian metabolic network is by conversion to acetyl-CoA by the cytosolic 
enzyme acetyl-CoA synthetase (ACS) [19-21]. Acetyl-CoA then enters the TCA 
cycle by condensing with oxaloacetate to form citrate, or can be used for fatty 
acid synthesis and protein acetylation [22]. It has been reported that the activity 
of ACS varies from tissue to tissue and that kidney, from where HEK293 cells 
are derived, is one of the tissues with higher activity [23, 24]. Indeed, the 
different metabolic signatures of 1G3 and HEK293 cells are certainly related 
with their different origins. Several human cell lines from different tissues, 
including HEK293 cells, have been proteomically profiled revealing differences 
in enzyme levels from multiple metabolic pathways, including fatty acid 
metabolism, amino acid metabolism and glutathione metabolism [25]. 
Hypoxanthine and thymidine, nucleotide precursors, were metabolites 
identified that were consumed rapidly by both cell lines. Although not essential, 
it has been reported that these two metabolites contribute to decrease the lag 
phase regardless of the seeding concentration by stimulating the initial growth 
rate [26]. Glycerol and isobutyrate were also accumulated in the supernatant 
towards the end of the growth phase in both cell cultures. The accumulation of 
these metabolites has been also reported for CHO cells [27]. The TCA cycle 
intermediate succinate was also secreted to the supernatant, as reported for 
MDCK cells [28] and CHO cells [27, 29, 30]. 
Metabolic Alterations Induced by Virus Infection 
 107 
The metabolic response of both cell lines to adenovirus infection was 
assessed by performing synchronous infections (MOI 5) at 1 and 3×10
6
 cell/ml 
using two culture systems, shake flasks and bioreactors. Bioreactors were used 
to make sure pH was not affecting AdV productivity and since it is known that 
values lower than 7.2 affect productivity [31, 32]. Besides being a good down 
scale model for several process parameters, the use of shake flask do not allow 
pH control and we have previously showed that HEK293 and 1G3 cell cultures in 
this conditions can achieve pH’s lowers than 6.5 [4]. Regardless of the culture 
system, cell line and CCI, glucose consumption and lactate production rates 
were up-regulated upon adenoviral infection. Most viruses induce aerobic 
glycolysis (also known as the Warburg effect) in the host cell metabolism [33, 
34], including human cytomegalovirus  [35],  hepatis C virus [36] and Dengue 
virus [37], among others [34]. It was recently shown that the expression of the 
viral gene E4ORF1 is necessary for adenovirus induced upregulation of 
glycolysis by activation of Myc and allow maximal adenovirus replication [38]. 
An important aspect of viral vector production is the so-called cell density 
effect on infection, described for adeno [7, 8, 39] and other viruses [40]. Here, 
adenovirus replication was negatively impacted at high CCI and the decrease in 
productivity was much higher for HEK293 cells [4]. The use of controlled 
bioreactors and glutamine replenishing allowed an increase in AdV 
productivities at CCI3, bringing the specific yields closer to those obtained at 
low CCIs. In these conditions, 1G3 cells maintained the same glutamine uptake 
rate in non-infected and infected cultures, while HEK293 cells increased 
glutamine consumption by 2-fold upon infection at both CCIs. These results 
confirmed that 1G3 cells are less dependent on glutamine metabolism than 
HEK293 cells, as previously reported [4]. This characteristic has also been 
described for PER.C6 cells [41]. Since glucose carbon is shunt into lactate 
production as well as fatty acid synthesis, glutamine is required as an 
anaplerotic substrate to fuel the TCA cycle. A number of viruses have also been 
shown to require glutamine for replication [34], such as polioviruses [42], 
human cytomegalovirus [43] and vaccinia viruses [44]. Interestingly, a 
metabolomics study of primary HFF cells infected with vaccinia virus showed 
that infection increases intracellular glutamine and glutamate levels but does 
not increase glycolytic metabolites [44].  
Chapter 3 
 108 
From the comprehensive analysis of medium composition performed in this 
work, only acetate (besides glutamine) was depleted in HEK293 cell cultures 
infected at CCI3. Therefore, the replication of adenovirus in this cell line at high 
cell densities should be examined with acetate supplementation. Overall, our 
systematic study using 
1
H-NMR showed that this technique can contribute to a 
better understanding of the metabolic needs for adenoviruses production, and 
permitted to highlight a number of metabolic differences of two human 
producer cell lines. 
1
H-NMR has been also applied to study the impact of 
echovirus infection [45], the effect of productivity enhancers on the metabolism 
of CHO cells [27], or to characterize  the composition of conditioned medium in 
stem cell cultures [46]. 
 Future studies should focus on carbon labelling experiments to follow the 
incorporation of tracer substrates into the different metabolic pathways 
recruited by infection. This will allow a more detailed metabolic signature of 
adenovirus infection, and help to devise cell and/or process engineering 
strategies like more specific fed-batch supplementations besides glucose and 
glutamine that will help to improve adenovirus production.  
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Peste des Petits Ruminants (PPR) is considered as one of the major 
constraints to the productivity of small ruminants in Africa and Asian countries. 
Currently PPR control is done by vaccination with an attenuated PPR strain 
(Nigeria 75/1) produced in monolayers of Vero cells grown in roller bottles or 
static flasks. 
This work focuses on the production of a PPR vaccine strain using stirred 
conditions as an advanced option for process scale-up. Non-porous 
microcarriers (Cytodex-1

) were used to support Vero cell growth in suspension 
cultures. The use of Ex-Cell
TM
 medium could improve cell specific productivities 
obtained with standard serum containing medium, independently of the type of 
system used, i.e. static as well as suspension stirred cultures.  
As an alternative, several cell lines adapted to grow as single cells in 
suspension (CHO-K1, BHK-21A and HEK293) and another anchorage dependent 
(MRC-5) were evaluated in their capacity to produce a PPR vaccine. BHK-21A and 
HEK293 cells grown as single cell suspension in serum-free medium were both 





/ml. However, for the HEK293 cells, these results were only obtained 
2-3 days later. CHO-K1 and MRC-5 cells have shown not to be suitable to 
adequately produce this virus.  
These results provide further insights into the feasibility of applying 
microcarrier cell culture technology to produce PPR vaccine in Vero cells as well 
as in the alternative use of single cell suspension cultures of BHK-21A, 
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Peste des Petits Ruminants (PPR) is an acute, highly contagious and fatal 
disease of sheep and goats and is considered as one of the major constraints to 
the productivity of small ruminants in Africa and Asian countries [1]. The 
causative agent, PPR virus (PPRV), is a member of the genus Morbillivirus within 
the Paramyxoviridae family and is antigenically closely related to the Rinderpest 
(RP) virus [2], another member of the genus Morbillivirus that causes similar 
diseases in wild and domestic ruminants. The PPR disease is characterized by 
high fever, ocular and nasal discharges, pneumonia, necrosis and ulceration of 
the mucous membrane and inflammation of the gastro-intestinal tract leading 
to severe diarrhea. The main characteristic of the pathogenesis of PPRV 
infection, as for all other Morbilliviruses, is the profound but transient 
immunosuppression induced by this virus in its host with the consequence of 
increased susceptibility to opportunistic infections and increased mortality. The 
PPR virus is enveloped, pleiomorphic and has a single-stranded RNA genome of 
negative-sense. It is composed of 15,948 nucleotides, the longest of all 
Morbillivirus genomes sequenced so far [3].  The viral replication occurs in the 
host cell cytoplasm and the virus is released by budding [4]. However, these 
mechanisms are not very efficient in this virus family and a substantial amount 
of the produced viruses are kept associated to the host cells membranes.  
Until recently an heterologous Rinderpest vaccine has been used for the 
control of PPR [5]; however, due to the ongoing Rinderpest eradication 
programs, the use of this vaccine for the control of PPR has been restricted or 
banned to avoid complications in RP sero-surveillance. The need for a PPR 
homologous vaccine led to the development of an attenuated viral vaccine 
based on the strain PPR 75/1, isolated in Nigeria in 1975 [6]. This strain was 
attenuated by 74 serial passages in Vero cell cultures [5] and it is currently the 
only vaccine permitted for use in sheep and goats [7], the efficacy being 




 [8].  
Nowadays this vaccine is produced in Vero cells using classical techniques, 
i.e in T-flasks or roller bottles. These strategies involve high efforts concerning 
consumables and have limited scalability, significantly increasing the 
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bioprocess costs. Thus there is a need for better vaccine production processes 
for controlling future PPR outbreaks.  
Vero cells (from African green monkey kidney), together with other 
anchorage-dependent cell lines like Madin-Darby bovine or canine kidney (MDBK 
or MDCK) and human diploid lung fibroblast (MRC-5), have been traditionally 
used for viral vaccine production; however, being strictly anchorage dependent, 
these cells require the use of microcarrier technology for production in scalable 
stirred tanks. Bioprocesses using Vero cells grown in microcarriers have been 
reported for the production of amongst others, Rabies virus [9], Reovirus [10], 
Japanese encephalitis virus [11], with or without the use of a serum-free 
medium. Stirred tank bioreactors allow for a fine control of cell environment 
(nutrients, pH, O
2
 and agitation) permitting different modes of operation (batch, 
fed-batch and perfusion). Nevertheless, the use of microcarriers not only 
significantly increases the cost of the process but also requires extra 
optimization steps during development (e.g. microcarrier type and 
concentration, optimum inoculation concentration, harvesting time) [9, 12, 13]. 
Thus, to avoid the use of microcarriers, some of the “more” industrial anchorage 
dependent cell lines (CHO, BHK and HEK293) have been adapted to grow as 
single cells in suspension [14-20], allowing for higher cell densities with 
concomitant increases in volumetric productivities and an easier scalability of 
the manufacturing processes. However, the use of these cell hosts for viral 
propagation is not straightforward: depending on the virus, host cell 
characteristics can affect viral infection and replication hampering either 
vaccine production and/or its efficacy.  
Another critical aspect in the production of live-attenuated viral vaccines is 
the maintenance of the attenuation characteristics of the vaccine strain, i.e. 
ensuring that no reversion to virulence takes place during the propagation and 
production phases of the bioprocess. A strategy commonly used to maximize 
the maintenance of the attenuated phenotype is to decrease the number of 
virus amplification steps. Vaccine production should be based on the virus seed 
lot system and the working virus seed lot should not be more than five 
passages from the master virus seed lot [21].  
It was recently reported that, for the Rinderpest (RP) virus vaccine strain, 
also attenuated by several passages in Vero cells, the attenuating mutations 
occur in most of its genes, none of which being sufficiently debilitating to 
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induce strong pressure for reversion [22]. In the case of the PPRV vaccine, the 
attenuated phenotype is not yet characterized and no data is available 
regarding the spontaneous reversion to virulence; due to the close relation to 
RP (same family and same genus) a similar behavior is expected.  
In this work a cultivation system using Vero cells and microcarrier 
technology was established for producing a PPRV attenuated vaccine. In parallel, 
the permissibility of BHK-21A, CHO-K1, MRC-5 and HEK293 cells for PPRV 
production was evaluated. Finally, the possibility of producing this vaccine in a 
commercially available defined, serum-free medium was also assessed.  
 
2. MATERIALS AND METHODS 
2.1. Cells and Virus  
Vero cells (ECACC, 84113001) were maintained in Minimum Essential 
Medium (MEM), supplemented with 2 mM glutamine and with 10% (v/v) Foetal 
Bovine Serum (FBS). BHK-21A cells (a subclone of ATCC accession CCL-10) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 2 mM 
glutamine and 5% (v/v) FBS. CHO-K1 cells (ATCC, CCL-61) were maintained in 
DMEM/HAM’s F12 containing 4 g/L glucose, 4 mM glutamine and 5% (v/v) FBS. 
MRC-5 cells (ECACC, 97112601) and HEK293 adherent cells (ATCC, CRL-1573) 
were maintained in MEM with 2 mM glutamine and supplemented with 5% (v/v) 
FBS. All media and supplements were from Gibco except the DMEM/HAM’s F12 
and the glucose, purchased from Sigma. All adherent cells were incubated at 
37ºC in a humidified atmosphere of 5% CO
2
 in air. Suspension-adapted human 
HEK293 cells were grown in 125 ml Erlenmeyer flasks, with 40 mL CD293, a 
serum-free medium (Gibco) supplemented with 6 mM glutamine at 37ºC in a 
humidified atmosphere of 8% CO
2
 in air, using orbital agitation (approx. 160 
rpm). Routinely an inoculum of 0.5 x 10
6
 cell/mL was used. Suspension-adapted 
human BHK-21A cells were grown in 125 ml Erlenmeyer flasks, with 35 mL 
SFM4CHO, a serum-free medium (Hyclone) with 35 mM glucose, 3.5 mM 
glutamine and 0.05% (w/v) Pluronic-F68 (Sigma), at 37ºC in a humidified 
atmosphere of 7% of CO
2
 in air, using orbital agitation (approx. 110 rpm). 
Routinely an inoculum of 0.35 x 10
6
 cell/mL was used.  
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The PPR vaccine strain used was PPRV (Nig 75/1), kindly provided by Dr. 
Geneviève Libeau (CIRAD-EMVT, France), at passage 75. This strain was 
routinely amplified in Vero cells and stored at -80ºC, using standard techniques 
[8]. The seed virus bank was prepared and stored in MEM medium with 2% (v/v) 




/mL, from passage 76 to 77 not exceeding 5 
passages from the master seed bank of the vaccine, according to Diallo et al [5]. 
 
2.2. Production of PPRV in monolayer cultures  
To evaluate the ability of different cell lines to produce PPRV, BHK-21A, 
MRC-5, CHO-K1, HEK293 and Vero cells were seeded at 0.1 x 10
6
 cell/mL in 
25 cm
2 
T-flasks, to a final culture volume of 5 mL per flask. 24-hours (h) after 
inoculation the cells were infected with PPRV using a multiplicity of infection 
(MOI) of 0.1. The flasks were incubated at 37°C in a humidified atmosphere of 
5% CO2 in air. The cultures were checked daily for development of cytopathic 
effect (cpe). The same strategy was used to evaluate the effect of lower MOIs 
(0.01 and 0.001) in PPRV production in Vero, HEK293 and BHK-21A cells. To 
monitor the infection kinetics, one flask was harvested daily and its content 
(cells plus supernatant) stored at -80ºC prior to virus titration. 
 
2.2.1. Effect of serum-free medium in PPRV production on Vero Cells 
Vero cells were inoculated directly into VP-SFM (Gibco) or Ex-Cell
TM
 for Vero 
(SAFC) (from this point onwards just referred as Ex-Cell
TM
) serum-free medium 
supplemented with 4 mM glutamine from cells grown in MEM containing 10% 
(v/v) FBS after a centrifugation (10 min, 500 g) to remove the serum containing 
medium. The cells were seeded and infected 24 hours after inoculation using a 
MOI of 0.01, and were monitored as described above (2.2). 
 
2.3. Production of PPRV in stirred cultures  
2.3.1. Vero cells on microcarriers cultures  
Cultures were carried out in 125-mL spinner vessels (Wheaton, Millville, USA) 
previously silanized with a solution of dimethyldichlorosilane (Merck, 
Darmstadt, Germany). Cytodex-1

 microcarriers (MCs) (GE HealthCare, Sweden) 
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were prepared (3g/L) according to the manufacturer’s instructions, and 
sterilized “in situ”. Prior to use, the MCs were washed twice with pre-warmed 
culture medium and incubated for 15 minutes at 37ºC before cell inoculation. 
The cell inoculum was obtained from 175 cm
2
 T-flasks (Nunc) with confluent 
Vero cells growing in MEM supplemented with 2 mM glutamine and 10% (v/v) 
FBS. The spinners were inoculated with 0.1 x 10
6
 cell/mL and were maintained 
in a humidified atmosphere of 5% CO
2
 in air at 37ºC. The cultures were stirred 
continuously at 50 rpm from the inset of inoculation. To evaluate the total cell 
number, an aliquot of 1mL of the culture suspension was washed once with 
phosphate buffered saline (PBS), then treated in 0.95 mL of 0.1M citric acid 
(Merck, Darmstadt, Germany) containing 0.1% (w/v) crystal violet solution 
(Merck, Darmstadt, Germany) and 1% (v/v) Triton X-100 (Sigma) and incubated at 
least 1 h at 37ºC. The released nuclei were counted using a Fuchs-Rosenthal 
counting chamber (Brand). 
The specific growth rate, µ (h
-1












       (1) 
where X represents the cell number per mL, t represents the time points of 
sampling expressed in hours (between 24 to 96 h that corresponds to the 
exponential phase of cell growth), the subscripts n and n-1 defining two 
succeeding sampling points.  
The cell doubling time (t
d




td           (2) 
  
2.3.1.1. Effect of MOI in PPRV production 
Cells were inoculated as described above (2.3.1) with MEM medium 
supplemented with 10% (v/v) FBS. 24 h later the cells were infected with PPRV 
using MOI’s of 0.1, 0.01 and 0.001. Samples were taken daily to perform cell 
counting and virus titration. 
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2.3.1.2. Effect of culture medium in PPRV production 
Cells were inoculated as described in 2.3.1 with MEM medium supplemented 
with 2% (v/v) FBS or with Ex-Cell
TM
 medium supplemented with 4 mM glutamine 
and with CaCl
2
 to a final concentration of 200 mg/mL to improve cell 
attachment onto microcarriers. The inoculum was obtained  from 175 cm
2
 T-
flasks (Nunc) with confluent Vero cells after centrifugation (10 minutes, 500 g)  
to change the MEM medium with 10% (v/v) FBS for the respective culture 
medium. 24 hours after inoculation the cells were infected with PPRV using a 
MOI of 0.01. At infection, in one of the experiments 90% of MEM medium with 
2% (v/v) FBS was replaced by Ex-Cell
TM
 Vero medium supplemented with 4mM 
glutamine. Samples were taken daily to perform cell counting and virus 
titration. 
 
2.3.2. HEK293 and BHK-21A cells in single cell suspension cultures: Effect of MOI 
in PPRV production 
HEK293 and BHK-21A cells were seeded routinely as described above (2.1) 
and 24 hours later were infected with a PPRV suspension using different MOIs 
namely, 0.1, 0.01 and 0.001. To monitor the infection kinetics 1 mL samples 
were taken daily and stored at -80ºC pending virus titration.  
 
2.3.3. PPRV production in Vero cells and BHK-21A cells using STB  
Bioreactor cultures were performed with 2L working volume in fully 
equipped Biostat DCU-I 2-L vessels (Sartorius Stedium, Biotech GmbH) with two 
6-blade Rushton impellers for BHK-21A cells or two 3-blade impellers for Vero 





was controlled with constant airflow by varying sequentially the nitrogen and 
oxygen partial pressures in gas inlet. For BHK-21A cells, pO
2
 was controlled at 
30% air saturation with an agitation rate of 60 rpm (0.02 L/min with ring 
sparger) and for Vero cells pO
2
 was controlled at 40% air saturation with an 
agitation rate of 50 rpm (0.1 L/min by headspace). pH was controlled at 7.2 by 
aeration with a CO
2
 gas-mixture and 1M NaHCO3. 
Vero cells inoculum was obtained from 175 cm
2
 T-flasks (Nunc) with 
confluent cells grown in MEM supplemented with 2 mM glutamine and 10% (v/v) 
and the process was done using the same culture medium.  Microcarriers were 
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treated as previously described in section 2.3.1 in the cell inoculation flask and 
the bioreactor vessel was also previously silanized. Before bioreactor 
inoculation, Vero cells (0.1 x 10
6
 cell/mL) were allowed to slightly attach to the 
microcarriers before transfer to the bioreactor. BHK-21A cells were culture 
routinely as described above (2.1) and the bioreactor was perform with an 
inoculum of 0.35 x 10
6
 cell/mL in serum-free medium. The cultures were 
infected at 24 hours-post inoculation with an MOI 0.01 for Vero cells and MOI 
0.01 for BHK-21A cells. To monitor the infection kinetics 1 mL samples were 
taken daily and stored at -80ºC pending virus titration. 
 
2.4. Virus Titration 
Virus titration (TCID
50
) was done with Vero cells in 96 well microtiter plates 
using standard cell culture procedures [8]. Briefly, 10-fold serial dilution of 
samples in MEM containing 10% (v/v) FBS were prepared. For each dilution 12 
replicates were done with 100 L virus suspension and 100 L cell suspension 
(0.2x10
6
 cell/mL) per well. All the test plates were incubated at 37 ºC in a 
humidified atmosphere of 5% CO
2 
in air. Cytopathic effect (cpe) was checked on 
day 12 of titration. End points (TCID
50
/mL) were calculated according to the 
statistical method of Spearman-Karber [23], simplified for calculations in MS 
Excel format. All the samples were titrated in triplicate and the experiments 
were repeated at least twice. Each sample was freeze/thawed (1x) to ensure 
release of virus from cell debris and cell membranes. This procedure is required 
because in this viral family, the virus release mechanisms are not very efficient 
and part of the virus stays cell-associated. This procedure can increase the 
harvested virus production titer by up to 1 log [24]. 
 
3. RESULTS 
3.1. PPRV production in Vero cells in static cultures 
To assess the effect of the MOI in PPRV productivity using static conditions, 
Vero cells grown as monolayers were infected 24 hours post-inoculation with 
MOIs of 0.1, 0.01 and 0.001.  
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Figure 4. 1: Effect of MOI in PPRV production using monolayer cultures of Vero cells under static 
conditions with MEM supplemented with 10% (v/v) FBS. Error bars represent the standard error of 
triplicates. 
 
The results, presented in Figure 4. 1, show that PPRV productivity was 




/mL) when a MOI of 0.01 was used; the lower 
productivity being obtained for 0.001. 
In order to select a serum-free medium for Vero cell growth and PPRV 
production, two different commercially available formulations, VP-SFM and 
Ex-Cell
TM
 where tested for their ability to produce PPRV. Cells cultured using 
serum containing medium were collected, centrifuged and cultured directly into 
the serum-free medium; 24 hours post inoculation they were infected with a 
MOI of 0.01.  
 
Figure 4. 2: Effect of serum-free media in the production of PPRV using monolayer cultures of Vero 
cells in static conditions (MOI of 0.01). MEM 10% FBS ( ); Ex-Cell
TM
 ( ); VP-SFM (  ). The lines are 






 medium showed to be able to slightly increase the PPRV volumetric 
productivity comparing to the PPRV productivity obtained using the MEM 
medium (Figure 4. 2). The use of VP-SFM resulted in 1 log decrease in the PPRV 
productivity. The maximum cell density obtained was similar for all the culture 
media used; however, for the serum-free media such maximum was achieved 1 
day later (data not shown) and thus the highest viral titer was obtained 1-2 days 
later than when MEM was used. The maximum viral titer obtained with the MEM 
medium was rapidly lost with increasing culture time showing that the virus is 
not very stable under these conditions. Although the maximum productivity is 
obtained at a later time, when serum-free media are used, the higher viral titers 
obtained could be maintained for longer periods of time.  
 
3.2. PPRV production in Vero cells on microcarrier cultures 
To evaluate the feasibility to produce PPRV in stirred tank bioreactors Vero 
cells were grown on Cytodex-1

 microcarriers with MEM supplemented with 10% 
FBS and infected with different MOIs.  
 
         
Figure 4. 3: Effect of MOI in cell growth (A) and PPRV production (B) by Vero cells grown on 3 g/L 
of Cytodex-1

 in spinner flask in MEM medium supplemented with 10% (v/v) FBS. Control Cells ( ); 
MOI 0.1 ( ); MOI 0.01 ( ); MOI 0.001 ( ); the arrow corresponds to time of infection. Error bars 
represent the standard error of triplicates and the lines are guides to follow the progression of the 
data. 
 
Cell concentrations of cultures infected with decreasing MOIs reached 
increasingly higher maximum cell yields (Figure 4. 3, A). As expected, the 
cultures also attained their maximum cell yield at different times, as a function 
of the MOIs used. At MOIs of 0.1 and 0.01 the cells stopped growing and the 
cell concentration started to decrease at about 96 hours post-infection (hpi). At 
Scalable culture systems using different cell lines for the Production of Peste des Petits Ruminants Vaccine 
 125 
the lowest MOI used (0.001) the maximum cell yield reached was slightly lower 
than that of the control. Cell growth rate was not affected after viral infection 
and was maintained at approx. 0.028 ± 0.004 h
-1
, corresponding to a doubling 
time of approx.  25 h. 
The volumetric PPRV titers are shown in Figure 4. 3, B. Cells infected at 
higher MOIs reached maximum titers earlier than the cultures infected at lower 
MOIs. Furthermore, for the lowest MOI, lower maximum viral yields were 
obtained. The cultures infected with the midrange MOI (0.01) led to the higher 









/mL) at 96 hpi. The lower MOIs tested allowed the maintenance of higher 
titers for longer whereas for the higher MOIs the maximum titers achieved were 
more rapidly lost along culture time.   
 
3.2.1. Effect of culture media composition in PPRV production in Vero cells on 
microcarrier cultures 
Figure 4 shows the effect of the culture media composition upon PPRV 
production in Vero cells grown on Cytodex-1

 microcarriers. The maximum cell 
concentration was achieved for cells grown in MEM supplemented with 10% FBS 
(1.4 x 10
6
 cell/mL). When the serum concentration was reduced to 2%, the 
specific cell growth rate was not affected (0.028 ± 0.004 h
-1
) but the maximum 
cell concentration decreased to 0.6 x 10
6
 cell/mL. The maximum cell density for 
cells grown in the Ex-Cell
TM
 medium was lower (0.8-1.0 x 10
6
 cell/mL) than for 
the cells grown in the 10% FBS containing medium.  
 
Figure 4. 4: PPRV productivity at a MOI of 0.01 from Vero cells grown in microcarrier cultures in 
different culture media. Ex-Cell
TM
(ex) - Cells inoculation with MEM 2% and 90% medium exchange at 
infection to Ex-Cell
TM 




Meanwhile, a decrease in viral yields was obtained when cells were grown in 
MEM with 2% FBS; the corresponding maximum titers were achieved at 96 hpi. 
After this period, and similarly to what was previously observed for static 
cultures (Figure 4. 2), a significant decrease in viral titer was observed for the 
remaining time of the culture. Although the maximum cell density was lower for 
the Ex-Cell
TM
 medium than for the MEM medium with 10% FBS, viral volumetric 
productivity was comparable, depicting an increased cell specific productivity 






 medium exchange at infection and 




 for cells grown in Ex-Cell
TM
). As for monolayer cultures 
grown in static conditions the higher titers were maintained for longer periods 
when Ex-Cell
TM
 medium was used. 
 
3.3. Evaluating different cell lines for the production of PPRV 
The ability of five cell lines to support the production of PPRV was assessed 
in monolayer cultures grown in stationary conditions: two anchorage-dependent 
cell lines (i) Vero (the cell line normally used for the production of this vaccine) 
and MRC-5 and (ii) three cell lines adapted to grow as single cells in suspension, 
293, BHK-21A, CHO-K1. The cells were infected at a MOI of 0.1 at 24 hours post 





maximum PPRV titer obtained for each cell line is presented in Figure 4.5.   
 
Figure 4.5: Effect of cell line in PPRV production using a MOI of 0.1 in Vero, MRC-5, HEK293, 
BHK-21A and CHO-K1 cells. (The data correspond to the maximal virus titer obtained and error 
bars represent the standard error of triplicates.) 
 
The virus was able to replicate and the titer increased by at least 2 orders of 
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contrast, there was no amplification of virus in MRC-5 and CHO-K1 cells. The 
maximum volumetric PPRV productivity occurred after 96 hpi for Vero cells and 
BHK-21A. A delay of 24 hours was observed for HEK293 cells, where the 
maximum titer was achieved around 120 hpi. 
 
   
Figure 4. 6: Effect of MOI and culture system in PPRV production on HEK293 (A) and BHK-21A cells 
(B). Error bars represent the standard error of triplicates. 
 
HEK293 cells are commonly used for viral production, namely for adenovirus 
[16, 17], its use for Rinderpest virus rescue from cloned cDNA having also been 
reported [25]. BHK cells have been used for decades in the production of the 
Foot and Mouth Disease vaccine [14] as well as for experimental rabies vaccine 
in suspension cultures [15]. As the results obtained show it is also possible to 
produce infectious PPRV in HEK293 cells and BHK-21A (Figure 4.5). Given their 
potential, these cell lines were selected for further studies regarding PPRV 
production. First, the effect of lower MOIs, namely 0.01 and 0.001, were tested. 
The results obtained showed that the productivity decreased for lower MOIs and 
the values obtained were somewhat than those obtained for Vero cells (Figure 
4. 6, front bars).  
 
3.4. PPRV production in single cell suspension cultures using HEK293 
and BHK-21A cells 
 
The feasibility of HEK293 and BHK-21A to grow as single cell suspensions in 
stirred tank bioreactors (STB) make them appealing alternatives for PPR 
production.  The results obtained at different MOIs in stirred conditions are 
shown in Figure 4. 6 (back bars). Independently of the MOI tested after viral 
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infection, BHK-21A cells reached a maximum cell concentration of 2.3 x 10
6
 
cell/mL; HEK293 cells grew to a maximum of 3.5 and 2.9 x 10
6
 cell/mL for the 
lower (0.001) and for the higher (0.1) MOIs tested, respectively. These values 
correspond to growth rates of 0.021 ± 0.002 h
-1
 for BHK-21A cells and 
0.018 ± 0.001 h
-1 
for HEK293 cells. The maximum volumetric productivities were 
obtained for BHK-21A at 96 hpi (comparable to Vero cells grown on 
microcarriers) and for HEK293 cells 2-3 days later, i.e. 144 hpi. The different 
MOIs did not affect the final viral yields and the values were similar to those 





Similar volumetric productivities were attained for Vero, BHK-21A and 
HEK293 cultures (Figure 4.5, Figure 4. 6). Since higher cell densities were 
achieved, it is obvious that HEK293 and BHK-21A cell specific productivities 











3.5. PPRV production in STB using Vero cells and BHK-21A cells 
To ensure that production of PPRV is possible in larger scales, the process 
was up-scale to 2 L for Vero and BHK-21A cells using the best MOI obtained for 
each cell line (MOI 0.01 and MOI 0.001, for Vero and BHK-21A cells respectively). 
Both cell lines presented similar growth profiles and PPR virus production than 
those presented at smaller scale (data not shown). The results obtained (Figure 
4. 7) showed that it is possible to maintain PPR virus volumetric productivities 
in STB.  
 
Figure 4. 7: PPRV production on Vero and BHK-21A cells in STB at 96 hours post infection. Error 
bars represent the standard error of triplicates. 
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4. DISCUSSION 
Given the importance of controlling PPR outbreaks, the aim of this work was 
to evaluate alternative conditions for scalable production of a PPR attenuated 
vaccine instead of the currently available PPR vaccine produced in Vero cells 
using static culture systems (roller bottles and/or T-flasks). Our first strategy 
was to assess the feasibility of microcarriers technology, in particular 
Cytodex-1
®
, for PPRV production in stirred tank bioreactor using Vero cells; the 
use of serum-free formulations (Ex-Cell
TM
) was also evaluated. 
Cytodex-1

 allowed for a maximum cell density of 1.5 x 10
6
 cell/mL when 
MEM supplemented with 10% FBS was used (Figure 4. 3). These results are in 
agreement with previous reports by Appaiahgari et al. [26] using similar culture 
conditions and Mendonça et al. [27] using higher microcarriers concentration 
(10 g/L).  
Regarding maximum cell concentration, one serum-free formulation 
(Ex-Cell
TM
) allowed for higher cell densities than MEM containing 10% FBS 
medium (1 and 1.5 x 10
6
 cell/mL, respectively).  Maximum cell yields of 1 to 
2 x 10
6
 cell/mL were previously reported for microcarrier cultures of Vero cells 
using either serum-free or low serum medium formulations [9, 10, 28]; however, 
all these reports used higher inoculum concentrations denoting smaller cell 
expansion ratios. With respect to virus production, serum-free medium allowed 
for higher cell specific productivities. The low PPRV thermostability at 37ºC [29, 
30] being a critical issue for bioprocess development, especially when serum 
containing medium is used, the fact that viral production titers could be 
maintained for longer periods of time at Ex-Cell
TM
 medium (Figure 4. 2) is a 
good indication for enlargement of the bioreactor harvesting window. Moreover, 
bioreaction perfusion strategies previously reported to increase significantly 
rabies virus production in Vero cells [13, 25] could thus be attempted. 
Although Vero cells cultivated using the microcarrier technology and the 
use of serum-free medium showed promising results for the larger scale of PPRV 
production the requirement for a solid matrix to support cell growth in 
bioreactors, make this a costly strategy.   
The ability to produce PPRV using of alternative cells lines able to grow as 
single cells in suspension (BHK-21A, HEK293 and CHO-K1), was evaluated. Their 
performance was compared with Vero and MRC-5 (traditionally used for vaccine 
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production) cells. CHO-K1 and MRC-5 cells have proved not to be suitable for 
PPRV production, eventually due to the lack of cellular receptors necessary for 
the virus to infect them. The cellular receptors are one of the major 
determinants of the host range and tissue tropism of a virus. It is known that 
most of the Morbillivirus use signaling lymphocyte activation molecules (CD150) 
as cellular receptors [31, 32] and some cell culture adapted strains have the 
potential to replicate in different cell lines; however, few things are known 
specifically for PPRV.  
Both BHK-21A and HEK293 were able to produce PPRV (Figure 4.5). In 
contrast to Vero, for the suspension cultures of BHK-21A and HEK293, the 
maximum volumetric titer was independent of the MOI and similar for all cell 
lines tested (Vero, BHK-21A and HEK293) (Figure 4. 6). This approach is an 
appealing alternative for virus production because an infection strategy based 
in a low MOIs overcome extra virus amplification steps, undesirable in industrial 
production, and minimize the virus passage effect. Similar conclusions were 
reported previously for other virus/host cells systems such as 
baculovirus/insect cells [33].  
The lower cell specific productivities obtained for HEK293 and BHK-21A, 
when compared with Vero cells, can result on the “lack of adaptation steps” of 
the virus to these cell lines. Viral infection and replication kinetics depend 
significantly on the virus and the host cell characteristics. It has been reported 
in the literature that PPRV is especially suited to grow in Marmoset B95a Cells 
(adherent cell line derived from the Epstein-Barr virus-transformed marmoset 
B-lymphoblastoid cells). B95a cells are not suitable for vaccine production 
purposes but they can be used for rapid isolation and propagation of several 
Morbilliviruses [24, 34-36]. In vitro, the PPR cytophatic effect is detected much 
earlier in B95a than in Vero cells confirming the dependency of viral replication 
on the cell substrate. PPRV adaptation to Vero cells is characterized by its slow 
and low production yields [5]. The viral stock used in our work was always 
prepared in Vero cells. 
Eventually, the PPRV productivities obtained for HEK293 or BHK-21A cells 
could be increased by a previous adaptation, by serial passage, of the virus to 
these cell substrates. However, the most important problem in preparing live-
attenuated viral vaccines in different cell substrates is (i) retaining the 
attenuation phenotypes and (ii) not causing the reversion to virulence. To our 
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knowledge the attenuation markers from the PPRV vaccine are not yet 
characterized, thus it is not possible to evaluate if the markers are maintained 
when the cell substrate used for PPRV vaccine production is changed. It is not 
possible to know if a low number of passages (<5) will affect pathogenecity; 
however, during development of the live attenuated PPRV vaccine the strain was 
not attenuated until passage 20 in Vero cells and just became avirulent at 
passage 55  [5]. It was also reported for RP virus (RPV), the closely related virus 
of the PPRV family, that the high attenuation and stability of the current vaccine 
(RBOK, attenuated RPV vaccine strain) are due to the accumulation of a number 
of separate mutations, none of which is itself so sufficiently debilitating that 
there is strong selective pressure in favour of the revertant [22].  To ensure that 
the attenuation phenotype was kept as much as possible, we have propagated 
PPRV in Vero cells and the other cell lines were only used for the final 
production run. Since a low MOI can be applied in PPRV production in the 
HEK293 and BHK-21A from of a seed virus produced in Vero cells the current 
seed bank for vaccine production can be applied, minimizing the virus passage. 
In conclusion, the comparison of Vero, HEK293 and BHK-21A cells showed 
that all these cell lines were capable of efficient virus amplification, reaching 
maximum volumetric titers of 10
6
 virus per milliliter. However, faster viral 
replication was observed in Vero and BHK-21A cells, maximum titers being 
reached 2–3 days earlier than in HEK293 cells. Industrially, this difference in 
viral growth kinetics between cell lines improves process economics. This 
makes the BHK-21A cells culture in single cell suspension the best choice for 
PPRV production, as an alternative to the Vero cell culture system. For using as 
a live-attenuated vaccine the immunogenicity and attenuation stability needs to 
be evaluated; thus the next step towards this novel approach for a PPRV vaccine 
production process is to prove its effectiveness in vivo (animal trials). 
The work described herein is the first report of a PPR candidate vaccine 
produced in suspension culture with serum-free medium. The results presented 
herein constitute valuable information for the development of a large-scale cell 





The authors acknowledge the financial support received from the European 
Commission (MARKVAC, FP6-2002-INCO-DEV-1). The authors are also grateful to 
Dr. Geneviève Libeau (CIRAD-EMVT, France) for providing the PPR vaccine strain. 
 
6. AUTHOR CONTRIBUTION 
Ana Carina Silva elaborated the experimental setup and design, performed 
the experiments, analyzed the data and wrote the chapter. 
 
7. REFERENCES 
[1] Shaila MS, Shamaki D, Forsyth MA, Diallo A, Goatley L, Kitching RP, et al. Geographic 
distribution and epidemiology of peste des petits ruminants virus. Virus Res. 
1996;43:149-53. 
[2] Gibbs EP, Taylor WP, Lawman MJ, Bryant J. Classification of peste des petits 
ruminants virus as the fourth member of the genus Morbillivirus. Intervirology. 
1979;11:268-74. 
[3] Bailey D, Banyard A, Dash P, Ozkul A, Barrett T. Full genome sequence of peste des 
petits ruminants virus, a member of the Morbillivirus genus. Virus Res. 2005;110:119-
24. 
[4] Takimoto T, Portner A. Molecular mechanism of paramyxovirus budding. Virus Res. 
2004;106:133-45. 
[5] Diallo A, Taylor WP, Lefevre PC, Provost A. Attenuation d’une souche de la peste des 
petits ruminants: candidat pour un vaccine homologue vivant. (attenuation of a virulent 
PPR strain: potential homologous live vaccine). Rev Elev Med Vet Pays Trop. 
1989;42:311-9. 
[6] Taylor WP, Abegunde A. The isolation of peste des petits ruminants virus from 
Nigerian sheep and goats. Res Vet Sci. 1979;26:94-6. 
[7] Diallo A, Minet C, Le Goff C, Berhe G, Albina E, Libeau G, et al. The threat of peste 
des petits ruminants: progress in vaccine development for disease control. Vaccine. 
2007;25:5591-7. 
[8] Diallo A. Peste des Petits Ruminants.  Manual of Diagnostic Tests and Vaccines for 
Terrestrial Animals. 5th ed: OIE; 2004. 
[9] Rourou S, van der Ark A, van der Velden T, Kallel H. A microcarrier cell culture 
process for propagating rabies virus in Vero cells grown in a stirred bioreactor under 
fully animal component free conditions. Vaccine. 2007;25:3879-89. 
[10] Butler M, Burgener A, Patrick M, Berry M, Moffatt D, Huzel N, et al. Application of a 
serum-free medium for the growth of Vero cells and the production of reovirus. 
Biotechnol Prog. 2000;16:854-8. 
Scalable culture systems using different cell lines for the Production of Peste des Petits Ruminants Vaccine 
 133 
[11] Wu SC, Huang GY. Stationary and microcarrier cell culture processes for 
propagating Japanese encephalitis virus. Biotechnol Prog. 2002;18:124-8. 
[12] Mendonca RZ, Prado JCM, Pereira CA. Attachment, spreading and growth of VERO 
cells on microcarriers for the optimization of large scale cultures.  Bioprocess and 
Biosystems Engineering1999. p. 565-71. 
[13] Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H. Optimization of virus yield as a 
strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol. 
2006;121:261-71. 
[14] Whiteside JP, Rayner RW, Spier RE. The improvement and standardization of the 
simplified process for the production of foot and mouth disease virus from BHK 
suspension cells. J Biol Stand. 1983;11:145-55. 
[15] Perrin P, Madhusudana S, Gontier-Jallet C, Petres S, Tordo N, Merten OW. An 
experimental rabies vaccine produced with a new BHK-21 suspension cell culture 
process: use of serum-free medium and perfusion-reactor system. Vaccine. 
1995;13:1244-50. 
[16] Ferreira TB, Ferreira AL, Carrondo MJ, Alves PM. Two different serum-free media 
and osmolality effect upon human 293 cell growth and adenovirus production. 
Biotechnol Lett. 2005;27:1809-13. 
[17] Ferreira TB, Ferreira AL, Carrondo MJ, Alves PM. Effect of re-feed strategies and 
non-ammoniagenic medium on adenovirus production at high cell densities. J 
Biotechnol. 2005;119:272-80. 
[18] Haldankar R, Kopchick JJ, Ridgway D. Stable production of a human growth 
hormone antagonist from CHO cells adapted to serum-free suspension culture. 
Biotechnol Prog. 1999;15:336-46. 
[19] Carver JH, Salazar EP, Knize MG. Chinese hamster ovary cells cultured in low 
concentrations of fetal bovine serum: cloning efficiency, growth in suspension, and 
selection of drug-resistant mutant phenotypes. In Vitro. 1983;19:699-706. 
[20] Kurano N, Leist C, Messi F, Gandor C, Kurano S, Fiechter A. Growth kinetics of 
Chinese hamster ovary cells in a compact loop bioreactor. 3. Selection and 
characterization of an anchorage-independent subline and medium improvement. J 
Biotechnol. 1990;16:245-58. 
[21] WHO. WHO Expert Committee on Biological Standardization.  WHO Tech Rep Ser. 
Fifty-fifth Report ed. Geneva: World Health Organization; 2005. 
[22] Baron MD, Banyard AC, Parida S, Barrett T. The Plowright vaccine strain of 
Rinderpest virus has attenuating mutations in most genes. J Gen Virol. 2005;86:1093-
101. 
[23] Darling AJ, Boose JA, Spaltro J. Virus assay methods: accuracy and validation. 
Biologicals. 1998;26:105-10. 
[24] Sreenivasa BP, Singh RP, Mondal B, Dhar P, Bandyopadhyay SK. Marmoset B95a 
cells: a sensitive system for cultivation of Peste des petits ruminants (PPR) virus. Vet Res 
Commun. 2006;30:103-8. 
[25] Baron MD, Barrett T. Rescue of rinderpest virus from cloned cDNA. J Virol. 
1997;71:1265-71. 
[26] Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a 
formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero 
cells. Vaccine. 2004;22:3669-75. 
[27] Mendonca RZ, Pereira CA. Cell metabolism and medium perfusion in VERO cell 




[28] Frazzati-Gallina NM, Paoli RL, Mourao-Fuches RM, Jorge SA, Pereira CA. Higher 
production of rabies virus in serum-free medium cell cultures on microcarriers. J 
Biotechnol. 2001;92:67-72. 
[29] Worrall EE, Litamoi JK, Seck BM, Ayelet G. Xerovac: an ultra rapid method for the 
dehydration and preservation of live attenuated Rinderpest and Peste des Petits 
ruminants vaccines. Vaccine. 2000;19:834-9. 
[30] Sarkar J, Sreenivasa BP, Singh RP, Dhar P, Bandyopadhyay SK. Comparative efficacy 
of various chemical stabilizers on the thermostability of a live-attenuated peste des 
petits ruminants (PPR) vaccine. Vaccine. 2003;21:4728-35. 
[31] Tatsuo H, Ono N, Yanagi Y. Morbilliviruses use signaling lymphocyte activation 
molecules (CD150) as cellular receptors. J Virol. 2001;75:5842-50. 
[32] Baron MD. Wild-type Rinderpest virus uses SLAM (CD150) as its receptor. J Gen 
Virol. 2005;86:1753-7. 
[33] Maranga L, Brazao TF, Carrondo MJ. Virus-like particle production at low 
multiplicities of infection with the baculovirus insect cell system. Biotechnol Bioeng. 
2003;84:245-53. 
[34] Takeda M, Kato A, Kobune F, Sakata H, Li Y, Shioda T, et al. Measles virus 
attenuation associated with transcriptional impediment and a few amino acid changes 
in the polymerase and accessory proteins. J Virol. 1998;72:8690-6. 
[35] Kobune F, Sakata H, Sugiyama M, Sugiura A. B95a, a marmoset lymphoblastoid cell 
line, as a sensitive host for rinderpest virus. J Gen Virol. 1991;72 ( Pt 3):687-92. 
[36] Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host 



















biotherapeutics: from cell 







This chapter was based on the following manuscript: 
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The main focus of this work was the improvement of the stability of the 
current PPRV vaccine. Firstly, new formulations based on the Tris buffer were 
tested, with and without the addition of sucrose and trehalose and compared 
with the formulation normally used to stabilize the vaccine, the Weybridge 
medium. The results show a virus half-life of 21 hours at 37ºC and 1 month at 
4ºC for the Tris/trehalose liquid formulation and, in the lyophilized form, the 





doses/mL) for at least 21 months at 4ºC (0.6 log lost), 144 hours at 37ºC (0.6 
log lost) and 120 hours at 45ºC (1 log lost).  
Secondly, a strategy based on culture medium composition manipulation 
aiming at improving the intrinsic PPRV vaccine stability was also evaluated. The 
addition of 25 mM fructose resulted in a higher virus production (1 log increase) 
with higher stability (2.6 fold increase compared to glucose 25 mM) at 37ºC.  
Increased concentrations of NaCl, improved virus release, reducing the cell-
associated fraction of the virus produced. Moreover this harvesting strategy is 
scalable and more suitable for a larger scale production than the freeze/thaw 
cycles normally used. 
The information gathered in this work showed that it is possible for the 
PPRV vaccine to have adequate short-term stability at non-freezing 
temperatures to support manufacturing, short-term shipping and storage. The 
identification of a more stable formulation should significantly enhance the 
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Peste des Petits Ruminants (PPR) is an acute, highly contagious and fatal 
disease of sheep and goats and is considered as one of the major constraints to 
the productivity of small ruminants in African and Asian countries [1]. The 
causative agent, PPR virus (PPRV), is a member of the genus Morbillivirus within 
the Paramyxoviridae family and is antigenically closely related to the Rinderpest 
(RP) virus [2], another member of the genus Morbillivirus that causes similar 
diseases in wild and domestic ruminants. Molecular epidemiology of PPRV based 
on the ‘F’ gene sequence from all over the world has defined the existence of 
four different lineages of virus (I–IV). Of the four known lineages of the PPR 
virus, lineage I and II have been found exclusively in West Africa, lineage III has 
been found in East Africa  and lineage IV is prevalent in India [3].  
For the control of PPR, some attenuated live cell culture vaccines are 
available. The first vaccine was developed by attenuating  the PPRV Nigeria 75/1 
isolate by Diallo et al. [4], which belongs to lineage I and is being used for 
protecting sheep and goats in African countries. Another vaccine, Sungri 96, 
was developed by attenuating the Sungri isolate of PPRV [5], a virus belonging 
to lineage IV (Asian lineage) as per F gene sequence analysis [3].  
As with all members of the Paramyxoviridae family, PPRV is heat sensitive; 
this is a serious drawback for the efficient use of the live attenuated vaccine in 
the endemic areas, which have hot climatic environments. In addition, these 
regions usually have poor infrastructures, being difficult to sustain a cold chain 
to ensure the maintenance of vaccine potency. Lyophilization in the presence of 
suitable excipients is a prevailing approach to stabilize such type of biological 
products. Previous studies with the lyophilized PPRV Nigeria 75/1 vaccine with 
lactalbumin hydrolysate-sucrose (LS), Weybridge medium (WBM) and lactalbumin 
hydrolysate-manitol (LM) have shown that the WBM formulation could maintain 
the virus titer for longer [6]. Different stabilizers i.e., LS, WBM, buffered gelatin-
sorbitol (BUGS) and trehalose dihydrate (TD) were also used to prepare the PPRV 
Sungri 96 vaccine. The results showed that LS and TD allowed for higher 
stability of the lyophilized PPRV vaccine [7]. LS stabilizer could also maintain the 
protective titer of the Vero cell adopted Rinderpest vaccine up to 4 hours at 
room temperature if reconstituted with 0.85% sodium chloride and 1M 
magnesium sulphate [8]. Another approach to stabilize the PPRV Nigeria 75/1 
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vaccine was the use of the dehydration method Xerovac in the presence of a 
formulation containing trehalose [9]. Under these conditions the vaccine is 
stable at 45ºC for 14 days with minimal loss of potency. The World Organization 
for Animal Health (O.I.E.) recommends the use of the WBM as stabilizing 
solution for the lyophilized PPRV vaccine. However this vaccine formulation is 
still very susceptible to thermal degradation [7]. 
Besides the stability during viral vaccines storage, the process of production 
can also affect the final virus potency, as the stability of enveloped viruses can 
be compromised in cell culture bulks due to temperature. Previous studies from 
our laboratory have shown significant increase in the intrinsic retrovirus 
stability, also an enveloped virus as PPRV, when production was carried out at 
high concentrations of glucose or fructose [10]. It was also observed that, 
independently of the osmotic agent used, higher medium osmolalities enhanced 
retrovirus stability [11]. Concerning the PPRV stability during production our 
group also showed that when the virus is produced in a serum-free medium, 
Ex-Cell
TM
, containing high glucose concentrations, the titers could be 
maintained for longer than when MEM medium low in glucose was used [12].  
In this work, we studied for the first time the effect of the Tris based 
formulation with trehalose or sucrose on the preservation of the PPRV Nigeria 
75/1 vaccine comparing it with the Weybridge formulation actually used for the 
production of this vaccine [13]. The stability during storage at both refrigerated 
and high relevant storage temperatures, as well their ability for protection upon 
lyophilization was evaluated. The effect of medium osmolality on the production 
and stability of the PPRV was also assessed.  
 
2. Materials and methods 
2.1. Cells and virus  
Vero cells (ECACC, 84113001) were maintained 37ºC in a humidified 
atmosphere of 5% CO
2
 in air with Minimum Essential Medium (MEM), 
supplemented with 2 mM glutamine and with 10% (v/v) Foetal Bovine Serum 
(FBS). All media and supplements were from Gibco. The PPR vaccine strain used 




France), at passage 75. This strain was routinely amplified in Vero cells and 
stored at -80ºC, using standard techniques [13].  
2.2. PPRV production and formulation 
Vero cells were seeded at 0.1 x 10
6
 cells/mL in 175 cm
2
 T-flasks, to a final 
culture volume of 35 mL per flask. 24-hours (h) after inoculation the cells were 
infected with PPRV using a multiplicity of infection (MOI) of 0.01. The flasks 
were incubated at 37°C in a humidified atmosphere of 5% CO
2
 in air. When the 
cells attained 90-100% confluence the medium was replaced with MEM medium 
with 2% (v/v) FBS. The cultures were checked daily for development of cytopathic 
effect (cpe) and the viruses were harvested when the cpe attained 70-80%. All 
the cells and medium were harvested, freeze-thawed twice to release the cell 
associated virus and the virus suspension was clarified by centrifugation at 
1500 g for 10 minutes at 4ºC before formulation. Equal volumes of the virus 
suspension and different formulations were mixed (See Table 5. 1 for 
formulations composition). The lactalbumin hydrolysate, sodium glutamate and 
Tris-HCl were purchased from Sigma; sucrose, anhydrous trehalose, EDTA and 
Tween 80 were purchased from Merck; the Hanks’ balance salt solution was 
purchased from Gibco. The formulations based on the Tris buffer were chosen 
based on formulations used for different enveloped viruses, namely retroviruses 
[14].   
 
Table 5. 1:Formulation composition. 
Formulation Composition 
1 - Weybridge medium 
(WBM) 
2.5% (w/v) lactalbumin hydrolysate, 5% (w/v) Sucrose, 
1% (w/v) sodium glutamate, in Hanks’ balance salt 
solution pH 7.4 [13] 
2 - Tris buffer (Tris) 
20 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.02% (w/v) 
Tween 80 
3 - Tris with sucrose 
(Tris/Suc) 
20 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.02% (w/v) 
Tween 80, 1 M Sucrose 
4 - Tris with trehalose 
(Tris/Tre) 
20 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.02% (w/v) 
Tween 80,  1 M Trehalose 
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2.3. Lyophilization 
All lyophilizations were done in a Christ Freeze-Dryer Epsilon 2-40 
(Germany). The lyophilization protocol was adapted to the lyophilizer from the 
protocol used at CIRAD, the reference laboratory for PPR [13]. Briefly,  (1) 
Freezing, -40 °C for 2 h; (2) Primary drying, -40 °C for 14 h at 0.060 mBar; (3) 
Secondary drying, -35 °C for 2 h; -30 °C for 2 h; -25 °C for 2 h; -20 °C for 2 h; -15 
°C for 14 h; -10 °C for 2 h; -5 °C for 2 h; 0 °C for 2 h; 10 °C for 2 h; 20 °C for 2 h; 
all at 0.060 mBar; and (4) Final drying, 35 °C for 2 h at 0.060 mBar. One milliliter 
of the formulated PPRV was dispensed in sterile 5 ml capacity glass vials 
(Wheaton) and partially sealed with vented rubber stoppers. At the end of the 
lyophilization process, the caps were closed and the samples were stored at 
different temperatures until reconstitution for titration. Some samples were 
reconstituted with 1 mL of distilled water and titrated immediately after 
lyophilization to evaluate the effect of the process on virus stability. The 
residual moisture content was determined using the HYDRANAL
®
 - moisture test 
kit (Fluka). 
2.4. Experimental design 
The experimental design used in this work is represented in Figure 5. 1. 
The details of different experiments are described in the following sections. 
 
 







PPRV liquid samples in different formulations were collected in CryoTubes 
from Nunc, and the tubes were directly stored at -80ºC; 24 hours after freezing, 
samples were thawed at room temperature (22-25ºC) and titrated to check the 
effect of the freezing process in the virus bioactivity. The remaining samples 
were kept in the freezer to check their stability along time. Studies were 
performed for a period of up to 3.5 years. 
 
2.4.2. Thermostability testing of liquid and lyophilized PPRV 
Sufficient numbers of lyophilized vaccine vials for each stabilizer were 
stored at 4ºC (up to 6 and 21 months for liquid and lyophilized formulations, 
respectively), at 37ºC and at 45ºC (up to 144 hours for both temperatures). 
Samples were taken along time and the lyophilized samples were reconstituted 
with 1 ml of distilled water. The samples stored at 4ºC were immediately 
titrated; those samples kept at 37 and 45ºC were stored at -80ºC until titration, 
in order to perform the titration of the samples at the same time.  
 
2.4.3. Thermostability testing of reconstituted PPRV 
Lyophilized vials for each formulation (WBM and Tris/Tre) were reconstituted 
with four diluents: milliQ water (H
2
O), Phosphate-Buffered Saline (PBS), MgSO
4 
1 
M and Tris/Tre with only 0.5 M trehalose. The osmolality of the suspensions 
obtained was measured in a Digital Micro Osmometer Type 5R (Hermann 
Roebling Messtechnik, Germany). For each formulation, three vials were 
collected and reconstituted separately with 1 ml each of diluent and then stored 
at 37ºC after dividing into several aliquots in 1.5 ml Eppendorf tubes. Samples 
were collected every 3 hours for a total of 9 hours and stored at -80ºC until 
titration, in order to perform the titration of the samples at the same time.  
 
2.4.4. Osmolality effect on PPRV production and stability 
To evaluate the effect of the osmolality on viral production, DMEM (Gibco) 
was supplemented with 10% (v/v) FBS (Gibco), glutamine at 2 mM (Gibco), 
glucose or fructose (Sigma) at 25, 83 and 139 mM. For sodium chloride (NaCl, 
Merck, Darmstadt, Germany) supplementation the medium was used with 
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5.5 mM glucose. Different concentrations of NaCl (12.5, 41.5, 69.5 mM) were 
added to adjust the medium osmolality to 340, 380 and 430 mOsm/kg. Medium 
osmolalities were determined by the measurement of the depression of the 
freezing point using an osmometer (Roebling, Berlin, Germany). The cells were 
adapted to the different medium conditions after 3-4 passages. 
Cells were seeded at 0.1 x 10
6
 cells/mL in 25 cm
2 
T-flasks, to a final culture 
volume of 5 mL per flask. 24-hours after inoculation the cells were infected with 
PPRV using a MOI of 0.1. The flasks were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air. To monitor the infection kinetics, one flask was 
harvested daily and its content (cells plus supernatant) stored at -80ºC prior to 
virus titration. 
The stability study was initiated by 1:10 dilution of the viral supernatant 
obtained at 96 hours post infection (hpi) in DMEM without any sugar or osmotic 
agent. These viral suspensions were incubated at 37ºC in a CO
2
 incubator and 
samples were taken at 0, 2, 4, 8, 12 and 24 hours and stored at -80ºC until the 
viral titer was determined. 
2.5. Virus titration 
Virus titration (TCID
50
) was performed with Vero cells in 96 well microtitre 
plates using standard cell culture procedures [13]. Briefly, 10-fold serial dilution 
of samples in MEM containing 10% (v/v) FBS were prepared. For each dilution, 12 
replicates were done with 100 L virus suspension and 100 L cell suspension 
(0.2x10
6
 cells/mL) per well. All the test plates were incubated at 37 ºC in a 
humidified atmosphere of 5% CO
2
 in air. Cytopathic effect was checked on day 
12 of titration. End points (TCID
50
/mL) were calculated according to the 
statistical method of Spearman-Karber [15], simplified for calculations in MS 
Excel format.  
2.6. Data Analysis 
Virus stability during storage can be directly correlated with the rate of viral 
titer decay. Le Doux et al. have shown that the activity of recombinant 
retroviruses declines at a rate that is proportional to the concentration of 
infectious virus [16]. In previous work our group has reported this to be the 




for retroviral and adenoviral vectors during storage [14]. In such cases, the 
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which, upon integration, yields the concentration of active virus (X
v












 is the initial concentration of active virus and k
d
 is the virus decay rate 
constant.  
Although initially developed for retroviral vectors, these equations were 
applied for PPRV as they also describe well the virus loss of infectivity (see 
below). To determine the virus decay rate as a function of temperature, PPRV 
were stored at different temperatures and sampled throughout time. Best-fit 
values for virus decay rate constants were determined by using non-linear 
regression analysis to fit the data to equation (2). Vector half-life can be used as 
a criterion for selecting the appropriate viral formulation. Based on equation (2), 
the virus half-life, t
1/2
, is given by: 
t
1/2
 = ln(1/2) / (-k
d
)              (3) 
Equation (3) is only valid for vector storage in solution at temperatures that 
do not require freezing (4, 37 and 45ºC). For the storage processes requiring 
lyophilization and freezing it is necessary to consider the process efficiency, as 
per equation (4)   
t
1/2




)       (4) 
where 
0
, is the storage process efficiency for the virus. 
Experimental data for each formulation tested was obtained from triplicate 
samples taken at specific points in time. Thus, the results presented correspond 
to means and the errors to the standard deviation. The k
d
 was estimated 
through fitting a nonlinear regression to experimental data. 
 
3. RESULTS 
The thermolability of live attenuated vaccines is a critical issue for 
vaccination in developing countries. The main focus of this research was the 
improvement of the stability of PPRV vaccine. Two strategies were evaluated: (i) 
firstly, the PPRV stability during storage and (ii) secondly, a strategy to improve 
the PPRV stability during production. 
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3.1. Stability during storage   
In order to increase the PPRV stability, formulations based on the Tris buffer 
(Tris), with and without the addition of sucrose (Tris/Suc), or trehalose 
(Tris/Tre), were tested and compared with the formulation normally used to 
stabilize the vaccine, the Weybride medium (see Table 1 for formulations 
composition). The design of the formulations considered: a buffer to avoid pH 
variations (Tris buffer); the addition of an antioxidant to avoid free-radical 
oxidation (EDTA); the addition of a surfactant to avoid virus aggregation (Tween 
80) and also a stabilizer (sucrose or trehalose) to protect the vaccine during 
storage at different temperatures. These options were chosen based on 
formulations used for different enveloped viruses, namely retroviruses [14]. 
 
3.1.1. Liquid and frozen formulations 
The efficacy of the formulations on the preservation of the titer of the PPRV 
vaccine was assessed, at first, in liquid and frozen form and afterwards in the 
lyophilized form. The kinetic profiles and data for virus degradation are 
presented in Figure 5. 2 and Table 5. 2.  
The results showed that PPRV is highly unstable in liquid formulations 
stored at 37ºC with half-lives ranging from 9 to 21 hours; these values could be 
increased to days when the temperature was reduced to 4ºC. In the case of the 
WBM a half-life of 9 hours at 37ºC and of 22 days at 4ºC was obtained.  For the 
Tris/Tre formulation, a half-life of 21 hours at 37ºC and of 30 days at 4ºC could 
be attained. Tris/Tre and Tris/Suc formulations were also able to retain the 




/ml) for at least 144 hours 
at 37ºC, in contrast to the WBM or the Tris formulation which only kept such 
titers for 72 hours. This data shows that the Tris/Tre formulation presents a 
superior capability to maintain the PPRV titer under the conditions tested.  
At -80ºC the storage process efficacy was very good for all the formulations 
with an insignificant titer drop after thawing, except for Tris, which presented 
one log loss after thawing. This was expected since the Tris formulation did not 
contain a cryoprotector. After the long term storage at -80ºC, the best stability 
was achieved for PPRV stored in Tris/Suc or Tris/Tre formulations with the titer 




formulations lost their titer faster, with more than one log gone in just 3 hours 
of incubation (data not shown).  
   
 
Figure 5. 2: Stability at 37ºC (A), 4ºC (B) and -80ºC (C) for 1:1 dilution of clarified PPR viruses 
produced in Vero cells with different formulations. WBM (); Tris (); Tris/Suc (); Tris/Tre ().The 
different lines represent the linear regressions of virus stability for each formulation tested. The 
horizontal dashed line represents the value corresponding to the presently used vaccine dose. 
 
Table 5. 2: PPRV decay rate constant (k
d
) and half-life (t
1/2
) for each non-lyophilized formulation 
stored at 37, 4 and -80ºC. 
Formulation 




















0.077 ± 0.008 
0.080 ± 0.009 
0.044 ± 0.002 





0.031 ± 0.003 
0.073 ± 0.007 
0.029 ± 0.003 





1.195 ± 0.650 


















cannot be determined because the process 
efficiency is lower than 50%. 
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3.1.2. Lyophilized formulations 
The Tris/Tre formulation described above showed to be a good candidate to 
protect PPRV during storage and was selected to proceed for the lyophilization 
study. PPRV with the different formulations (WBM and Tris/Tre) was lyophilized 
simultaneously using a conventional freeze-drying technique to compare the 
quality of vaccine after lyophilization. This gave origin to a residual moisture 
content of approximately 5% for both formulations used, slightly higher than 
the optimum moisture content recommended by O.I.E for the PPR vaccine, i.e. 
3.5%. After lyophilization, both formulations presented a negligible loss of titer, 
resulting in process efficiencies closely to 100%. The lyophilized formulations 
were stored at 4, 37 and 45ºC; time decay profiles are presented in Figure 5. 3 
and decay rates presented in Table 5. 3.  For WBM stored at 45ºC, no virus was 
detected after 24 hours of storage; at 37ºC its half-life was only 7 hours. In the 
case of the Tris/Tre formulation a virus half-life of 49 hours and 67 hours, 
corresponding to only 1.3 logs and 0.7 logs of titer loss after 6 days of storage, 
respectively, for 37 and 45ºC, was obtained. At 4ºC both formulations showed 
similar, higher half-lives of 10 months.  
 
Table 5. 3: PPRV decay rate constant (k
d
) and half-life (t
1/2
) for each lyophilized formulation stored 
at 45, 37 and 4ºC. 
Formulation 






























0.062 ± 0.019 
0.069 ± 0.026 
11 
10 
0.096 ± 0.020 


















Figure 5. 3: Stability at 4ºC (A), 37ºC (B) and 45ºC (C) of PPRV lyophilized in WBM and Tris/Tre. 
PPRV were reconstituted using water and stored at -80ºC until titration. WBM (); Tris/Tre ().The 
different lines represent the linear regressions of virus stability for each formulation tested. The 
horizontal dashed line represents the value corresponding to the presently used vaccine dose. For 
the WBM at 45ºC no virus was detected after 24 hours of storage. 
3.1.2.1. Stability of lyophilized formulations after reconstitution 
Currently, the O.I.E. recommends water as the reconstitution solution for 
PPRV lyophilized vaccine. While water has the advantage of not causing a drop 
in pH following vaccine reconstitution, it cannot provide any additional 





Tris/Tre formulation with 0.5 M trehalose) were tested for the reconstitution of 
the lyophilized PPRV for stability at 37ºC for 9 hours. The osmolalities of the 
suspensions obtained are shown in Table 4 together with the decay rate 
constants and half-lives. The results showed that for all the solutions tested the 
virus half-lives at 37ºC varied between 3 and 7 hours. Thus, even with solutions 
giving rise to high osmolalities (Table 5. 4), no impact occurred on PPRV 
stability.  
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) and osmolality for lyophilized formulations 











































0.166 ± 0.026 
0.096 ± 0.059 
0.192 ± 0.024 









0.262 ± 0.083 
0.160 ± 0.084 
0.192 ± 0.113 





The samples were kept at 37ºC during 9 hours. 
 
3.1.3. Stability after long term storage 
The stability of the PPRV at 37ºC and 45 ºC for the frozen formulations 
thawed after 3.5 years at -80ºC and the lyophilized formulation stored for 21 
months at 4ºC was similar to those obtained under the same conditions for the 
vaccine stored for few days (data not shown). Therefore, either freezing or 
lyophilization can effectively be used for long term storage of the vaccine. 
3.2. Stability during production  
The second strategy to improve the PPRV stability was based on culture 
medium composition manipulation, aiming at improving the virus intrinsic 
stability. Nowadays PPRV is produced in Vero cells using classical techniques, i.e 
in T-flasks or roller bottles with MEM or DMEM medium supplemented with low 
glucose concentrations; the virus obtained has a low stability, as low as 2 to 6 
hours half-life at 37ºC [13].  
Glucose, along with glutamine, represents the major energetic and carbon 
sources for most cells in culture. Nevertheless, glucose presents several 
disadvantages as it is rapidly consumed and inefficiently metabolized, partly 
being converted to lactate that can be inhibitory to cell growth. Fructose can be 
used to replace glucose as it originates low amounts of lactate and has been 
previously shown to enhance retrovirus vector production and stability at high 
concentrations; irrespective of the osmotic agent used, high medium 





3.2.1. Effect of increasing osmolality in cell growth and PPRV production 
The effect of the cell culture medium osmolality (340, 380 and 430 
mOsm/Kg) on Vero cell growth and PPRV production was assessed by the use of 
increasing concentrations (25, 83 and 139 mM) of the sugar source, glucose or 
fructose, and the sodium chloride salt (NaCl) (12.5, 41.5 and 69.5 mM) as an 
osmotic agent. Table 5. 5 summarizes the results obtained for all conditions 
tested and Figure 5. 4 illustrates the Vero cells growth and PPRV production 
curves using 25 mM glucose (A; control) and 12.5 mM  NaCl (B).  
 







































25 mM glucose 
83 mM glucose 
139 mM glucose 
25 mM fructose 
83 mM fructose 
139 mM fructose 
12.5 mM NaCl 
41.5 mM NaCl 










0.031 ± 0.002 
0.023 ± 0.004 
0.023 ± 0.001 
0.027 ± 0.001 
0.026 ± 0.004 
0.019 ± 0.004 
0.024 ± 0.003 
0.025 ± 0.005 





























6.2 ± 0.2 
6.3 ± 0.2 
7.1 ± 0.1 
6.4 ± 0.1 
5.9 ± 0.1 
6.1 ± 0.3 
5.6 ± 0.3 












 – Maximum virus 
titer. 
  
Figure 5. 4: Vero cells growth and PPRV production under different medium compositions.  
(A) 25 mM glucose as carbohydrate source; (B) 5.5 mM glucose as carbohydrate source and 12.5 
mM NaCl. Non-infected cells (); Infected cells (); Cell associated virus (); Extracellular virus 
(). The lines are guides to follow the progression of the data.  
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The infection was made at 24 hours post inoculation; since a low MOI is 
used, only after 48 hours of infection is it possible to observe an increase in the 
viral titer that follows the growth of the cells.  The maximum virus titer is 
achieved between 72 to 144 hpi and the maximum cell infected concentration 
around 120 hours of culture. The non-infected cells could grow to higher 
concentrations than the infected ones when using the carbohydrates as osmotic 
agents; when NaCl was used the maximum cell concentrations were similar but 
the viability of the non-infected cells could be maintained for longer. The results 
showed a decrease in the cellular yields obtained for increased osmolalities. 
NaCl addition hampered the Vero cell growth when compared with standard 25 
mM glucose medium (340 mOsm/kg); at concentrations higher than 12.5 mM 
the higher osmolalities resulted in lower PPRV titers. The viral yields decreased 
with the increase of fructose concentration but with glucose the viral titer was 





/mL), corresponding to 1 log increase in comparison to what 
happens when glucose is used at the same concentration. During the PPRV 
production two fractions of the virus are present, an extracellular and a cell-
associated fraction. The cell associated fraction is higher than the extracellular 
fraction by 1 log in virus titer (Figure 5. 4 A), when the osmotic agent is a 
carbohydrate (glucose or fructose). When the NaCl was used at the end of the 
production phase, there was an inversion of this phenomenon with more virus 
released to the extracellular fraction as compared to the cell-associated fraction 
(Figure 5. 4 B); i.e. the presence of the salt in the culture medium seems to 
promote the viral release. To test this hypothesis other experiments were 
performed. PPRV production was initiated using standard conditions in order to 
avoid the decrease in the cellular yield and consequent decrease in the 
maximum viral yield; 72 hpi NaCl was added to the culture medium, 12.5, 41.5 
and 69.5 mM concentrations being tested. The amount of viruses present in the 
cell-associated fraction decreased with the increase of the NaCl concentration 
and consequently in the osmolality of the culture medium, during the maximum 






Figure 5. 5: PPRV production in 5.5 mM glucose with addition of NaCl at 72 hours post infection 
(hpi). NaCl 12.5 mM (,); NaCl 41.5 mM (,); NaCl 69.5 mM (,). Full symbols represent cell 
associated virus and open symbols represent extracellular virus. The lines are guides to follow the 
progression of the data.  
 
3.2.2. Effect of increasing osmolality in PPRV stability 
Previous studies from our laboratory have identified an important increase 
in the intrinsic retroviral vector stability when production was carried out at 
high concentrations of glucose or fructose [10]. Thus, the implication of 
increased concentrations of the carbohydrate source on PPRV intrinsic stability 
was studied. The viruses produced under the different conditions were diluted 
1:10 in culture medium without the carbohydrate source or NaCl and incubated 
at 37ºC for 24 hours. The results presented in Table 5. 6 show that for most of 
the conditions tested the PPRV stability at 37ºC were in the same range of decay 
values as those reported in section 3.1.1 for the different liquid formulations.  
 








25 mM glucose 
83 mM glucose 
139 mM glucose 
25 mM fructose 
83 mM fructose 
139 mM fructose 
12.5 mM NaCl 
41.5 mM NaCl 
69.5 mM NaCl 
0.125 ± 0.026 
0.067 ± 0.018 
0.057 ± 0.015 
0.043 ± 0.021 
0.109 ± 0.035 
0.088 ± 0.022 
0.099 ± 0.030 
















 Not determined 
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Most of the half-lives are in the 5-8 hours range but when the PPRV viruses 
were produced using 25 mM fructose the virus half-life increased to 16 hours, 
whereas with increasing concentrations of glucose (83 and 139 mM) the values 
were in the 10-12 hours range. This shows slight increases in the viral intrinsic 
PPRV stability when these culture conditions were applied. 
 
4. Discussion 
This study focused on the stability evaluation of PPRV, a heat-labile 
enveloped virus, during storage and production. Our investigation into the 
effect of different formulations to protect the PPRV during storage identified a 
Tris/Tre formulation to yield higher stability, both in liquid and lyophilized 
form; this formulation originated virus half-lives of 21 and 67 hours at 37ºC, 
respectively, in the liquid and lyophilized forms; at 4ºC those values increased 
to 30 days and 10 months, respectively (Table 5. 2 and Table 5. 3). The stability 
of the PPRV vaccines is normally reported only for lyophilized and not for liquid 
formulations; thus the liquid conditions evaluated here cannot be directly 
compared with other data. However our data showed that the Tris/Tre liquid 
formulation is superior to the WBM, the normally used formulation. This higher 
stability in liquid gives more flexibility for the preparation of the vaccine 
solutions prior to lyophilization. At 4ºC, both lyophilized formulations (Tris/Tre 
and WBM) showed similar, higher half-lives of 10-11 months (Table 5. 3). These 
results are superior to the 30 days reported by Sarkar et al for the WBM under 
the same conditions, for the PPRV Sungri 96 vaccine [7]. At 37ºC, the  
lyophilized WBM showed an half-life of 7 hours (Table 5. 3), similar to the 10 
hours reported by Sarkar et al for the same formulation used in the PPRV 
vaccine of the Asian origin [7].  At 45ºC the lyophilized Tris/Tre formulation 
presented an half-life of 49 hours (Table 5. 3) which  is similar to the result 
reported by Worrall et al for the Xerovac process with another trehalose 
formulation [9]. Our results at 45ºC showed to be better than those reported for 
all the formulations tested by Sarkar et al yielding half-lives of less than 3 hours 
at this temperature [7]. Furthermore, the Tris/Tre formulation seems to be less 
sensitivity to moisture content in the lyophilized form in relation to the WBM, an 




the moisture content is high. In terms of vaccine stability after reconstitution it 
is important to guarantee that when the vaccine is delivered the correct dose is 
used. In this work different solutions were tested for reconstitution; for all it 




/mL, used as reference for 
shelf-life of the vaccine, corresponding to at least 10 vaccine doses in each vial, 
until the 9 hours of study (Table 5. 4). In order to have the higher number of 
doses per vial after reconstitution, the vaccine should be delivered as soon as 
possible. Overall, the Tris/Tre formulation presents advantages over the WBM, 
being a good new candidate formulation for the PPRV vaccine. 
Concerning the PPRV production with medium manipulation, in all cases and 
for all osmolytes (glucose, fructose or NaCl) used, a decrease in the cell yield 
was observed with the increase of osmolality (Table 5. 5), coherent with the 
decrease in cell growth that has been observed for animal cell cultures grown 
under prolonged high osmotic pressures [18-21]. An important increment 
(1 log) in the maximum virus titer obtained was also observed when fructose at 
25 mM was used compared to glucose at the same concentration (Table 5. 5). 
For glucose, the titer is maintained with the increase of osmolality; this could be 
due to an increase in cell-specific productivity, corroborating what is known in 
different cells namely in hybridoma cells [18], in CHO cells [20, 22] and in insect 
cells [23], that at higher osmolalites there is an increase in recombinant protein 
production. On the contrary the increased fructose concentration did not result 
in an increase of virus productivity; however comparing both sugar sources at 
the same concentration, productivity is higher when fructose is used except at 
the high value of 139 mM. This can result from the fact that cells grown with 
fructose, as the sugar source normally produce lower lactate concentrations due 
to the slower uptake by the cells, and consequently the pH of the culture is not 
so affected maintaining the cells in a more physiological environment [24, 25]. 
It is also known that Vero cells can grow with fructose at concentrations as low 
as 5 mM [26]; we have tested 10 mM (data not shown) and the results were 
similar to those using 25 mM, i.e., for these concentrations of fructose the 
optimum for virus production has been reached. In this case it seems that Vero 
cells can metabolize well the carbohydrate, in contrast to what happens with 
other cell types where, the faster metabolization of fructose only happens at 
higher concentrations [10]. The improvements observed in the maximum titers 
could not be explained only by the cell culture environment. Therefore other 
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parameters need to be considered in virus production.  It was observed that 
when the virus was produced at higher concentrations of glucose (83 and 
139 mM) or fructose at 25 mM (Table 5. 6) the stability of the virus produced 
increased slightly. The increments verified in the virus stability were not due to 
chemical protective effects per se: (i) because the infectivity kinetics assays 
were performed in diluted medium without osmotic agents to ensure that the 
intrinsic virus stability was being measured and (ii) because in the range of 
sugar concentrations used normally, the sugar does not show a chemical 
stabilizing influence [10]. Taking into account that a fraction of the carbon 
sources in the medium is used to synthesize lipids for the membranes of the 
producer cells, a correlation between the carbon sources and virus productivity 
and stability at this level is expected. In the case of glucose, the increase in the 
virus stability could be due to the fact that higher concentrations increased the 
osmotic pressure resulting in the rearrangement of the cytoplasmatic 
membrane composition and increased fluidity, as a result of cell adaptation to 
the osmotic stress. For retrovirus it has been reported that a decrease in the 
cholesterol phospholipids ratio due to higher osmolality increased the virus 
stability [11] and in the retrovirus producer cells glucose plays a major role in 
lipid biosynthesis [27]. On the contrary for fructose the increase in virus 
stability was only observed for the lower concentration tested (25 mM) and 
osmolality increase showed no effect (Table 6). The enhancement in virus 
stability with 25 mM fructose was superior to those obtained by increasing 
glucose concentration. This could be due to fructose reducing the lactate 
production and with that sustain better the pH of the culture, a parameter that 
can affect the virus stability. On the other hand, it can have an impact on the 
lipid composition of the cell and virus membrane, independently of the osmotic 
pressure, probably by being a better lipogenic substrate than glucose as 
reported by Delhotal-Landes et al for human fibroblast cultures [28]. In the case 
of retrovirus producing cells, the impact of the sugar source in the lipids 
biosynthesis was more significant for glucose probably because only at higher 
concentrations does fructose lead to a change in the cell metabolism [27].  
Further insights on the metabolism of different sugars and their effect on cell 
and virus membrane and more detailed studies would need to be performed, 
namely using a combination of NMR and mass spectroscopy like performed for 




osmotic agent its effect did not result in higher virus productivities mainly 
because its use reduced significantly the cell growth (Table 5. 5). Nevertheless 
it is worthwhile to highlight that the increase in the concentration of NaCl in the 
culture medium from the beginning of the culture or after 72 hpi improved virus 
release, reducing the cell-associated fraction of the virus produced with the 
highest results obtained at 41.5 mM (Figure 5. 5). These results are in 
agreement with what has been reported for Dengue virus, i.e. increasing 
osmolalities improves virus production reflected in an increase in extracellular 
viruses versus cell-associated viruses [29]. The increase of NaCl concentration 
in the culture medium has also been reported to be important in the release 
and maturation of some alphaviruses, namely the Sindbis virus, in different cell 
lines [30, 31]. Moreover this harvesting strategy is scalable and more suitable 
for a larger scale production than the freeze/thaw cycles normally used. Higher 
release of the virus from Vero cells is an advantage for PPRV production since it 
is well known that numerous PPR viruses stay cell-associated. 
 
5. Conclusions 
The work presented herein show that an alternative Tris trehalose 
formulation is superior to the Weybridge medium, recommended by the O.I.E., 
for PPRV formulation and storage, maintaining the PPRV titers for longer both at 
liquid and lyophilized forms. This candidate formulation could not only facilitate 
the transport and preservation of the vaccines, but also all the logistics steps 
before and after lyophilization, since it presented higher stability in the liquid 
form and seems to be less sensitive to the final moisture content. These facts 
could give rise to more batches passing all the quality controls at the end of the 
lyophilization process, lowering the costs of the vaccine, even taking into 
account that the candidate formulation could be slightly more expensive due to 
the higher cost of trehalose in relation to the other components. Regarding the 
medium manipulation, the use of fructose (25 mM) as a carbon source resulted 
in 1 log increase in virus yield with a 2.6 fold increase in virus stability 
compared to glucose. The addition of NaCl to the culture medium promoted 
higher release of the virus from the cells, ensuring a better harvesting strategy 
than the freeze/thawing steps. A combination of these production and 
harvesting strategies with the new candidate formulation could have a major 
Strategies for improved stability of Peste des Petits Ruminants Vaccine  
 157 
impact in the manufacturing costs of the PPRV vaccine since higher virus titers 
with higher stability can be achieved. 
The new formulation and the alterations in the production process needs to 
be validated and tested in animals to confirm the efficacy of the vaccine; 
nevertheless the presented results constitute valuable information to improve 
the PPRV vaccine production and stability substantially. 
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Technology transfer to Ethiopia:  








This chapter was based on the following manuscript: 
 
Testing a new formulation for Peste des Petits Ruminants vaccine in 
Ethiopia. Vaccine, Silva A.C., Yami M., Libeau G., Carrondo M.J.T. , Alves P.M. 




In this paper extended tests on a new candidate formulation for Peste des 
Petits Ruminants (PPR) vaccine carried out at National Veterinary Institute (NVI) 
in Ethiopia are presented. This work was performed in the frame of the 
VACNADA project from GALVMED which aimed at procuring vaccines against 
neglected veterinary diseases to African vaccine producing laboratories, in 
particular PPR.  
After the eradication of Rinderpest, Peste des Petits Ruminants became the 
next veterinary disease on target for elimination, requiring an effective and 
thermostable vaccine. In this work, a Tris/Trehalose formulation was evaluated 
in thermal stability studies, in comparison to the current used formulation of 
the live attenuated PPR vaccine, the Weybridge medium. The extended results 
presented herein show an increased thermal stability of the vaccine, especially 
at 37 and 45ºC, as expected from previously published results (Silva A.C. et al 
2011). Furthermore, during the course of this project, the NVI teams have 
clearly demonstrated ability to produce higher quality PPR vaccines after a 
successful transfer of the technology. These results should significantly 
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Peste des Petits Ruminants (PPR) is a highly contagious and fatal viral 
disease affecting sheeps, goats and wild ruminants. The disease is considered 
as one of the major constraints to the productivity of small ruminants in African 
and Asian countries [1].  For the control of PPR live attenuated cell culture 
vaccines based on two strains, PPRV Nigeria 75-1 [2] and PPRV-Sungri 96 [3], are 
available. The vaccines have been used worldwide with high efficacy in sheep 
and goat populations, providing at least 3 years immune protection after single 
dose immunization [4]. The Nigeria 75/1 vaccine strain has proven its 
effectiveness, regardless of the lineage type circulating in a particular 
country/region [4].  
PPR virus (PPRV) is a member of the genus Morbillivirus within the 
Paramyxoviridae family. PPRV is heat sensitive, a serious drawback for the 
efficient use of the live attenuated vaccine in the endemic areas, which have hot 
climatic environments. Although infrastructures in these regions are improving, 
cold chains required to ensure the maintenance of vaccine potency are still 
fragile. Thus, improvement of the production and stability for the conventional 
PPR vaccines are worthwhile goals.  
Ethiopia has the most important livestock population in Africa, ranked 9
th
 in 
the world [5]. Sheep and goat populations are estimated to be 20.7 million and 
16.4 million respectively, [6] with over 60% of the small ruminants in risk of 
contracting PPR [5]. The National Veterinary Institute (NVI) is the producing 
laboratory of the PPR vaccines in the country and also exports the vaccine for 
neighboring countries. Improving the production and stability of the PPR 
vaccines produced at NVI will contribute to the control of PPR. This paper 
presents results from the transfer operation of a new candidate formulation to 
the production platform of PPR vaccine at NVI and shows the first stability 
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2. PPR in the VACNADA project 
The programme Vaccines for Control of Neglected Animal Diseases in Africa 
(VACNADA) aimed to improve the capacity of selected African vaccine 
production laboratories to make quality vaccines in the quantities required 
impact on four prioritized neglected diseases of cattle, sheeps and goats, and 
poultry: contagious bovine pleuropneumonia (CBPP), contagious caprine 
pleuropneumonia (CCPP), PPR and Newcastle disease [7]. This was a 2-year 
project that finished in December 2011 [7]. VACNADA was implemented by the 
African Union - Interafrican Bureau for Animal Resources (AU-IBAR) in 
partnership with the Global Alliance for Livestock Veterinary Medicines 
(GALVmed), AU-PANVAC and the French Centre for International Cooperation in 
Agronomic Research for Development (CIRAD).  
CIRAD’s mission is to contribute to rural progress in developing countries 
by undertaking research and experiments with partners in these countries. 
CIRAD operates as a reference laboratory for the Food and Agriculture 
Organization (FAO) and the World Organization for Animal Health (OIE) for 
animal diseases, notably PPR. It has contributed to scientific knowledge on PPR 
diagnostic and control. Additionally has developed the live attenuated vaccine 
against this disease (PPRV Nigeria 75-1) [2]. Within the VACNADA project, CIRAD 
had supported the activities regarding to PPR vaccine production and control. 
The work plan to attain the VACNADA project objectives and purposes for PPR 
was based on the output of an “European Commission” funded project entitled – 
“Development of marker vaccines, companion diagnostic tests and improvement 
of epidemiological knowledge to facilitate control of Rinderpest and PPR viruses 
(MARKVAC)”. In this project, the task of optimizing the development of simple 
and robust methods for the production of the PPR vaccine plus the formulation 
to enhance stability during storage were accomplished by the Instituto de 
Biologia Experimental e Tecnológica (IBET). IBET possesses an expertise in the 
domain of animal cell technology processes for biomedical applications. The 
proven development results obtained have been previously published in this 
journal [8, 9]. Work done in the MARKVAC project identified an alternative 
Tris/Trehalose formulation as being superior to the Weybridge medium, 
recommended by the OIE, for PPR vaccine formulation and storage, maintaining 
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the PPRV titers for longer, both at liquid and lyophilized forms. This candidate 
formulation was transferred to NVI PPR vaccine production platform. 
 
3. Implementation and testing of developed formulation to 
improve PPR vaccine stability at NVI 
3.1. Setting-up the transfer and testing protocol 
Detailed information about the production and formulation strategies and 
the technology available at IBET were transferred to NVI. A work plan for 
implementation was also set in place. This was followed by a working visit from 
IBET to NVI for site training, technical discussion and approval of the testing 
programme, in order to improve the production and stability of PPR vaccine. As 
planned, NVI had available a vaccine lot at the time, so that the actual tests 
could be started during this working visit.  
During the visit several members of NVI from the production staff to the 
quality control were involved. Furthermore, members of AU-PANVAC, an 
independent quality control of the vaccines produced in Africa and concerning 
PPR, were also involved in the discussion given their experience in the process 
of thermostability for the Rinderpest and PPR vaccines (Xerovac) [10]. 
The final programme designed to evaluate the PPR vaccine stability at 
different relevant temperatures is presented in Figure 6. 1, both in liquid and 
lyophilized form, with the standard (Weybridge medium – WBM) and the new 
candidate (Tris/Trehalose) formulations as depicted in Table 6. 1. 
.  
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Table 6. 1: Formulation composition. 
Formulation Composition 
WBM 2.5% lactalbumin hydrolysate (w/v), 5% saccharose (w/v), 1% 
sodium glutamate (w/v), in Hank’s balance salt solution pH 7.2. 
(use as control, [11])  
Tris/Tre 20 mM Tris-HCl pH 7.4, 2 mM EDTA, 0.02% Tween 80; trehalose 
1 M. [8] 
Note: Vaccine liquid bulk was diluted 1:1 with the corresponding formulation. 
 
3.2. Results obtained at NVI 
Using the standard Vero cell culture production process in Roux bottles at 
NVI, two batches were prepared using two different culture media (GMEM vs 
DMEM), differing mainly in the buffer capacity and amino acid composition, in 
order to evaluate the production yields. IBET was able to follow the harvesting, 
formulation, vialling, lyophilization, labeling and first titration of samples before 
storage and lyophilization at NVI.  The competence, operational skills and 
coordination of the NVI staff in accomplishing all these tasks were 
outstandingly robust under difficult laboratorial and plant conditions. It became 
clearly obvious that the technology transfer had been totally successful given 
the experienced team at NVI.   
The first conditions evaluated were the storage of the vaccine bulk with the 
formulation at -20ºC and -80ºC (Figure 6. 2). These conditions are relevant for 
the storage of the vaccine bulk hold up time prior to quality control release for 
lyophilization. The results obtained (Figure 6. 2) confirmed that it is important 
to formulate the vaccine before storage to keep the titers as high as obtained 
during production. Since NVI has a very high track record of production batches 
passing the quality control tests, the advantage of keeping higher titers during 
the storage, prior to quality control release for lyophilization, far outweigh 
formulation extra costs in the few vaccine rejection cases. The results in Figure 
6. 2 indicate that storage in liquid formulation is preferentially better at -80ºC 




Figure 6. 2: Stability of PPRV in liquid formulations stored at -20 and 80 ºC. The vaccine liquid bulk 
was diluted 1:1 with the corresponding formulation and stored at the respective temperature. 
 
PPRV, being a live-attenuated vaccine, is particularly unstable at high 
temperatures, unless stored as a dry product with low residual moisture 
content. Lyophilization or freeze-drying is the most commonly used method for 
drying vaccines and other biopharmaceuticals.  This process is also used to 
stabilize PPR vaccine and was maintained for the new candidate formulation. 
The effect of storage of the lyophilized PPR vaccine at -20, 4, 37 and 45ºC was 
evaluated and is depicted in Figure 6. 3 and Figure 6. 4.  
 
 
Figure 6. 3: Stability of PPRV in lyophilized formulations stored at -20 and 4 ºC. 
The vaccine liquid bulk was diluted 1:1 with the corresponding formulation, lyophilized under standard 
conditions and stored at the respective temperature.  
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Figure 6. 4: Stability of PPRV in lyophilized formulations stored at 37 and 45 ºC. 
The vaccine liquid bulk was diluted 1:1 with the corresponding formulation, lyophilized under standard 
conditions and stored at the respective temperatures.  
 
As expected, the lyophilized PPR vaccine is even more stable at lower 
temperatures, with a slightly better stability for formulations stored at -20ºC 
than at 4ºC, during the 9 months of study.  The major differences between the 
formulations tested were observed at 37 and 45ºC. Under these conditions, the 
Tris/Trehalose formulation showed to be much more powerful in maintaining 
titers for the lyophilized vaccine than the standard formulation. These short 
term stability studies showed also that the production of the PPR vaccine using 
DMEM medium, instead of GMEM, also enhance stability (data not shown). The 
results presented herein, showing the Tris/Trehalose formulation substantially 
improving PPR vaccine storage stability, confirm data from a laboratory test 
already published for this new candidate PPR vaccine formulation, lasting for 21 
months at 4ºC [8]. As these results show a parallel evolution to the earlier 
laboratory tests, one can envisage a shelf life under lyophilized conditions and 
storage at 4ºC of at least 21 months. 
The costs involved reformulating the existing vaccines can be significant, 
depending on the changes introduced. In addition to the technical development 
for a novel, thermostable formulation, the cost of preclinical and clinical testing 
required to support regulatory approval must be taking into account. In this 
case, the change is only a few chemicals used for production and formulation as 
the production process is essentially maintained, making it easier to be adopted 
sooner than those involving major changes. The media components for the new 
candidate production and formulation are also already used in other types of 






The presented results herein confirm that replacing the formulation from 
Weybridge medium to Tris/Trehalose significantly improves the stability of the 
PPRV vaccine produced at NVI. It is important to highlight that the decay of the 
titer for the Tris/Trehalose formulation at 45 °C for 4 days, is less than 2 log 





/mL) and still compatible with vaccine efficacy [11].  
This will not only benefit the vaccine producer but also the end users of the 
vaccine by diminishing the vaccine cost, helping to ensure the effectiveness of 
the vaccine and reducing  dependency on the cold chain.  
Thus, it is strongly recommended to: 
1 – Use DMEM instead of GMEM medium for production; 
2 – Formulate with Tris/Trehalose instead of the normally used Weybridge 
medium; 
3 – Formulate immediately after production so that titer losses currently 
occurring during the pre-release quarantine can be avoided. 
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1. Discussion 
Viral vectors are a useful tool to deliver and present vaccine antigens. In the 
last decades we have witness incredible advances in vaccine development. In 
fact, the WHO estimates that vaccination has reduced global human mortality 
rates by infectious diseases by approximately three million deaths per year. In 
addition, the control of livestock health by vaccination increases food security 
and in developing countries reduces the social economic burden where people 
sustainability relies mostly on agriculture. Recently, contributed to the 
eradication of Rinderpest, one of the deadly infectious diseases of cattle [1], 
was achieved pinpointing the usefulness of committed vaccination plans in 
improving animal health and ultimately economics. 
Viruses are also important players in the gene therapy field. Significant 
developments occurred with the increasing number of successful clinical trials 
with promising results and the recent approval of three gene therapy products 
in the market. 
For viral products manufacturing, highly specialized cells are needed, which 
mainly depend on the desired characteristics of the viral product and the 
regulatory requirements. Currently, more than 50 cell culture-based human viral 
vaccines are being manufactured and many more are under development. Given 
the increasing demand of viral products, the development of robust, scalable 
and safe cell culture systems for viral production is in the focus of both 
academic and industrial research. Despite the technological progress and the 
promising prospects of disease control by vaccination, several challenges still 
stand. 
The work developed in this thesis aimed at overcoming critical bottlenecks 
in viral production processes. Two distinct viral products, Adenovirus vectors, 
the most used vector in gene therapy and with high potential also for 
recombinant candidate vaccines under development and Peste des Petits 
Ruminant attenuated virus vaccine (PPR vaccine), applied to control PPR, a 
relevant veterinary disease were investigated. Diverse culture strategies, with 
different cell lines, were applied to improve quantity and quality of the virus 
obtained. Both products share similar challenges but there are also product 
specific bioprocess bottlenecks that need to be addressed. The knowledge 
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gained with the different strategies used provides novel insights for the 
implementation of production platforms for different viral products.  
 
1.1. Process development for virus production 
The successful production of virus and viral vectors for vaccination relies on 
robust bioprocesses.  The appropriate cell line and optimal process parameters 
strongly affecting cell growth and virus replication must be addressed (Figure 
7. 1). 
 
Figure 7. 1: Virus production process requirements. 
 
1.1.1. Choice of the cell line 
 
The ideal production process for a viral or other biotherapeutic product 
should follow several benchmarks: i) use of cell lines compliant with regulatory 
safety concerns; ii) use of animal component-free culture medium and iii) rapid 
production process that yields high concentrations of the product in a cost 
effective way. The expected virus productivity (cell-specific and volumetric 
productivities) depends on the virus and the cell line used to propagate it. To 
address these issues different approaches were evaluated for the two viral 
products used in this thesis, (i) Adenovirus vectors (Chapter 2), and (ii) PPR 
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1.1.1.1. Cell lines for AdV production 
 
Recombinant adenoviral vectors are derived from virus deleted in the E1 
gene region; thus, they can replicate only in complementing cell lines that carry 
the E1 genes. Two recombinant human cell lines are commonly used in the 
production of such first-generation replication defective adenovirus vectors: a 
human embryonic kidney cell (HEK293 cells) originally transformed with sheared 
fragments of adenovirus type 5 (Ad5) DNA [2] and a human embryonic 
retinoblast cell line (designated PER.C6 cells) transformed with Ad5 E1A and E1B 
encoding sequences [3]. PER.C6 cells have been preferred for this purpose, 
since they contain no overlapping sequences with the Ad5 vectors, minimizing 
or eliminating the probability of generating replication-competent adenovirus 
(RCA). RCAs are frequently encountered in the large-scale production of 
recombinant adenovirus vectors with HEK293 cells [4]. 
In this thesis a human-amniocyte derived single cell clone, 1G3 cells, was 
evaluated in its ability to produce AdV vectors in a scalable approach (Chapter 
2).  In order to reduce the chances of RCA generation in AdV production 
1G3 cells were transformed with a plasmid containing the Ad5 E1A and E1B 
genes plus modified sequences from the pIX gene, with little overlap between 
vector and cellular DNA upon vector production. This resulted in no detectable 
RCA levels in a total of 40 independent small scale assays of 15 serial passages 
of AdV. On the other hand, in HEK293 cells the presence of RCA was detected in 
3 out of 20 assays. These results suggest that 1G3 cells can offer a safer 
alternative for AdV production, in comparison with HEK293, due to the 
restricted viral genome sequences that were inserted in the host cell genome. 
The 1G3 cell line was successfully adapted grow as single cells in 
suspension in serum-free medium growing to high concentrations (Chapter 2) 
and producing volumetric AdV productivities in the same range of HEK293 cells. 
It was identified a safer alternative host cell line for the production of AdV due 
to the low probability of RCA. 1G3 cells, being a human cell line have the 
potential to be used for the production of other biologics besides AdV. They 
have the same cellular origin than CAP cells [5] and those were already 
evaluated for recombinant proteins production [6, 7] and are capable of 
producing influenza [8],  respiratory syncytial virus and poliovirus [9]. For 
human use, the produced viruses will replicate in the correct host, glycosylation 
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of the glycoproteins will have the correct human pattern and highest immune 
response can be expected [10, 11].   
 
1.1.1.2. Cell lines for PPR production 
 
The PPR vaccine has been manufactured using Vero cells [12]. However the 
current process of vaccine production still relies in the use of Roux flasks and 
roller bottles, which present several limitations namely concerning scale-up.  
In this work and, since Vero cells used for this process are anchorage 
dependent, the first attempt to evaluate the production of PPR vaccine in 
scalable bioreactors was based on the use of microcarrier technology (Chapter 
4). Vero is currently the most widely accepted cell line by regulatory authorities 
for vaccine development due to the fact that Vero-derived human vaccines have 
been in use for nearly 30 years for the production of polio, rabies virus and 
influenza H5N1 [13], among others [14]. Our results show that PPR vaccine can 
also be produced in Vero cells using microcarrier technology. The use of serum-
free medium not only increased viral yield but allowed its maintenance for a 
longer period of time (Chapter 4).  This is a significant improvement since PPR 
vaccine presents lower stability at elevated temperatures namely at 37ºC, 
temperature during production. A larger window for harvesting is now possible, 
facilitating process and leading to higher recovery yields. Starting with higher 
titers for lyophilization also contributes to improve long thermal stability of a 
virus preparation during storage as observed for Rinderpest vaccine [15] and 
Adenovirus vectors [16] where more concentrated preparations presented 
better stability than those with lower concentration. Nonetheless the increased 
price of the serum-free medium formulations, the higher yields (vaccine doses 
per batch) obtained may contribute for the reduction of vaccine production 
costs. 
Recently, Vero cells were adapted to suspension culture [17]. However, the 
licensing cost for the use of these proprietary suspension cells may be 
prohibitive for the production of a veterinary vaccine for Africa, as is the case of 
PPR vaccine. Therefore, alternative cells able to grow in suspension were 
assessed in their capacity to proliferate the PPR virus (Chapter 4). CHO-K1 and 
MRC-5 cells have proved not to be suitable for PPRV production, eventually due 
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to the lack of cellular receptors necessary for the virus to infect them [18, 19].  
It has been shown that the expression of viral receptors correlates to 
susceptibility of production of the corresponding virus namely influenza, 
respiratory syncytial virus and poliovirus in different cell lines [9].  
On the contrary, HEK293 and BHK-21A cells were permissive to PPR virus 
infection, allowing the recovery of similar titers to those obtained in Vero cells 
using lower MOI’s (Chapter 4). The lower virus needs for infection with these 
suspension cells could contribute for the reduction of the master virus bank 
utilization in the production process. This is very attractive due to the high 
costs associated to virus bank maintenance. Moreover, in BHK-21A cells higher 
viral titers are attained earlier in the bioprocess than HEK293 cells, reducing the 
production process time. The approval by regulatory authorities is facilitated 
when using cell lines that have already been approved and historically safe in 
the production of different biologicals. BHK-21A cells are thus a valuable option 
for PPR vaccine production as they are also the cell substrate for other 
veterinary vaccines namely Foot and Mouth disease (FMD) [20] for several years.  
Additionally, the manufacturing facilities can be operated in campaign between 
PPR and FMD for example, reducing the costs of implementation of a new 
process.  
 
1.1.2. Cell culture and infection conditions 
 
The viruses used in this thesis belong to distinct families and consequently 
present completely different life cycles. AdV is a non-enveloped DNA virus with 
a protein capsid protecting the genome. On the contrary, PPR is an RNA virus 
with a lipidic envelope that is obtained by budding out of the producing cell. 
The production process for each type of virus has to be adapted to the virus life 
cycle to potentiate higher productivities and quality of the desired viral product. 
In the case of AdV, a lytic virus, high MOIs are usually used to warranty a 
synchronous infection. The use of lower MOIs (0.1-0.0001) [21] have been 
applied for AdV resulting in similar titers than those for high MOIs (5-20). 
Nevertheless, with low MOIs there is a need of medium replacement every 2 
days to maintain the cell growth of non-infected cells which results in higher 
process times and higher virus volumes to be handled in the downstream 
processing. The effect of MOI in the production of AdV in 1G3 cells was 
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evaluated and the results showed that higher titers are obtain using a MOI or 5-
10 (Chapter 2). The results are in the order of magnitude that is normally used 
for HEK293 [22, 23] and Per.C6 cells [24].   
 
For PPR production lower MOIs (lower than 1) were assessed (Chapter 4). The 
PPR vaccine was attenuated by serial passage in Vero cells culture and it is 
known than repeated passage at high MOI can generate defective interfering 
virus particles (DIP), which can have undesirable measurable biological effects 
[25-27]. The presence and/or production DIP in higher MOI infections play a role 
in reducing the production and accumulation of infectious progeny viruses [28]. 
Krell [29] reported that low MOI minimizes the generation of DIP during 
successive virus amplification steps and thus increases production of infectious 
viruses. Based on these observations, the virus master bank used for each 
production run should be prepared with the lowest MOI possible to ensure 
reproducibility and higher virus titers in each batch.  
We show that for the production of PPR in Vero cells, using microcarriers in 
stirred conditions (Chapter 4) a MOI of 0.01 allows higher infectious titers. For 
the alternative cell lines permissive to PPR, HEK293 and BHK-21A cells, a lower 
MOI (0.001) could be applied to originate similar virus titers than those of Vero 
cells. This approach is an appealing alternative for virus production because an 
infection strategy based in low MOIs overcome extra virus amplification steps, 
undesirable in industrial production, and minimizes the virus passage effect. 
Similar conclusions were reported previously for other virus/host cells systems 
such as baculovirus/insect cells [30], influenza virus [31], amongst others. 
 
Stirred tank bioreactors (STB) are scalable and hydrodynamically well 
characterized systems with simple design and operation. In particular, 
environmentally controlled stirred tank bioreactors allow the on-line monitoring 
and control of critical culture variables (e.g. temperature, oxygen, pH) known to 
affect virus productivity (revised in Chapter 1).  
The capability of using this system for PPR production was evaluated with 
Vero and BHK-21A cells (Chapter 4). The results showed that both cell lines can 




/mL) in STB. Nevertheless, 
upscaling it will be straightforward as BHK-21A cells grow as single cells in 
suspension. For large scale production of Vero cells inocula preparation is more 
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challenging since cells must be harvested from microcarrires and transfered to 
other culture vessels (See Chapter 1). For lower scales, up to 5L, the inoculation 
of the bioreactors can be done with cells from static cultures that are easier to 
detach from the growing surfaces than those in microcarriers. 
 
1.1.3. Metabolic alterations induced by virus infection 
 
The ‘‘cell-density effect’’ in HEK293 and PER.C6® cultures is well described 
in the literature for AdV production, meaning that cell specific productivity 
drops with increased of CCIs [24, 32, 33]. This effect seems to limit the range of 
the CCI to 0.5–1x10
6
 cell/mL in order to maintain high productivities. To 
investigate if the same phenomena occurred for 1G3 cells, the effect of CCI in 
cells productivity was first evaluated in shake flask (Chapter 2). A decrease on 
the cell specific productivity was also observed for 1G3 cells with increasing 
CCI’s, although at a lower extent then in HEK293 cells. The use of fully 
controlled STB for AdV production bioprocess resulted in an increase of the 
productivities for all tested CCIs (Chapter 2) in comparison to shake flask 
cultures. The control of pH in STB may have contributed for the higher 
productivities than in shake flask which presented,  during infection, values 
lower than 7, which are below the optimum value described in the literature for 
AdV production (7.2 for HEK293 [34] and 7.3 for PER.C6® [35]). In this system, 
the decline in cell specific productivities on CCI also occurred for HEK293 with a 
10-fold decrease in the specific AdV productivities at the higher CCIs. This 
effect was completely abolished for 1G3 cells in STB cultures; in fact an increase 
of 2.9-fold was observed for CCI 3 relatively to CCI 1.   
To try to undisclosed why 1G3 cells could produce higher virus titers than 
HEK293 cells, metabolism of both cell lines was evaluated. From the first 
analysis (Chapter 2), the main carbon sources, glucose and glutamine, were at 
limiting concentrations at higher CCI’s for both cell lines, which could also 
affect the AdV productivities, as previously reported for HEK293 cells at CCI 3 
[22]. 1G3 cells, like HEK293 and PER.C6® cells exhibited a preference for 
glucose over glutamine metabolism with a ratio Y
Glc/Gln
 in the order of 5–10 
mol/mol [24, 36].  Still, in stirred culture systems the Y
Glc/Gln
 was higher for 1G3 
cells than for HEK293 cells, which may suggest that glutamine depletion during 
infection could have less impact on the AdV productivity of this cell line. It has 
been reported that feeding with glucose and glutamine could not reconstitute 
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the cell specific productivity at a CCI 3 [22]. In fact, only a complete medium 
exchange at the time of infection could improve the productivity of HEK293 
cells at this cell concentration [22].  
The analysis of extracellular metabolites was done by 
1
H-NMR (Chapter 3) 
aiming to understand the metabolic features of 1G3 cells that could be 
contributing to the increase productivity at higher CCIs. Metabolic profiling 
identified significant differences between 1G3 and HEK293 cells in uninfected 
cultures concerning glutamine and acetate metabolism, as well as different 
rates of by-product secretion. The main response to adenoviral infection in both 
cell lines was significantly increased glucose consumption and lactate 
production rates. Therefore, the stimulation of glycolysis to support production 
of infectious particles was not cell specific. Performing cultures with and 
without glutamine confirmed the exhaustion of this amino acid is a main cause 
of lower adenovirus production at high cell densities, and highlighted different 
degrees of glutamine dependency of each cell line to meet the energetic and 
biosynthetic needs for virus replication. 
Further information on the intracellular metabolites is needed for a better 
understanding on the virus-host interactions on the metabolism. A metabolic 
network for both cell lines could be created and metabolic flux analysis be 
applied. Based on a detailed understanding of the pros and cons of individual 
host cells for process performance, properties of other cell lines, specific 
aspects of virus–host cell interaction and process options can be better 
evaluated. Overall, a thorough comparison of cell lines might help to develop 
process optimization strategies, as well as to assess quality differences 
concerning the virus produced. 
 
 
1.1.4. Viral stabilization and storage 
 
Although lyophilization technology has resulted in the development of many 
successful live, attenuated viral and bacterial vaccines, most of these vaccines 
still require storage at 2-8°C or even below, which necessitates a cold chain for 
acceptable long term stability [40]. To sustain vaccine efficacy, a cold chain is 
usually required to maintain vaccine below ambient temperature, from the 
location of manufacture to the site of vaccine administration. Unfortunately, 
Chapter 7 
Ana Carina Silva - PhD dissertation 
184 
cold chain temperature maintenance is not technologically feasible in many 
remote areas of the world. In fact, because of improper handling techniques, a 
lack of refrigerators, or power failures, vaccines can be exposed to elevated 
temperatures for several weeks. Although several guidelines have helped 
ensure appropriate storage and efficacious vaccine administration, the vaccine 
cold chain remains error-prone, logistically difficult, expensive, and probably 
unrealistic in many parts of the developing world [40]. 
In the case of Adenovirus vectors, the stability issues applied to this virus 
were not covered during this thesis. In fact several works have been previously 
done to stabilized this viral product [41-45], including work performed in our 
laboratory that I also contributed for, using new compatible solutes [46]. We 
have showed that with a Tris formulation with sucrose or ectoin, AdV could be 
stored in liquid at 4ºC, presenting and half-life of 87 days. These characteristics 
facilitate their use as vaccines or viral vectors since no extraordinary 
stabilization processes are necessary to maintain their efficacy. 
PPR vaccine is a safe and efficacious vaccine, however the main constrains of 
their use is their low stability at higher temperatures by being an attenuated 
vaccine and an enveloped virus. Two strategies were applied to improve the 
stability of the PPR vaccine by manipulations: 1) culture medium composition 
and 2) final formulation (Chapter 5). Previous work in our laboratory with 
retrovirus vectors (also enveloped viruses) have shown that changing the carbon 
source or osmotic pressure during production could increase the intrinsic 
stability of the vectors by changing the composition of the lipid membrane [47, 
48]. This information was applied to the PPR which resulted also in higher virus 
intrinsic stability when the production is performed using fructose or higher 
concentrations of glucose (Chapter 5).  
To improve the stability of the PPR vaccine during the production process it 
was also evaluated a strategy for harvesting without the traditional freeze 
thawing cycles. The addition of NaCl 24h before harvesting allowed the recovery 
of the cell associated virus without compromising their stability due to the 
detrimental effects of freezing the virus lacking a freezing protector. This 
approach has been also efficacious to release dengue virus from Vero cells 
during production [49]. Moreover this harvesting strategy is scalable and more 
suitable for a larger scale production than the freeze/thaw cycles normally 
used.  
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An alternative formulation (Tris/Trehalose) was recognized has allowing for 
higher stability than the traditional Weybridge medium under different storage 
conditions. This formulation could facilitate the production and formulation 
process before and after lyophilization, since it presented higher stability in 
liquid form and less sensitivity to final moisture content. More lyophilized 
batches may pass all the quality controls at the end process, lowering the costs 
of the vaccine, even taking into account that the candidate formulation could be 
slightly more expensive due to the higher cost of trehalose in relation to the 
other components. 
Overall, enhancing vaccine stability can help to (1) expand immunization 
coverage (with minimal increases to the cost of distribution and cold chain 
upkeep), (2) ensure that administered vaccines are fully potent, (3) reduce 
vaccine wastage (when high temperature excursions occur or are suspected), 
and (4) lower inventory turnover (by increasing the product shelf-life of 
stockpiled vaccines, especially at ambient temperatures). As benefits continue 
to be demonstrated, immunization programs may increasingly request 
thermostable vaccine products—further encouraging vaccine manufacturers to 
meet the commercial demand for them [50]. 
A better understanding of the molecular basis or the origin of the 
instabilities of viruses and bacteria should result in the more rational design of 
stable vaccine formulations. In addition, alternative methods of processing such 
as spray drying may also lead to improved vaccine stability [51].  
 
1.2. Application of new developments to vaccine production 
The Tris/Trehalose formulation for PPR vaccine (Chapter 5) was transferred 
to NVI in Ethiopia under the VACNADA project (Chapter 6). This project aimed 
to support sustainable improvements to the quality and quantity of vaccines of 
neglected animal diseases namely PPR, in selected African vaccine production 
laboratories. It was implemented by the partnership between AU-IBAR, CIRAD 
and GALVmed giving inputs in capacity building through staff development, 
market intelligence and upgrading of laboratory equipment, facilities and 
processes. 
The technology transfer was successfully accomplished since a good 
communication between the involved teams was easily conceived. The 
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competencies, conditions available and needs of NVI were identified and all the 
information needed was prepared and adapted to the task. A local training was 
performed with several attendees of the different departments involved in the 
PPR vaccine production at NVI to guaranty an efficaciously transfer of the 
technology. After following the processing of the first batch of PPR vaccine with 
the new formulation (Chapter 6) it was possible not only to validate the results 
obtained in the development (Chapter 5) but also to contribute to improve the 
thermostability of the PPR vaccine produced at NVI placing them in an 
advantageous position to their direct competitors. 
The costs involved reformulating existing vaccines can be significant, 
depending on the changes introduced. In addition to the technical development 
for a novel, thermostable formulation, the cost of animal testing required to 
support regulatory approval must be taking into account. In this case, the 
change introduced was only in a few chemicals used for production and 
formulation as the production process is essentially maintained, making it 
easier to be adopted soon. The media components for the new candidate 
production and formulation are also already used in other types of vaccines, 
thus there is no need for regulatory approval of such base materials. Since PPR 
is a veterinary vaccine, the regulatory restrictions are less stringent than those 
for human use which facilitate the application of new technologies.  
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2. Main Conclusions and Future directions 
This PhD thesis addressed several challenges that are faced during the 
development of a virus production process for vaccine or gene therapy 
applications. This work contributed to the state of the art on process 
development for viral products in mammalian cells, namely Adenovirus and PPR 
virus vaccine, but also to other systems that could face similar challenges 
(Figure 7. 2). It covers work in research and development from the selection of 
the cell line to the final formulation of the biological product and to the transfer 
of part of the process to a production facility.  
 
Figure 7. 2: Schematic view of the work developed in thesis including challenges, strategies and 
outcomes. CCI – cell concentration at infection; MOI – multiplicity of infection; RCA – replicative competent 
adenovirus. 
 
1G3 cells (Chapter 2) are good alternative cell host for the production of 
Adenovirus vector and PPR virus can be produced in HEK293 and BHK-21A cells 
(Chapter 4). The processes developed in this thesis present better scalability, 
easy handling, higher titers and product quality (e.g. higher stability) than those 
traditionally used under the conditions tested (Table 7.1).  
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Table 7. 1: Production processes developed for PPR and Adenovirus production. 
Virus 




Traditional Thesis Output 
Cells HEK293 1G3 Vero Vero BHK-21A HEK293 
Medium Serum-free Serum-free Serum Serum free Serum free Serum free 
System 
Suspension Suspension Adherent Suspension Suspension Suspension 










24h 24h 24h 24h 
MOI 5 5 0.01 0.01 0.01-0.001 0.01-0.001 



































CCI – cell concentration at infection; TOI – time of infection; MOI – multiplicity of infection; TOH – 
time of harvest; ip – infectious particles; TCID
50
 – tissue culture infectious dose 50%. 
 
Metabolic characterization during growth and Adenovirus production 
performed by 
1
H-NMR (Chapter 3) showed significant differences between 1G3 
and HEK293 cells. Adenovirus replication decreases more drastically at high cell 
density infection of HEK293 cells than of 1G3 cells.  
Concerning PPR vaccine stability (Chapter 5), an alternative formulation 
(Tris/Trehalose) was identified that present’s higher performance at elevated 
temperatures than the one in use (Table 7.2).  
 
Table 7. 2: PPRV half-life (t
1/2





Traditional Thesis Output 
Weybridge Tris/Trehalose 
Liquid 
4ºC 22 days 30 days 
37ºC 9 hours 21 hours 
Lyophilized 
4ºC 11 months 10 months 
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In the PPR-GEP (PPR Global Control and Eradication Programme) workshop for 
PPR vaccine producers organized by FAO and OIE (in Kathmandu, Nepal 
December 2014) several guidelines for the needs of PPR vaccine have been 
deliberate by all the participants. Most of the laboratories involved in the 
manufacturing will need to increase their production capabilities to achieve the 
future vaccine demands and to consider adopting new formulations to provide 
thermostable products for the eradication campaign to be successful. The 
results of this thesis contributed to meet those decisions. It was shown not only 
that using scalable vaccine production processes using Vero or BHK-21A cells 
could be applied to PPR vaccine (Chapter 4), but also a new formulation could 
improve the vaccine thermostability (Chapter 5).  The transferred of the 
Tris/Trehalose formulation to the NVI in Ethiopia (Chapter 6) showed that with 
proper training, good communication and collaboration between experts, the 
needed alterations in the production laboratories could be successfully 
accomplished.  
 
Still, to achieve a robust and efficient virus production platform, some 
trends identified throughout this thesis need verification and other 
technologies could be applied: 
 The use of disposable, single-use bioprocessing technologies, such as 
bioreactor bags in PPR vaccine and AdV production could be also 
evaluated since they eliminate cleaning validation steps and provide 
significant time and cost savings. 
 The application of metabolic flux analysis combined with non-invasive 
and high content analytical techniques like NMR with labelled substrates 
will allow identified the metabolic requirements for cell growth and viral 
production that affect productivity. 
 The knowledge gained by the identification of the limiting metabolic 
nodes may be used to improvement the viral productivities and surpass 
the “cell density effect” by using target metabolic engineering as already 
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